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ABSTRACT 
Modulating Protein Homeostasis to Ameliorate  
Lysosomal Storage Disorders 
by 
Fan Wang 
The goal of this project has been to develop therapeutic strategies for protein 
misfolding diseases caused by excessive degradation of misfolded proteins and loss of 
protein function. The focus for this work is lysosomal storage disorders (LSDs), a group 
of more than 50 known inherited metabolic diseases characterized by deficiency in 
hydrolytic enzymes and consequent buildup of lysosomal macromolecules. Gaucher’s 
Disease (GD) is used as a representative of the family of LSDs in this study. GD is 
caused by mutations in the gene encoding lysosomal glucocerebrosidase (GC) and 
consequent accumulation of the GC substrate, glucocerebroside. The most prevalent 
mutations among GD patients are single amino acid substitutions that do not directly 
impair GC activity, but rather destabilize its native folding. GC normally folds in the ER 
and trafficks through the secretory pathway to the lysosomes. GC variants containing 
destabilizing mutations misfold and are retrotranslocated to the cytoplasm for ER-
associated degradation (ERAD). However, evidence shows that if misfolding-prone, 
mutated GC variants are forced to fold into their 3D native structure, they retain catalytic 
activity. This study describes strategies to remodel the network of cellular pathways that 
maintain protein homeostasis and to create a folding environment favorable to the folding 
of unstable, degradation-prone lysosomal enzyme variants. We demonstrated that folding 
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and trafficking of mutated GC variants can be achieved by modulating the protein folding 
network in fibroblasts derived from patients with GD to i) upregulate the expression of 
ER luminal chaperones, ii) inhibit the ERAD pathway, and iii) enhance the pool of 
mutated GC in the ER amenable to folding rescue. We also demonstrated that the same 
cell engineering strategies that proved successful in rescuing the folding and activity of 
mutated GC enable rescue of mutated enzyme variants in fibroblasts derived from 
patients with Tay-Sachs disease, a LSD caused by deficiency of lysosomal 
hexosaminidase A activity. As a result, the current study provides insights for the 
development of therapeutic strategies for GD based on the modulation of general cellular 
pathways that maintain protein homeostasis that could in principle be applied to the 
treatment of multiple LSDs. 
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Chapter 1 
Introduction 
1.1.  Protein folding 
1.1.1.  From polypeptide sequence to native three-dimensional structure 
Proteins are biochemical molecules involved in almost every biological process in 
the cell. They consist of linear chains of amino acids joined together by peptide bonds. In 
order to display biological functions, newly synthesized polypeptides need to fold three-
dimensionally to assume their native structure (Alberts et al., 2002).  
Anfinsen’s pioneer experiments on protein folding demonstrated that proteins can 
fold spontaneously into their native structure in vitro. This evidence suggests the native 
folding of a protein, which is the biologically functional conformation, is the most 
thermodynamically favored among all possible three-dimensional conformations that a 
polypeptide sequence can assume. In other words, three-dimensional folding of proteins 
is dictated solely by information contained in the amino acid sequence (Anfinsen, 1973; 
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Anfinsen et al., 1961). However, unassisted folding may occur in time scales too slow to 
be compatible with cellular physiology (Griffiths and Simons, 1986). Therefore, living 
organisms have evolved proteins that, by chaperoning newly synthesized proteins 
through their folding process, accelerate the folding of proteins in vivo (Figure 1.1) (Ellis 
and Hartl, 1999). Molecular chaperones include a variety of proteins that promote native 
folding of unfolded or misfolded proteins and prevent interactions between misfolded or 
partially folded protein intermediates, which would otherwise lead to deleterious 
consequences for the cell, including the formation of insoluble aggregates (Dobson, 
2003; Fink, 1999).  
 
 
Figure 1.1. Protein folding in vivo. Each protein is present in a dynamic equilibrium 
between folded and unfolded conformations. Molecular chaperones promote the native 
folding of a protein and prevent interactions between misfolded or partially folded 
protein intermediates. Misfolded proteins are either rapidly degraded or aggregate into 
insoluble deposits, which are resistant to degradation. 
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A number of competing biological pathways maintain the conformational 
integrity of the proteome to ensure their biological functions. These pathways, which 
regulate protein synthesis, folding, trafficking, and degradation, comprise an integrated 
network that maintains protein homeostasis (known as proteostasis network) (Balch et al., 
2008; Mu et al., 2008b). Impairment of folding is often due to the inability of the 
proteostasis network to cope with destabilizing effects of genetic mutations or 
environmental factors. Recent efforts have been devoted to devising strategies to 
modulate the proteostasis network to promote folding of unstable, degradation-prone 
proteins (Hartl et al., 2011). Modulation of the proteostasis network is expected to 
remodel the folding free energy landscape of unstable proteins, thus limiting the 
accumulation of misfolding intermediates and maximizing native folding (Figure 1.2) 
(Powers et al., 2009).  
 
 
Figure 1.2. Modulating the proteostasis network to enhance the cellular folding 
capacity. The folding process is driven by a free-energy funnel. The unfolded state of a 
protein, at the top of the funnel, is associated with the highest free energy. Protein 
folding involves the progression of the unfolded protein through a number of folding 
intermediates characterized by lower free energy. Folding intermediates may also reach 
relatively stable off-pathway conformations. Reprogramming proteostasis network 
influences the folding free energy landscape and lowers the population of misfolded 
proteins. U: unfolded state; M: misfolded state; F: folded state. (Adapted from Powers 
et al. 2009) 
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1.1.2. Protein misfolding 
A number of factors including genetic mutations (Hochstrasser, 1996) or 
environmental conditions (Dobson, 1999; Jaenicke, 1991) cause impairment of protein 
folding and lead to accumulation of misfolded intermediates. The fate of misfolded 
proteins is either degradation or aggregation into insoluble deposits (Figure 1.1) (Bence 
et al., 2001). Because the native structure of a protein is tightly linked to its biologic 
activity, failure of a protein to achieve its native fold or to remain correctly folded results 
in loss of protein activity, which, in turn, often gives rise to the development of a wide 
variety of human diseases depending on the identity of the misfolded protein (Dobson, 
2003). Protein misfolding diseases encompass a large group of ailments ranging from 
neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, to metabolic 
diseases such as LSDs and type II diabetes, and include even many types of cancers. 
Protein misfolding diseases can be generally classified as: i) loss-of-function diseases, 
which are caused by rapid disposal of misfolded protein through the cell’s degradation 
system, and ii) gain-of-toxic-function diseases, which are characterized by the aberrant 
accumulation of misfolded proteins and formation of insoluble aggregates (Dobson, 
1999).  
 
1.2. The protein quality control system 
The protein Quality Control (QC) system is a complex network of pathways that 
promotes folding and trafficking of newly synthesized proteins (Bukau et al., 2006). The 
QC system is composed of i) molecular chaperones, which facilitate the folding of 
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proteins into their native conformations and prevent misfolding and aggregation (Lee and 
Tsai, 2005), and ii) the ubiquitin-proteasome system, which catalyzes the degradation of 
misfolded proteins (Ravid and Hochstrasser, 2008). This sophisticated network 
guarantees the biogenesis of properly folded, biologically active proteins and avoids the 
formation of non-native off-pathway events such as the accumulation of misfolded or 
aggregated proteins (Trombetta and Parodi, 2003).  
Misfolded proteins typically expose patches of hydrophobic amino acid residues 
on their surfaces, which often cause the formation of aberrant intermolecular interactions 
and lead to the deposition of insoluble, possibly toxic aggregates (Kiefhaber et al., 1991). 
Molecular chaperones assist folding and assembly of nascent proteins or folding 
intermediates by shielding these hydrophobic patches (Lee and Tsai, 2005), thereby 
greatly reducing the risk of non-native interactions between folding intermediates within 
the crowded cellular milieu. As correctly folded proteins are released by the molecular 
chaperones, they can undergo post-translational modifications and reach their cellular 
localization (Lee and Tsai, 2005). Proteins that do not fold into their native 
conformations are rapidly eliminated by the ubiquitin-proteasome system (Bukau et al., 
2006). The ubiquitin-proteasome system is a complex multi-enzymatic degradation 
machinery that catalyzes the degradation of misfolded proteins by preventing the 
accumulation of misfolded proteins. The ubiquitin-proteasome system contributes to 
maintaining a physiologic balance between folded and misfolded proteins (Ravid and 
Hochstrasser, 2008). 
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1.2.1. Folding of proteins traversing the secretory pathway 
Approximately one-third of proteins in eukaryotic cells are destined to 
extracytoplasmic compartments, including the extracellular space, organelles such as 
lysosomes, and the cell membrane. This project focuses on folding and trafficking of 
lysosomal proteins; thus these processes will be analyzed in this section in details. 
Proteins destined to extracytoplasmic compartments are translocated into the 
Endoplasmic Reticulum (ER) immediately after translation and are processed through the 
secretory pathway. Folding of secretory proteins occurs in the ER. Only natively folded 
proteins can exit the ER and move through the Golgi apparatus to their final destinations 
(Trombetta and Parodi, 2003).  
The ER consists of an interconnected network of tubules, vesicles and cisternae 
(Rapoport, 1992). Secretory proteins are synthesized by ribosomes that are docked onto 
the ER membrane, guided by the protein sequence that targets the ER (Daniel et al., 
2008). Newly synthesized polypeptide chains enter the ER lumen co-translationally 
through Sec61, a translocation channel embedded in the ER membrane (Daniel et al., 
2008). As they are translocated into the ER lumen, polypeptide chains immediately 
interact with ER resident proteins that assist their folding (Ellgaard et al., 1999). Proteins 
that achieve a folded state exit the ER and move to the Golgi apparatus, whereas 
misfolded proteins are retrotranslocated to the cytoplasm for ER-associated degradation 
(ERAD; (Werner et al., 1996)).   
The Golgi apparatus is comprised of a series of five to eight membrane-covered 
sacs called Golgi cisternae (Griffiths and Simons, 1986). Vesicles that contain ER 
proteins fuse with the cis-Golgi network, progress through the stacks of Golgi cisternae, 
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and reach the trans-Golgi network (Arvan et al., 2002). Each Golgi cisterna contains a 
variety of enzymes that catalyze glycosylation of secretory proteins and promote their 
packaging into secretory vesicles. These vesicles are then discharged from the trans-
Golgi network and move to their final destinations (Alberts et al., 2002; Traub and 
Kornfeld, 1997).  
Lysosomes are acidic organelles rich in hydrolases that catalyze degradation of a 
variety of metabolic byproducts such as lipids, polysaccharides, and glycoproteins 
(Kornfeld and Mellman, 1989). The recognition and targeting of lysosomal proteins is 
mediated by specific receptor proteins, such as the mannose-6-phosphate receptor 
(M6PR) protein, on the membrane of sorting vesicles that shuttle between the trans-Golgi 
network and lysosomes (Matovcik et al., 1990). Lysosomal hydrolase precursor proteins 
are tagged with mannose-6-phosphate (M6P) molecules in the cis-Golgi apparatus. The 
M6PR recognizes the M6P tag and thereby mediates sorting and trafficking of lysosomal 
proteins (Griffiths et al., 1988).  
Because lysosomes play a fundamental hydrolytic role in the cell, deficiency in 
activities of lysosomal hydrolases typically results in accumulation of lysosomal 
substrates, which often causes the development of devastating human diseases 
collectively referred to as lysosomal storage disorders (LSDs; Futerman and van Meer, 
2004).  
 
1.2.2. The ER folding quality control system 
ER chaperones, which make up about 10% of the proteins of the ER lumen, play 
an important role in promoting protein folding and maturation, and targeting irreversibly 
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misfolded proteins to ER-associated degradation (ERAD) (Figure 1.3) (Hammond and 
Helenius, 1995; Nishikawa et al., 2005). As newly synthesized polypeptides are 
translocated into the ER, they immediately interact with glucose-regulated protein 78 
(GRP78/BiP), which facilitates their folding while preventing their aggregation 
(Nishikawa et al., 2001). Substrates are labeled with oligosaccharide precursors 
(GlcNAc2-Man9-Glc3) and subsequently trimmed by ER glucosidases to allow 
recognition by the lectin chaperones (calnexin (CNX) and calreticulin (CRT); (Vembar 
and Brodsky, 2008)). Upon removal of the outermost glucose residue (GlcNAc2-Man9), 
natively folded proteins exit the ER and proceed through the secretory pathway, whereas 
misfolded intermediates are re-glucosylated by UDP-glucose:glycoprotein 
glucosyltransferase (UGGT). This cycle repeats itself until substrates either fold into their 
native conformation or are recognized as irreversibly misfolded. Misfolded proteins are 
extracted from the folding cycle by ER degradation-enhancing α-mannosidase-like lectins 
(EDEM, (Fagioli and Sitia, 2001; Hosokawa et al., 2003; Lederkremer and Glickman, 
2005)). ER mannosidases, particularly mannosidase I, trim three to four mannose 
residues on the oligosaccharide group to mark misfolded substrates for ERAD (Fagioli 
and Sitia, 2001; Nakatsukasa and Brodsky, 2008; Wu et al., 2006). Misfolded proteins are 
then polyubiquitinated by ubiquitin ligases and retrotranslocated via the p97 complex 
from the ER to the cytoplasm for proteasomal degradation (Figure 1.3) (Fiebiger et al., 
2004).  
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Figure 1.3. The ER quality control system. As newly synthesized polypeptides are 
translocated into the ER, they are immediately recognized by BiP, which promotes 
substrate folding and solubility. They are then marked with an oligosaccharide precursor 
(GlcNAc2-Man9-Glc3), which is sequentially trimmed to allow substrate interaction 
with the lectin chaperones calnexin (CNX) and calreticulin (CRT). Specifically, 
interaction with the lectin chaperones occurs upon cleavage of the two terminal glucoses 
by glucosidase I and II and is terminated by removal of the last outermost glucose 
residue (GlcNAc2-Man9) by glucosidase II. At this point, natively folded proteins exit 
the ER while partially folded intermediates are reglucosylated by UDP-
glucose:glycoprotein glucosyltransferase (UGGT) and re-enter the lectin folding cycle. 
In order to prevent excessive accumulation of folding intermediates, unstable 
misfolding-prone substrates are processed by ER mannosidase I, which cleaves three to 
four mannose residues from the oligosaccharidic group and promotes substrate binding 
with the ER degradation-enhancing α-mannosidase-like lectins (EDEM). ERAD 
substrates are then retrotranslocated to the cytoplasm via the Sec61 retrotranslocon, and 
polyubiquitinated. Substrate retrotranslocation is mediated by the p97 complex, which 
includes ubiquitin fusion degradation 1 (Ufd1) and nuclear protein localization 4 (Npl4). 
p97 ATPase provides the driving force for substrate extraction and shuffling to the 
proteasome.  
 
Aberrant accumulation of misfolded proteins triggers ER stress, which in turn 
leads to the induction of  the unfolded protein response (UPR) (Hampton, 2000). The 
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UPR consists of a series of intracellular signal transduction pathways to restore a 
physiologic balance between folded and misfolded proteins in the ER (Schroder and 
Kaufman, 2005). The UPR sets two primary responses in the cell: i) inhibition of protein 
synthesis to reduce the load of newly synthesized proteins that enter the ER and ii) 
upregulation of ER chaperones. If, however, proteotoxic stress persists, the UPR 
culminates with induction of apoptosis (Ron and Walter, 2007). 
 
1.3. Lysosomal Storage Disorders (LSDs) 
1.3.1. Cellular pathogenesis of LSDs 
Lysosomal storage disorders (LSDs) are a group of more than 50 known inherited 
metabolic diseases characterized by intra-lysosomal accumulation of undegraded 
metabolites (Futerman and van Meer, 2004). Substrate accumulation gives rise to 
progressive cellular impairment and organ dysfunction; hence, LSDs affect nearly every 
part of the body in people of all ages and races. Although leading to different clinical 
manifestations, the pathogenesis of most LSDs is caused by mutations in genes encoding 
for specific lysosomal enzyme and loss of the corresponding lysosomal hydrolytic 
function, which results in substrate accumulation (Futerman and van Meer, 2004).  
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1.3.2. Gaucher’s Disease 
Gaucher’s disease (GD) is the most common among LSDs with an overall 
prevalence of 1 in 60,000 people worldwide (Agmon et al., 1993) and with the highest 
frequency (1 in 1,000) encountered in the Ashkenazi Jewish population (Beutler et al., 
1993). GD is an autosomal recessive disorder mainly caused by loss of lysosomal 
glucocerebrosidase (GC) activity and consequent accumulation of GC substrate, 
glucosylceramide (Schueler et al., 2004). Affected organs include the spleen, liver, 
kidneys, lungs, bone marrow and in some patients, even the brain. Patients show varied 
degrees of hepatosplenomegaly, anemia, thrombocytopenia, skeletal lesion symptoms, 
and neurodegeneration (Zhao and Grabowski, 2002). GD has been classified in three 
common clinical subtypes (Grabowski, 1997). Type 1 (adult form) is the most common 
type of GD, especially in the Ashkenazi Jewish population. Type 2 (acute infantile) and 
type 3 (chronic) are rarer than type 1, but are associated with neuronopathic symptoms 
such as brain damage (Grabowski, 1997).  
More than 200 mutations in the gene encoding GC (GBA; Hruska et al., 2008) 
have been identified. Nonsense and splice-site mutations or deletions and insertions have 
an inactivating effect on the enzyme. Most missense mutations do not directly impair GC 
catalytic activity but rather destabilize its folding (Grace et al., 1994; Schmitz et al., 
2005). Unstable GC variants are retrotranslocated to the cytoplasm for ERAD, leading to 
partial or complete loss of GC activity in the lysosomes (Figure 1.4). However, unstable 
GC variants containing misfolding mutations could retain catalytic activity if forced to 
fold into their native 3D structures (Sawkar et al., 2002; Sawkar et al., 2006b; Yu et al., 
2007). 
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Figure 1.4. Glucocerebrosidase (GC) folding and trafficking through the secretory 
pathway. Newly synthesized GC progresses through a series of folding intermediates 
in the ER until it reaches native folding. GC traffics through the Golgi apparatus to the 
lysosome, where it hydrolyses glucosylceramide to glucose and ceramide. Destabilized 
GC variants are targeted for degradation through ERAD. 
 
The LeuPro substitution at position 444 (L444P) is one of the most frequently 
encountered misfolding mutations (Figure 1.5) (Schmitz et al., 2005). GD patients who 
are homozygous for the L444P GC allele typically present severe neuronopathic 
symptoms (Grabowski, 1997). The L444P substitution severely destabilizes the native 
structure of GC and results in complete loss of its activity (Grabowski, 1997). L444 is 
located in the hydrophobic core of a domain structurally distinct from the enzyme 
catalytic domain. The L444P substitution most likely causes a local conformational 
change that disrupts the domain’s hydrophobic core and leads to domain misfolding (Dvir 
et al., 2003; Grace et al., 1994). In this study, fibroblasts derived from GD patients 
homozygous for L444P were used to investigate strategies to modulate the proteostasis 
network and rescue the native folding of this severely destabilized variant.  
Another common mutation is the AsnSer substitution at position 370 (N370S; 
Figure 1.5; Jonsson et al., 1987). N370 resides in the enzyme active site domain. The 
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N370S GC variant retains about 10% hydrolytic activity of the wild type enzyme (Grace 
et al., 1994). Although there is no clear link between genotype and phenotype, patients 
carrying the N370S mutation never present CNS symptoms, suggesting that the residual 
activity of the N370S GC is sufficient to avoid severe manifestation of the disease.  
 
 
Figure 1.5. X-ray structure of glucocerebridosidase (GC). GC structure contains 
three domains, which are represented in magenta, green and blue. The two most 
prevalent GC mutations, L444P and N370S, are circled in red. (Adapted from Dvir et 
al. 2003) 
 
1.3.3. Therapeutic options for Gaucher’s disease  
Currently available therapeutic options for GD are enzyme replacement therapy 
(ERT) and substrate reduction therapy (SRT) (Futerman et al., 2004). ERT (Cerezyme®) 
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consists of intravenous injection of the native enzyme (Beutler, 2004). Although safe and 
successful for the Type I form of the disease, it is inadequate for neuronopathic forms due 
to the inability of the injected protein to cross the blood-brain barrier and reach the CNS 
(Altarescu et al., 2001). In addition, because of the short half-life of the enzyme and 
consequent poor delivery to certain affected areas, such as bones and lungs, this treatment 
imposes significant burdens on the patients, including weekly injections and considerably 
high costs (Desnick and Schuchman, 2002; Wraith, 2006). An alternative treatment is 
SRT, which is based on the use of small molecule N-butyldeoxynojirimycin (NB-DNJ, 
Zavesca®) (Cox et al., 2000; Platt et al., 2001). NB-DNJ prevents the synthesis of 
glucosylceremide by inhibiting glucosyltransferase, an enzyme involved in the 
biosynthesis of glycosphingolipids in the Golgi (Futerman and Pagano, 1991; Jeckel et 
al., 1992; Trinchera et al., 1991). Glucosyltransferase inhibition allows restoring the 
cellular physiologic ratio of substrate concentration to GC hydrolytic activity, thereby 
reducing substrate buildup in the lysosome. However, because NB-DNJ treatment 
reduces synthesis of all the gluco-based glycolipids, considerable side effects arise 
(Buccoliero et al., 2002; Kolter et al., 2002). Thus, SRT is only used to treat non-
neuronopathic GD patients for whom ERT is not an option (Cox et al., 2003). 
A number of small molecule “chemical chaperones” have been recently reported 
to provide an alternative therapeutic option for the treatment of GD based on rescuing the 
native folding of mutated GC variants. Chemical chaperones are small molecules that are 
structurally similar to the enzyme inhibitors, bind to the misfolding-prone enzymes and 
stabilize their conformations, thus facilitating ER export and trafficking to the lysosomes 
(Fan, 2003; Ulloa-Aguirre et al., 2004). Natively folded mutated enzyme variants are 
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often stable once they reach the lysosome, as they were evolutionarily selected to be 
stable at acidic pH. Chemical chaperones are displaced by the enzyme substrate, which is 
typically present at high concentration in the lysosomes. Chemical chaperone-based 
treatments have been recently explored to rescue the folding of mutated enzyme variants 
in GD cells (Sawkar et al., 2006b). In particular, treatment of fibroblasts from GD 
patients with N-(n-nonyl)-deoxynojirimycin (NN-DNJ) enhances ER secretion and 
lysosomal activity of N370S GC (Sawkar et al., 2002). Chemical chaperone therapy 
(CCT) has the potential to combine the advantages of both ERT and SRT, namely oral 
bioavailability, potential to cross the blood brain barrier, and low cost. However, only GC 
variants containing mutations in the active site domain are amenable to chemical 
chaperoning. This feature is likely due to the intrinsic mechanism of chemical chaperones 
that stabilize the folded enzyme pool by mimicking the mechanism of binding of the 
enzyme inhibitor and thus interacting specifically with the enzyme active site. GD cells 
harboring the L444P GC mutation, which resides in a structural region separate from the 
enzyme active site domain, are rarely responsive to CCT (Khanna et al., 2010). As 
mentioned before, L444P is the most common mutation associated with the 
neuronopathic form of GD. Hence, the cure of neuronopathic GD, as well as a number of 
other neuronopathic LSDs, remains a completely unmet medical need.  
 
1.3.4. Tay-Sachs disease 
Tay-Sachs disease is caused by deficient activity of lysosomal enzyme 
hexosaminidase A (HexA) and cellular storage of gangliosides GM2 (N-
AcGalβ1,4(NeuAcα2,3)Galβ1,4Glc-ceramide) (Jeyakumar et al., 2002; Tropak et al., 
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2004). Mutations in the gene encoding HexA impair HexA folding and lead to extensive 
ERAD, which causes loss of HexA activity in the lysosome (Jeyakumar et al., 2002). The 
G269S substitution, one of the most prevalent HexA mutations, is a misfolding, non-
inactivating mutation (Maegawa et al., 2007). Similar to GC variants containing 
misfolding mutations, native folding of G269S HexA mutant results in increase in 
enzymatic activity (Mu et al., 2008b; Tropak et al., 2004).  
 
1.4. Ca2+ homeostasis 
1.4.1. Intracellular Ca2+ homeostasis  
The ER is the main dynamic Ca
2+
 storage compartment in the cell (Meldolesi and 
Pozzan, 1998). This organelle regulates Ca
2+
 flows in response to extracellular stimuli or 
intracellular signaling by releasing Ca
2+
 ions from the ER ([Ca
2+
]=1 mM) and taking up 
Ca
2+
 ions from the cytosol ([Ca
2+
]=100 nM) (Brostrom and Brostrom, 2003; Verkhratsky, 
2005). Even though [Ca
2+
]ER is estimated to be in the mM range, the concentration of free 
Ca
2+
 ions in the ER is much lower due to the presence of Ca
2+
-binding proteins that bind 
Ca
2+
 ions with high capacity and low affinity (Meldolesi and Pozzan, 1998). Some of 
these proteins function as Ca
2+
 buffers and are capable of rapidly releasing large fluxes of 
Ca
2+
 to the cytosol upon ER channel openings. Other Ca
2+
-dependent proteins are ER 
luminal chaperones such as BiP, Calnexin, and Calreticulin. Thus, fluctuations in 
[Ca
2+
]ER affect the activities of ER chaperones and the maintenance of Ca
2+
 homeostasis 
is crucial to guarantee the folding of proteins in the ER (Michalak et al., 2002).  
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The maintenance of intracellular Ca
2+
 homeostasis is achieved by regulating Ca
2+
 
channels in the ER membrane as well as those in the plasma membrane. Ca
2+
 is released 
from the ER through ryanodine receptors (RyR) or inositol 1,4,5-trisphosphate (IP3) 
receptors, and pumped into the ER by Ca
2+
-ATPases (SERCA pumps; Figure 1.6) 
(Baumann and Walz, 2001). The entry of Ca
2+
 across the cell membrane involves voltage 
and ligand-gated Ca
2+
 channels, such as L-type voltage-gated Ca
2+
 channels (LTCC) (Lee 
et al., 2002; Putney et al., 2001).  
 
1.4.2. Impairment of Ca2+ homeostasis in GD  
The hallmark of GD is the accumulation of glucosylceramide, GC substrate, 
which may lead to impairment of neuronal functions. Particularly, neurons show 
enhanced levels of tubular ER elements and an increase in ER Ca
2+
 release (Korkotian et 
al., 1999). Analyses of Ca
2+
 release from rat brain microsomes cultured in the presence of 
glucosylceramide revealed that glucosylceramide induces Ca
2+
 release via RyR (Figure 
1.6), through a mechanism that may involve the redox sensor of the RyR, but has no 
effect on Ca
2+
 release via IP3 receptors. A number of other glycosphingolipids and 
sphingolipids were not found to affect Ca
2+
 release (Lloyd-Evans et al., 2003). In 
addition, it was shown that enhancement of ER Ca
2+
 release by glucosylceramide via the 
RyR leads to neuronal cell death, suggesting that impaired Ca
2+
 homeostasis may play a 
significant role in the neuropathophysiology of GD (Pelled et al., 2005).  
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Figure 1.6. Impairment of Ca
2+
 homeostasis in GD cells. [Ca
2+
]ER is regulated by 
ryanodine receptors (RyR), inositol 1,4,5-trisphosphate (InsP3R) receptors, and Ca
2+
-
ATPases (SERCA pumps). L-type voltage-gated Ca
2+
 channels (LTCC) mediate Ca
2+
 
flow through the plasma membrane. The accumulation of GC substrate, 
glucosylceramide, causes Ca
2+
 release via RyR. 
 
1.4.3. Impairment of Ca2+ homeostasis is a common theme among LSDs 
Evidence shows impairment of Ca
2+
 homeostasis in a number of LSDs. Excessive 
accumulation of ganglioside GM2 in a mouse model of Sandhoff disease significantly 
reduces the rate of ER Ca
2+
 uptake through SERCA pumps. This effect was prevented by 
feeding Sandhoff disease mice with N-butyl-deoxynojirimycin (NB-DNJ), an inhibitor of 
glycolipid synthesis that reduces GM2 storage (Pelled et al., 2003). Changes in SERCA 
activity could be mimicked by culturing neuronal cells derived from the mouse model of 
Sandhoff disease in the presence of a SERCA inhibitor, thapsigargin, or by adding GM2 
to the culture medium (Pelled et al., 2003). Reduced ER Ca
2+
 uptake through SERCA 
pump caused by substrate accumulation was also observed in a mouse model of 
Niemann–Pick A disease (Ginzburg and Futerman, 2005).  
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Chapter 2 
State of the art 
2.1. Proteostasis regulators 
Modulation of the proteostasis network was recently explored as a strategy to 
rescue the folding of unstable proteins. Small molecules that modulate general cellular 
pathways to influence protein folding and degradation were reported to rescue the folding 
of unstable, degradation-prone proteins (Lu et al., 2010; Mu et al., 2008b). These small 
molecules were thus defined as proteostasis regulators (Balch et al., 2008). Proteostasis 
regulators were shown to enhance the folding, trafficking and activity of multiple enzyme 
variants associated with the development of two clinically distinct LSDs, namely 
Gaucher’s and Tay-Sachs disease (Mu et al., 2008b). A table summarizing the small 
molecules used in this study is reported in Appendix A. 
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2.1.1. Celastrol 
The heat shock response is a conserved reaction of the cell in all organisms to 
elevated temperatures (heat shock or heat stress) or other stressful stimuli (Lindquist, 
1986). Its activation leads to the upregulation of heat shock proteins that promote native 
folding and prevent denaturation and aggregation of misfolded proteins (Lindquist, 1986; 
Morimoto et al., 1997). The expression of heat shock proteins is regulated by the 
transcription heat shock factor 1 (Wu, 1995).  
Celastrol is a small molecule that induces the heat shock response in human cells 
through the activation of the heat shock transcription factor 1 (Appendix A; Westerheide 
et al., 2004; Wu, 1995). Treatment of fibroblasts derived from GD patients with celastrol 
was shown to partially restore the folding of multiple GC variants (Mu et al., 2008b). The 
activity of L444P GC was dramatically enhanced to 23% of wild type cellular activity, 
which would be compatible with effective treatment (Schueler et al., 2004). Celastrol 
treatment was also reported to enhance GC activity in GD cells harboring N370S and 
G202R GC variants (Mu et al., 2008b). However, the narrow therapeutic window of 
celastrol (0.2-1 μM, due to the cytotoxicity observed using higher concentrations) is a 
major concern associated with the use of celastrol as a drug candidate. Nevertheless, 
celastrol was used to demonstrate proof-of-principle that it is possible to modulate 
general pathways that control proteostasis to rescue the native folding of unstable 
proteins and to motivate the discovery of less toxic equivalents.  
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2.1.2. MG-132 
Inhibition of proteasomal degradation causes accumulation of misfolded proteins, 
which, in turn, leads to upregulation of chaperone expression in the cytoplasm and in the 
ER (Awasthi and Wagner, 2005; Bush et al., 1997; Liao et al., 2006). Treatment of GD 
patient-derived cells with a widely used proteasome inhibitor, MG-132, dramatically 
rescues folding and activity of L444P GC (Appendix A; Mu et al., 2008b; Schueler et al., 
2004). In cells treated with MG-132, the L444P GC variant, which is normally barely 
detectable in the lysosome due to extensive ERAD, is trafficked to the lysosome to an 
extent similar to WT GC (Sawkar et al., 2005). However, MG-132 also present a narrow 
therapeutic window (0.2-0.8 µM) and results in cytotoxicity if administered at high 
concentrations (Mu et al., 2008b). 
 
2.1.3. Proteostasis regulation in fibroblasts derived from patients with Tay-Sachs 
disease 
Modulation of the proteostasis network to rescue native folding of unstable, 
degradation-prone proteins was also explored in fibroblasts derived from patients with 
Tay-Sachs disease, an LSD clinically distinct from GD but also caused by deficiency of a 
fundamental lysosomal enzyme. As previously described, Tay-Sachs disease is caused by 
mutations in the gene encoding hexosaminidase A (HexA, (Tropak et al., 2004)). 
Impaired folding of HexA in the ER leads to extensive ERAD and consequent loss of 
lysosomal HexA activity (Jeyakumar et al., 2002). The G269S mutation destabilizes 
HexA native structure causing loss of enzyme activity. MG-132 treatment enhances 
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HexA activity to a level expected to ameliorate clinical symptoms (Mu et al., 2008b; 
Tropak et al., 2004). Similar results were observed in cells treated with celastrol (Mu et 
al., 2008b). Interestingly, the highest increase of HexA activity in Tay-Sachs cells was 
obtained using the same range of concentration of celastrol and MG-132 reported in the 
Gaucher’s disease study.  
 
2.2.  Modulation of Ca2+ homeostasis 
The use of inhibitors of Ca
2+
 channels was also explored as a strategy to enhance 
the cellular folding capacity by modulating the proteostasis network.. In GD neurons, 
glucosylceramide accumulation impairs Ca
2+
 homeostasis by depleting [Ca
2+
]ER via RyRs 
(Korkotian et al., 1999; Lloyd-Evans et al., 2003; Pelled et al., 2005). The folding and 
activity of mutated GC was enhanced in GD cells cultured in the presence of calcium 
channel blockers, and in particular L-type Ca
2+
 channels (LTCC) blockers such as 
diltiazem and verapamil (Mu et al., 2008a).  
LTCC blockers bind to high voltage activated channels on the plasma membrane 
and thus lower cytosolic free [Ca
2+
] (Hockerman et al., 1997; Triggle, 2006). 
Phenylalkylamines, benzothiazepines, and 1,4-dihydropyridines are the three main 
classes of LTCC blockers and act by binding to three distinct LTCC receptor sites 
(Hockerman et al., 1997). Verapamil and diltiazem, prototypes of phenylalkylamines and 
benzothiazepines, respectively, are FDA-approved drugs for the treatment of 
hypertension and cardiac arrhythmias (Hockerman et al., 1997). Mu et al. reported that 
treatment with either diltiazem or verapamil inhibits LTCC and partially restores the 
  
23 
 
activity of N370S and L444P GC in fibroblasts derived from GD patient (Mu et al., 
2008a). The authors also reported that treatment with diltiazem or verapamil rescue the 
folding of mutated enzyme variants associated with neuronopathic forms of other LSDs, 
namely α-mannosidosis and type IIIA mucopolysaccharidosis  (Mu et al., 2008a).  
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Chapter 3 
Objectives 
The objective of this work is to develop cell and protein engineering strategies to 
restore the folding and activity of unstable, degradation-prone enzyme variants associated 
with the development of lysosomal storage disorders (LSDs). LSDs are a group of 
inherited diseases characterized by deficient activities of lysosomal enzymes. A number 
of enzyme variants derive from mutations that do not impair enzyme activity, but rather 
destabilize their native folding. Mutated proteins that fail to fold into their native 
conformation are retrotranslocated to the cytoplasm for ER-associated degradation 
(ERAD). However, if these mutated protein variants can be forced to fold into their 3D 
native structure, they retain their catalytic activity. The aim of this work is to modulate 
endogenous cellular pathways that underlie maintenance of protein folding (the 
proteostasis network) to enhance the innate folding capacity of the cell and promote 
native folding of unstable protein variants.  
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Gaucher’s disease (GD), the most common LSD, is used as a model system in this 
study. Evidence showed that culturing fibroblasts derived from GD patients at reduced 
permissive temperature results in enhanced folding and activity of mutated GC variants 
(Sawkar et al., 2006a). These culturing conditions are expected to influence the cellular 
folding pathways thereby providing a folding environment favorable for mutated GC 
folding. For this reason, we hypothesized that the innate protein folding machinery under 
physiologic conditions is unable to cope with the destabilizing effect of the L444P 
substitution. To test this hypothesis, we propose to modulate the proteostasis network to 
enhance the innate cellular folding capacity of fibroblasts derived from patients with GD 
and test the folding, cellular localization and activity of mutated enzyme variants.  
Loss of GC activity has been repeatedly studied in patient-derived fibroblasts 
(Jonsson et al., 1987). The cellular accumulation and enzymatic activity of GC variants in 
fibroblasts are used as an indication of the severity of GD manifestations and of the 
development of neuronopathic symptoms (Beutler et al., 1984; Michelakakis et al., 1995). 
Moreover, patient-derived fibroblasts are specifically used for diagnostic purposes 
because residual activity of mutated GC variants is related to the clinical severity of the 
disease (Bodamer and Hung; Meivar-Levy et al., 1994). Thus, fibroblasts derived from 
patients with GD were used in this study. Particularly, we focused on fibroblasts derived 
from patients carrying the L444P GC allele because it is normally associated with 
neuronopathic symptoms in homozygous patients.  
This work is organized under the following specific aims: 
Aim 1. Modulating Ca
2+
 homeostasis to enhance the folding and activity of 
mutated GC. The accumulation of GC substrate, glucosylceramide, causes Ca
2+
 efflux 
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from the ER through RyRs. Since [Ca
2+
]ER affects the function of the ER chaperones, we 
suspected that excessive [Ca
2+
]ER efflux impairs ER folding in GD cells. We 
hypothesized that folding and activity of mutated GC variants could be rescued by 
counteracting the effect of glucosylceramide accumulation on [Ca
2+
]ER depletion. We 
used RyR blockers and LTCC blockers to restore intracellular Ca
2+
 homeostasis and 
study the effect of [Ca
2+
]ER on the folding of the L444P GC mutant in patient-derived 
fibroblasts.  
Aim 2. Inhibiting ERAD to prolong ER retention of mutated GC.  We 
hypothesized that ERAD, which catalyzes the degradation of misfolded proteins, is the 
rate limiting steps in the folding of unstable enzyme variants. We propose to inhibit 
specific steps of the ERAD pathway to prevent the disposal of mutated enzyme and 
enhance the pool of folding intermediates amenable to folding rescue. We treated 
fibroblasts derived from patients with GD with small molecules that target the 
recognition or retrotranslocation of misfolded substrates for ERAD pathway and evaluate 
the folding and activity of enzyme variants.  
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Chapter 4 
Results 
4.1. Ca2+ homeostasis modulation enhances the amenability of 
L444P glucosylcerebrosidase to proteostasis regulation in 
fibroblasts derived from patients with Gaucher’s disease 
4.1.1. Introduction 
Ca
2+
 homeostasis plays a fundamental role in the biogenesis of secretory proteins. 
The activities of a number of ER chaperones including BiP/GRP78, Calnexin (CNX), and 
Calreticulin (CRT) are influenced by fluctuations in [Ca
2+
]ER
 
(Michalak et al., 2002), 
which is highly regulated through Ca
2+
 release and uptake mechanisms. In GD cells, the 
accumulation of GC substrate, glucosylceramide, causes excessive [Ca
2+
]ER release, 
specifically via RyRs (Korkotian et al., 1999; Lloyd-Evans et al., 2003; Pelled et al., 
2005). We speculated that by affecting ER Ca
2+
 mobilization, glucosylceramide 
accumulation impairs ER folding, and thus may further hamper the folding of unstable 
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GC variants. Interestingly, impairment of Ca
2+
 homeostasis is a common theme in LSDs, 
as substrate accumulation causes lowered [Ca
2+
]ER in Sandhoff disease (Pelled et al., 
2003) and Niemann-Pick type A disease (Ginzburg and Futerman, 2005)  
Based on the notions that i) [Ca
2+
]ER
 
affects ER chaperone expression and activity 
(Michalak et al., 2002), and ii) mutated GC folding is rescued by enhancement of the 
innate cellular folding capacity (Mu et al., 2008b), we hypothesized that the folding of 
LSD-associated enzymes could be restored by inhibiting [Ca
2+
]ER depletion. We used 
fibroblasts derived from patients with GD carrying the L444P GC allele to investigate the 
effect of [Ca
2+
]ER modulation on the folding, trafficking and activity of this unstable GC 
variant. We demonstrated that modulation of [Ca
2+
]ER
 
through inhibition of RyRs in 
L444P GC fibroblasts, although not directly promoting considerable rescue of L444P GC 
folding, creates a “wild-type like” ER environment, more amenable to proteostasis 
regulation, particularly through upregulation of the ER chaperone BiP. We also profiled 
global gene expression of cells treated with a RyRs blocker and a proteostasis modulator, 
MG-132, and report mechanistic studies validating the influence of selected ER 
chaperones, and particularly BiP, on L444P GC folding. 
 
4.1.2. Results 
Inhibition of [Ca
2+
]ER depletion enhances MG-132 function as a proteostasis 
regulator in fibroblasts derived from GD patients carrying L444P GC 
Fibroblasts derived from patients with GD carrying the L444P GC variant were 
treated with small molecule RyRs blockers, including ryanodine (Appendix A; Buck et 
al., 1992; Nagasaki and Fleischer, 1988), dantrolene (Appendix A; Ward et al., 1986), 
  
29 
 
ruthenium red (Buck et al., 1992), and 1,1'-diheptyl-4,4'-bipyridinium (DHBP) dibromide 
(Buck et al., 1992; Kang et al., 1994), and GC activity was evaluated with the intact cell 
GC activity assay as previously described (Sawkar et al., 2002). L444P GC activity was 
observed to increase up to 1.3-fold in cells treated with ryanodine (10-20 μM final 
medium concentration) for 48 hrs, and decrease with increasing time of incubation. 
Although this modest increase in GC activity is expected to ameliorate GD symptoms 
(Schueler et al., 2004), we attempted to further enhance ryanodine-mediated L444P GC 
folding by combining ryanodine with a proteostasis regulator, MG-132, which is known 
to rescue L444P GC folding through a mechanism distinct from [Ca
2+
]ER modulation (Mu 
et al., 2008b). Co-administration of ryanodine (20 µM) and MG-132 (0.4 µM) for 72 hrs 
resulted in a 2.6-fold increase (p<0.001) in L444P GC activity compared to untreated 
cells, which is higher than the increase in activity observed using ryanodine (1.1-fold) or 
MG-132 (2.1-fold) under the same conditions (Figure 4.1.1A). We hypothesized that 
ryanodine at least partially restores Ca
2+
 homeostasis, reestablishing a “wild type-like” 
folding environment in the ER of L444P GC fibroblasts that is normally characterized by 
Ca
2+ 
efflux induced by substrate accumulation and thus impaired folding. Restoring a 
more “wild-type like” ER environment is not sufficient to considerably enhance the 
folding of L444P GC, a severely destabilized enzyme variant normally immediately 
targeted to ERAD. However, by preventing [Ca
2+
]ER depletion, ryanodine treatment 
renders L444P GC cells more amenable to proteostasis regulation via MG-132. 
Among the RyRs blockers tested, dantrolene was also observed to enhance L444P 
GC activity increase induced by MG-132 treatment. Co-administration of dantrolene (1 
µM) and MG-132 (0.4 µM) resulted in 2.1-, 2.3-, and 2.5-fold increase in L444P GC 
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activity after 48, 72 and 96 hours of incubation, respectively (Figure 4.1.1B). Ruthenium 
red and DHBP were observed to marginally influence L444P GC activity, and were not 
used in further studies due to their cytotoxic effect (data not shown). 
 
 
Figure 4.1.1. Treatment with RyRs blockers and MG-132 enhances GC activity in 
L444P GC patient-derived fibroblasts. Cells were cultured with A) ryanodine and MG-
132, and B) dantrolene and MG-132. GC enzymatic assays were performed after 48, 72 
and 96 hrs. Reported L444P GC activities were normalized to the activity of untreated 
cells (left y axis) and corresponded to the fraction of WT GC activity (right y axis). The 
data is reported as mean ± SD. 
 
Because glucosylceramide accumulation causes [Ca
2+
]ER depletion, we 
hypothesized that inhibition of glucosylceramide synthesis would provide an alternative 
mechanism to RyRs inhibition to prevent abnormal [Ca
2+
]ER efflux. Inhibition of 
glucosylceramide synthesis was investigated using N-butyl-deoxynojirimycin (NB-DNJ; 
Appendix A) (Platt et al., 2001) and MG-132. A barely detectable increase in L444P GC 
activity was observed in patient-derived fibroblasts cultured with NB-DNJ for up to 192 
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hrs and assayed every 24hrs. However, co-administration of NB-DNJ (5 nM) and MG-
132 (0.4 µM) resulted in 2.8-fold increase in L444P GC activity (p<0.01), which is 
higher than the 2.3-fold increase obtained with MG-132 alone (Figure 4.1.2), 
demonstrating that inhibition of glucosylceramide synthesis in GD cells recapitulates the 
effect of RyRs blockers on L444P GC folding. 
 
 
Figure 4.1.2. Inhibition of glucosylceramide synthesis enhances the activity of L444P 
GC in patient-derived fibroblasts. Cells were treated with NB-DNJ and MG-132 for 
192 hrs. Relative GC activities (p<0.01) were calculated as described in Figure 4.1.1. 
Experiments were repeated three times; data points were reported as mean ± SD.  
 
To confirm that the detected increase in GC activity is caused by partial 
restoration of L444P GC folding and trafficking, the protein’s glycosylation state was 
evaluated with endoglycosidase H (EndoH). EndoH hydrolyzes immature N-glycan 
complexes; thus, Western blot analyses of EndoH treated proteins using a GC specific 
antibody reveal a low MW band corresponding to partially glycosylated, ER-retained GC 
(EndoH-sensitive) and a high MW band corresponding to fully glycosylated lysosomal 
GC (EndoH-resistant) (Maley et al., 1989). The total protein content of cells cultured 
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with ryanodine (20 µM), dantrolene (1 µM), MG-132 (0.4 µM), or a combination thereof, 
was subjected to EndoH treatment and GC was detected by Western blot (Figure 4.1.3A). 
The quantification of EndoH-sensitive or resistant bands is reported in Figure 4.1.3B. In 
untreated cells 90% of L444P GC was EndoH-sensitive, and total GC amount and 
glycosylation state did not change with cell growth (Figure 4.1.3A-B). Dantrolene or 
ryanodine treatment resulted in a 1.6- and 1.9-fold increase in total L444P GC, 
respectively, and a decrease of EndoH-sensitive fraction to 60% of total GC (Figure 
4.1.3B). MG-132 treatment caused an increase of total and EndoH-resistant L444P GC, 
as previously reported (Mu et al., 2008b). In cells treated with MG-132 and ryanodine or 
MG-132 and dantrolene (corresponding to 2.5- and 2.1-fold activity increase, 
respectively), the total GC content increased 2.4- and 2.1-fold, respectively, and nearly 
50% of L444P GC was present in the EndoH-resistant form (Figure 4.1.3B). 
  
33 
 
 
Figure 4.1.3. L444P GC glycosylation state of patient-derived fibroblasts treated 
with RyRs blockers and MG-132. A) L444P GC glycosylation state in cells treated with 
ryanodine (20 µM), dantrolene (1 µM), MG-132 (0.4 µM), or a combination thereof for 
48 hrs. EndoH treated and untreated samples were analyzed by Western blot. B) 
Quantification of bands in EndoH-treated samples. EndoH-sensitive bands (ER retained 
GC) is reported in the white portion of the bars, and that of EndoH-resistant bands 
(lysosomal GC) is reported in the black top portions. Band analyses and quantifications 
were conducted using NIH Java Image analysis software. Dant: Dantrolene; Rya: 
Ryanodine. 
 
BiP expression is upregulated in fibroblasts derived from GD patients 
carrying L444P GC treated with ryanodine and MG-132 
Cell treatment with MG-132 and ryanodine partially restore L444P GC activity to 
33% of wild type GC, which is expected to be compatible with effective treatment 
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(Schueler et al., 2004). Thus, RyRs blockers and MG-132 were used to identify 
transcriptional changes in the proteostasis network potentially associated with the rescue 
of L444P GC folding. 
Quantitative RT-PCR of the mRNA for representative ER chaperones was used to 
investigate the influence of RyRs blockers and MG-132 on the ER folding machinery 
(Kleizen and Braakman, 2004). L444P GC cells were incubated with MG-132 (0.4 µM), 
dantrolene (1 µM), ryanodine (20 µM), or a combination thereof (Figure 4.1.4), and 
relative mRNA expression levels for BiP, Calnexin (CNX), Calreticulin (CRT), and 
GRP94 were evaluated. BiP expression was increased by ryanodine treatment (2.4-fold), 
and ryanodine and MG-132 co-treatment (6.0-fold). Similar results were obtained with 
dantrolene (2.7-fold), and dantrolene and MG-132 (2.9-fold) (Figure 4.1.4A). The 
difference in ryanodine- and dantrolene-mediated BiP upregulation might result from 
their binding to distinct sites of RyRs (Fill and Copello, 2002). Analogous results were 
observed for CNX expression upon treatment with ryanodine (3.1-fold), and ryanodine 
and MG-132 (5.3-fold), or treatment with dantrolene (1.8-fold), and dantrolene and MG-
132 (3.2-fold) (Figure 4.1.4B). Enhancement of CRT and GRP94 mRNA expression was 
altered less than 2.5-fold (Figure 4.1.4C and D). 
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Figure 4.1.4. Transcriptional expression of representative ER chaperones in L444P 
GC patient-derived fibroblasts treated with RyRs blockers and MG-132. Relative 
mRNA expression of A) BiP (p<0.01), B) CNX (p<0.01), C) CRT (p<0.05), and D) 
GRP94 (p<0.05) evaluated by quantitative RT-PCR in L444P GC fibroblasts treated with 
ryanodine (20 μM), dantrolene (1 μM) and MG-132 (0.4 μM) for 24 hrs. mRNA 
expression levels of treated cells were corrected for the expression of the housekeeping 
gene GAPDH, and normalized to those of untreated cells. The data is reported as mean ± 
SD.  
 
ER chaperone protein concentrations in cells treated with ryanodine and MG-132 
were evaluated by Western blot (Figure 4.1.5A) and bands were quantified with ImageJ 
software (Figure 4.1.5B). BiP protein accumulation was enhanced by co-treatment with 
ryanodine and MG-132 (2-fold), compared to untreated cells or cells treated with either 
molecule, but we failed to observe significant changes in CNX, CRT, and GRP94 protein 
levels. These results are consistent with RT-PCR analyses; with the exception of CNX 
expression, for which the transcriptional increase is not reflected at the translational level, 
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suggesting that CNX upregulation induced by cell treatment with MG-132 and ryanodine 
does not translate into enhanced accumulation of CNX protein. 
 
 
Figure 4.1.5. Translational expression of representative ER chaperones in L444P 
GC patient-derived fibroblasts. A) Western blot analyses and B) quantification of 
representative ER chaperones in cells treated with ryanodine (20 μM), and MG-132 (0.4 
μM) for 48 hrs. GAPDH expression is used as loading control. Experiments were 
repeated three times and the data  is reported as mean ± SD. 
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Proteostasis regulation and modulation of Ca
2+
 homeostasis alters global 
gene expression in fibroblasts derived from GD patients carrying L444P GC  
Global gene expression was evaluated as described in Materials and Methods in 
cells treated with MG-132 (0.4 μM), ryanodine (20 μM), and both MG-132 and 
ryanodine, for 24 hrs.  We particularly focused on the expression of genes encoding for 
ER chaperones, UPR-associated proteins, LSD, lipid metabolism, and ERAD (Figure 
4.1.6; expression levels are reported as fold-change relative to untreated cells in 
Appendix B; p<0.01). 
 
 
Figure 4.1.6. Profiling of gene expression in L444P GC patient-derived fibroblasts 
treated with MG-132 and ryanodine. Transcriptional modulation of genes encoding for 
ER-resident chaperones, and associated with UPR, LSD, lipid metabolism, and ERAD in 
L444P GC fibroblasts untreated and treated with MG-132 (0.4 μM) and ryanodine (20 
μM). The expression of representative genes is reported as a heat map (p<0.01); colors in 
the heat map represent deviation from the average control phenotype: green, lower 
activity; red, higher activity.   
  
38 
 
Among ER chaperones, BiP was upregulated by MG-132 (1.8-fold increase), not 
considerably affected by ryanodine, but further upregulated by co-treatment with both 
MG-132 and ryanodine (2.3-fold). This data suggests a synergistic effect of RyRs 
inhibition and proteostasis regulation on BiP expression and that BiP expression level 
may correlate with the rescue of L444P GC activity. Other ER chaperones and BiP co-
chaperones, including GRP94, Erdj1, Erdj3, and BAP were found to be modestly 
upregulated by MG-132 and ryanodine. Interestingly, even though their expression is 
virtually unaltered by treatment with ryanodine, in most cases co-administration of MG-
132 and ryanodine resulted in upregulation of their expression to an extent higher than 
treatment with MG-132 alone. Analysis of the ER chaperones involved in the CNX/CRT 
cycle revealed that again treatment with ryanodine alone barely changes gene expression, 
but may attenuate or enhance the change in expression caused by MG-132. Particularly, 
ryanodine enhances the upregulatory effect of MG-132 on CNX and EDEM3, while it 
attenuates the upregulatory effect on α-glucosidase I and II, which suggests that 
ryanodine functions by enhancing the ER folding capacity and attenuating ERAD in cells 
treated with MG-132 (Appendix B). 
The expression of genes involved in the unfolded protein response (UPR) was 
also analyzed. UPR is a complex tripartite pathway activated by excessive load of 
unfolded and misfolded proteins in the ER (Ron and Walter, 2007). Three ER 
transmembrane proteins are responsible for the transduction of UPR signals: double-
stranded RNA-activated protein kinase-like ER kinase (PERK), inositol requiring kinase 
1 (IRE1), and activating transcription factor 6 (ATF6, Ron and Walter, 2007). The three 
UPR signal transduction pathways are all induced upon culturing cells with MG-132, but 
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do not seem to be significantly affected by ryanodine. As part of the first UPR branch, 
activation of double-stranded RNA-activated ER kinase (PERK; Perkins et al., 1999) 
induces phosphorylation of the translation initiation factor-2 (eIF2), which lowers 
translational initiation to reduce the load of protein that enters the ER. PERK and eIF2α 
were upregulated by MG-132 (1.5- and 1.4-fold respectively, Appendix B), but not 
significantly affected by treatment with ryanodine. Phosphorylated eIF2α also induces the 
translation of ATF4, a key regulator of the cellular response to amino acid deprivation 
(1.3-fold increase, MG-132; 1.5-fold increase, MG-132 and ryanodine; Kleizen and 
Braakman, 2004). When ER proteostasis is restored, PERK is quickly de-phosphorylated 
by GADD34, which expression was also found to be upregulated (1.7-fold, MG-132; 1.9-
fold, MG-132 and ryanodine). These results, taken together, suggest that the PERK arm 
of the UPR is both upregulated and inhibited, suggesting that cell treatment with MG-132 
and ryanodine simultaneously initiate cycles of moderate UPR activation and inhibition. 
We suggest that MG-132 and ryanodine cause brief pulses of UPR, optimal to induce 
controlled enhancement of the cellular folding capacity and to promote native folding of 
unstable, misfolding-prone GC variants without disruptive effects on the proteostasis 
network.  
The second UPR branch is responsible for enhancement of the ER protein 
processing capacity. It consists in a relatively long adaptation process, which includes 
upregulation of ER chaperones expression, enhancement of ERAD, and enlargement of 
the ER, collectively initiated by the proteins ATF6 and XBP-1 (Schroder and Kaufman, 
2005). IRE1 is an ER transmembrane protein structurally similar to PERK that contains 
an ER luminal signal sensing domain and a cytoplasmic protein kinase domain (Lee et 
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al., 2003). Binding of unfolded proteins to the IRE1 luminal domain triggers trans-
autophosphorylation of its kinase domains, which is responsible for splicing of XBP1 
mRNA, an activator of ER chaperones and ERAD genes expression (Lee et al., 2003). 
The unspliced form of XBP1 mRNA encodes for XBP1 precursor, a more labile protein 
that represses UPR target genes. As the cell recovers and IRE1 is inactivated, XBP1 
precursor inhibits the pathway activated by the spliced XBP1 form. Interestingly, IRE1 is 
downregulated 2.0-fold in cells treated with MG-132, while ryanodine attenuates this 
downregulation to 1.6-fold decrease in expression (Appendix B).  In cells treated with 
MG-132 the expression of unspliced XBP1 is downregulated (1.2-fold). Several XBP-1-
dependent UPR target genes, as reported by Lee et al., are listed in Appendix B, and 
include the DnaJ/Hsp40-like genes, p58IPK, ERdj4, and HEDJ, as well as EDEM, 
protein disulfide isomerase-P5, and ribosome-associated membrane protein 4 (RAMP4) 
(Lee et al., 2003). Depending on the specific co-chaperone interaction, BiP can promote 
either folding or ERAD of misfolded proteins. Erdj4 and p58IPK are both involved in 
BiP-mediated degradation via ERAD and are both upregulated (Erdj4: 2.8-fold by MG-
132, and 4.6-fold by MG-132 and ryanodine; p58IPK: 1.8-fold by MG-132, and 2.5-fold 
by MG-132 and ryanodine). Other XBP-1-dependent UPR target genes are mildly 
upregulated by MG-132 and ryanodine. ATF6, along with XBP1, transduces the response 
of this branch of the UPR. ATF6 is a type II transmembrane glycoprotein with a stress-
sensing segment that faces the ER lumen and a basic leucine zipper motif oriented to the 
cytoplasm (Schroder and Kaufman, 2005). Under ER stress, ATF6 is translocated from 
the ER to the Golgi where it is activated by site 1 protease (S1P) and site 2 protease (S2P) 
cleavage, which promote its translocation to the nucleus, where it induces the expression 
  
41 
 
of UPR genes (Figure 4.1.6. and Appendix B) (Schroder and Kaufman, 2005). Both 
ATF6 and its excising gene S1P are upregulated by MG-132 treatment (1.2- and 1.7-fold, 
respectively), suggesting that the ATF6-dependent branch of the UPR is induced. Several 
UPR target genes, such as SREBPs that promotes lipid biogenesis, are also activated by 
S1P and S2P by proteolytic cleavage. 
The third branch of the UPR is activated when ER proteostasis cannot be re-
established and culminates with induction of apoptosis (Scorrano et al., 2003). Cell death 
induced by ER stress is activated by translocation of the death effectors BAX and BAK 
from the ER to the mitochondria (Scorrano et al., 2003).  IRE1-mediated activation of 
Jun N-terminal kinase (JNK) might contribute to cell death by inactivating the anti-
apoptotic regulator BCL-2 (Urano et al., 2000). PERK-mediated upregulation of the 
transcription factor CHOP is also suggested to repress BCL-2 expression (Oyadomari and 
Mori, 2004). Gene expression profiling reported in Appendix B shows that BAX is 
downregulated by MG-132, thus preventing apoptosis, while BAK is upregulated (1.7-
fold increase in expression), suggesting that MG-132 acts by inducing specific apoptotic-
promoting machinery. Interestingly, although BCL-2 is downregulated 6.2-fold by MG-
132, ryanodine attenuates MG-132 downregulation (5-fold), suggesting that restoring 
Ca
2+
 homeostasis through RyRs inhibition has an anti-apoptotic effect in GD cells.  
LSD-associated genes were found to be generally upregulated by MG-132 and to 
exhibit a higher increase in expression upon treatment with both MG-132 and ryanodine. 
Specifically, genes associated with the development of Gaucher’s, Niemann-Pick, Tay-
Sachs, and Fabry diseases were upregulated by MG-132 (1.5-, 3.4-, 1.9- and 6.0-fold, 
respectively) and MG-132 and ryanodine (1.4-, 3.9-, 2.0- and 7.3-fold, respectively). The 
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increase in L444P GC expression by MG-132 and ryanodine co-treatment was confirmed 
at the protein level by Western blot analyses (Figure 4.1.7). UPR activation is known to 
enhance lipid metabolism to increase the size of the ER and dilute the load of misfolded 
proteins (Schroder and Kaufman, 2005). Because LSD-associated proteins are enzymes 
normally involved in lipid degradation, we suggest that LSD genes' upregulation in 
L444P GC cells treated with MG-132 and ryanodine is a response of the cell to MG-132-
induced UPR activation.  L444P GC and other LSD-associated enzyme variants are 
normally targeted to ERAD. Thus, increasing the concentration of newly synthesized 
enzyme through small molecule treatment could be a particularly appealing therapeutic 
strategy as it inevitably increases the pool of ER intermediates amenable to folding 
rescue.  
 
 
Figure 4.1.7. Total GC accumulation in L444P GC patient-derived fibroblasts 
treated with ryanodine and MG-132. Western blot analyses of total GC in cells treated 
with ryanodine (20 μM), and MG-132 (0.4 μM) for 48 hrs. GAPDH expression is used 
as loading control. 
 
The ER membrane SREBP1 and SREBP2 regulate lipid metabolism (Schroder 
and Kaufman, 2005). They form a complex with SREBP cleavage-activating protein 
(SCAP). Changes in cellular lipid and cholesterol levels induce a conformational change 
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in SCAP, which in turn escorts SREBPs to the Golgi, where S1P and S2P sequentially 
activate their cytosolic domain by proteolytic cleavage. SREBP1 and 2 are upregulated 
by treatment with MG-132 (1.2- and 1.7-fold, respectively). However, co-treatment with 
ryanodine and MG-132 attenuates MG-132 upregulatory effect. In addition, the 
expression of a number of genes involved in sphingolipid biosynthesis that are 
upregulated by UPR (Schroder and Kaufman, 2005) is increased in cells treated with 
MG-132. For instance, serine palmitoyltransferase (SPTLC, LCB1) is composed of two 
subunits, and both of their expression is increased 1.5-fold by treatment with MG-132. 
Sphingomyelin synthase 1 (SGMS1) and sphingosine-1-phosphate phosphatase 1 
(SGPP1) expression is also upregulated 1.2- and 2.5-fold, respectively, by MG-132 
(Epstein et al., 2012).  
This effect of MG-132 on L444P GC expression also explains the increase in 
L444P GC folding previously observed in GD cells treated with MG-132 and a chemical 
chaperone (N-(n-nonyl)-deoxynojirimycin, NN-DNJ) (Mu et al., 2008b). L444P GC was 
initially shown not to be amenable to chemical chaperoning (Sawkar et al., 2002), for 
which the mechanism, as mentioned before, is based on active site binding-mediated 
stabilization of the native enzyme structure, and most likely does not affect the 
independently folding domain containing the L444P substitution (Brumshtein et al., 
2007). A dramatic increase in L444P GC activity was demonstrated by subjecting MG-
132-treated L444P GC patient-derived cells to brief, temporally spaced pulses of low 
concentration NN-DNJ treatment. Such dosing schedule was devised to promote MG-
132-mediated enhancement of the folded L444P GC pool that can be chaperoned through 
the secretory pathway by NN-DNJ (Mu et al., 2008b). MG-132-induced L444P GC 
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upregulation provides a complementary explanation to the synergistic effect of MG-132 
and NN-DNJ on L444P GC folding. Although additional experiments are required to 
investigate this speculation, we suggest that GC upregulation could be exploited to 
enhance rescue of mutated GC folding by combining it with enhancement of cellular 
folding via proteostasis modulation. 
UPR activates ERAD to enhance the degradation of misfolded proteins (Travers 
et al., 2000). Activation of ERAD, in turn, attenuates ER stress-induced UPR by lowering 
the accumulation of ERAD substrates, thus restoring proteostasis. Chaperones in the ER 
lumen sense the accumulation of misfolded proteins. As described above, ER chaperones, 
and particularly BiP, are upregulated by cell treatment with MG-132 and ryanodine. 
Recognition of misfolded proteins in the ER is typically coupled with their targeting to 
the cytoplasm through the retrotranslocation channel. Genes involved in non glycosylated 
substrates targeting are generally upregulated by MG-132 (Appendix B). SEL1L and 
Hrd1, which form an ER membrane retrotranslocation complex, undergo an 1.8- and 1.9-
fold increase in expression, respectively. CNX/CRT-mediated retrotranslocation of 
glycosylated proteins involves EDEM3-catalyzed substrate extraction and 
retrotranslocation by p97. p97 is upregulated 1.3- and 2.7-fold by MG-132 treatment and 
MG-132 and ryanodine co-treatment, respectively. Sec61A1 and p58IPK, two 
components of the translocon complex are upregulated by both MG-132 treatment and 
MG-132 and ryanodine co-treatment (Sec61A1: 1.5- and 1.3-fold by MG-132 treatment 
and MG-132 and ryanodine co-treatment, respectively; p58IPK: 1.8- and 2.5-fold by 
MG-132 treatment and MG-132 and ryanodine co-treatment, respectively). As misfolded 
substrates are extracted from the ER to the cytoplasm, they are ubiquinated. 
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Retrotranslocation and ubiquitination of substrates are effectively coupled by the activity 
of E3 ubiquitin ligases. Among ubiquitination-associated proteins, UBE1, an ubiquitin-
activating enzyme, is upregulated 1.4-fold by MG-132. E2 ubiquitin-conjugating enzyme 
UBC7, and E3 ubiquitin ligases SEL1L, HRD1, TEB4, GP78 all exhibit increases in 
mRNA expression (1.8-, 1.8-, 1.9-, 2.3- and 2.7-fold respectively; Appendix B), 
indicating a general upregulatory effect on the ubiquitination pathway. Finally, substrates 
are tethered to the proteasome and de-ubiquitinated prior to proteasomal degradation. The 
cytoplasmic complex P97-UFD1-NPL4 is involved in proteasomal targeting and 
degradation, and its three components are all significantly upregulated by MG-132 (2.7-, 
3.8- and 3.0-fold, respectively), but not particularly affected by ryanodine treatment. 
MG-132 and ryanodine treatment also influence the expression of proteins that 
directly affect the activity of RyRs. RyRs are inactivated by Ca
2+
/calmodulin-dependent 
protein kinase II (CAMK2) phosphorylation (Wang and Best, 1992), an effect reversed 
by phosphatase PPP1C and by CAMK2 inhibitor (CAMK2N1). CAMK2 δ and γ subunits 
were upregulated by MG-132 (1.5- and 3.3-fold), and by MG-132 and ryanodine (1.6 and 
3.8-fold), while CAMK2 inhibitor and PPP1C were greatly downregulated (CAMK2N1: 
4.0-fold decrease, MG-132; 5.9-fold decrease, MG-132 and ryanodine. PPP1C α subunit: 
1.9-fold decrease, MG-132). 
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Plasmid-induced BiP overexpression and chromosomal BiP upregulation 
enhance MG-132 function as a proteostasis regulator in fibroblasts derived from 
GD patients carrying L444P GC 
In order to test whether ryanodine and MG-132-induced ER chaperone 
upregulation directly influences L444P GC folding, we attempted overexpressing the 
genes of interest in GD cells. Patient-derived fibroblasts were transfected with 
tetracycline-inducible plasmids encoding BiP, CNX, CRT, or GRP94 and induced for 24, 
48, and 72 hrs as described in Methods. L444P GC activities are reported in Figure 4.1.8. 
As expected, GC activity was undetectable in untreated cells (cells transfected with 
empty vector, pcDNA4/TO). BiP overexpression resulted in modest restoration of L444P 
GC folding (1.4-fold upon induction with 0.2 µg/ml tetracycline for 72 hrs; Figure 
4.1.8C). In order to recapitulate the effect of RyRs blockers and MG-132 co-treatment on 
BiP upregulation, cells transfected for BiP overexpression were cultured in the presence 
of MG-132. The combined effect of BiP overexpression (tetracycline 0.2 µg/ml) and 
MG-132 (0.4 µM) for 48 hrs resulted in 6.0-fold increase in L444P GC activity with 
respect to the activity of untreated cells, compared to a 3.3-fold increase in cells treated 
only with MG-132 (Figure 4.1.8B).  Remarkably, this increase in L444P GC activity 
corresponds to 75% of wild type GC activity. Overexpression of CNX, CRT and GRP94 
did not result in considerable increase in L444P GC activity, with the exception of a 
modest increase observed upon overexpression of CRT (Figure 4.1.8H). 
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Figure 4.1.8. GC activities of L444P GC patient-derived fibroblasts overexpressing 
BiP, CNX, CRT, or GRP94 and treated with MG-132. Chaperone expression was 
induced by media changes with tetracycline-supplemented media 24 hrs post-transfection 
and every 24 hrs thereafter. GC enzymatic assays were performed after inducing the 
expression of (A-C) BiP, (D-F) CNX, (G-I) CRT, and (J-L) GRP94 for 24, 48, and 72 
hrs. Relative GC activities were obtained normalizing the activity of cells transfected 
with empty pcDNA4/TO (□), cells transfected with empty pcDNA4/TO and treated with 
0.4 μM MG-132 (■), cells transfected with chaperone-expressing pcDNA4/TO (△), and 
cells transfected with chaperone-expressing pcDNA4/TO and treated with 0.4 μM MG-
132 (▲), by the activity of untreated cells transfected with empty pcDNA4/TO. The data 
is reported as mean ± SD. 
 
 
Cellular accumulation of Myc-tagged recombinantly expressed chaperones was 
confirmed by ELISA analyses. Tetracycline induction (0.2 µg/ml) caused a 3 to 5-fold 
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increase in recombinant protein concentration (Figure 4.1.9). Because GC activity assays 
were conducted by investigating a range of induction conditions, this variability in 
protein accumulation did not hamper our ability to study the effect of different 
chaperones on L444P GC activity. 
 
 
Figure 4.1.9. Plasmid-induced chaperone expression in L444P GC patient-derived 
fibroblasts. ELISA analyses of induced and non-induced transfected cells expressing A) 
BiP, B) CNX, C) CRT and D) GRP94. Chaperone expression was induced with 0.2 
μg/ml tetracycline for 48 hrs before whole cell lysates were collected, and incubated in 
anti-Myc antibody coated plates. Recombinant chaperones were detected with 
chaperone specific antibodies.  
 
To further test the hypothesis that BiP expression directly influences the rescue of 
L444P GC folding, we attempted upregulating chromosomal BiP expression. The Ca
2+
 
ionophore A23187 is known to induce the BiP promoter (BiP670) at concentrations that 
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do not induce depletion of cytoplasmic [Ca
2+
] (Appendix A; Chao and Lin-Chao, 1992; 
Drummond et al., 1987). GC activity was evaluated in L444P GC patient-derived 
fibroblasts cultured with A23187 and/or MG-132 (Figure 4.1.10). Co-treatment with 
A23187 and MG-132 resulted in a 2.7-fold increase in L444P GC activity, which is 
higher than what was observed in cells treated with A23187 (1.3-fold) and MG-132 (2.0-
fold), confirming that upregulation of BiP expression enhances MG-132 mediated rescue 
of L444P GC folding. 
 
 
Figure 4.1.10. L444P GC activity of patient-derived fibroblasts treated with 
A23187 and MG-132. Relative L444P GC activities of cells treated with A23187 and 
MG-132 for 48 hrs (p<0.01). GC activities were obtained as described in Figure 4.1.1 
and reported as mean ± SD. 
 
Ryanodine ameliorates cytotoxicity induced by proteostasis regulation in 
fibroblasts derived from GD patients carrying L444P GC 
Korkotian et al reported that treatment with ryanodine (50 µM) limits the 
neurotoxic effect of glucosylceramide accumulation and significantly reduces neuronal 
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death (Korkotian et al., 1999). We asked a) if ryanodine treatment also rescues 
cytotoxicity caused by glucosylceramide accumulation in L444P GC fibroblasts, b) if 
MG-132 treatment by inducing ER stress and UPR causes cytotoxicity and apoptosis, 
and, in that case, c) whether ryanodine treatment limits MG-132-induced cytotoxicity in 
L444P GC fibroblasts. Cells treated with these small molecules were tested with the 
CytoGLO
TM
 Annexin V-FITC Apoptosis Detection Kit and analyzed by flow cytometry. 
This assay allows detecting membrane rearrangement (Annexin V binding) and 
fragmentation (propidium iodide (PI) binding), which normally occur during early and 
late apoptosis, respectively. Fluorescence intensities of both Annexin V-FITC and PI in 
cells treated with small molecules were evaluated and compared to the values obtained 
from untreated cells. A total number of 10,000 cells were counted, and the number of 
cells that bind to Annexin V-FITC or PI in cells treated with small molecules was 
compared to the number of cells that bind to Annexin V-FITC or PI in untreated cells. As 
shown in Table 4.1, Annexin V binding increased 28% in wild type fibroblasts treated 
with MG-132, which was reduced to 15% by treatment with ryanodine and MG-132. 
Thapsigargin (1 µM) and tunicamycin (1 µM) were used as controls as they are known to 
induce cytotoxicity by activating the UPR (Chen et al., 2007; Duksin and Bornstein, 
1977) and resulted in 14% and 13% increase in Annexin V binding, respectively, 
compared to untreated cells (Table 4.1). When the same experiment was conducted using 
GD fibroblasts carrying L444P GC, Annexin V binding increased 18% and 19%, 
respectively, suggesting that L444P GC cells are more susceptible to the cytotoxic effect 
induced by thapsigargin and tunicamycin treatment than wild-type fibroblasts.  In L444P 
GC fibroblasts Annexin V binding increased 43% upon MG-132 (0.4 µM) treatment 
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(considerably higher than in wild-type fibroblasts). MG-132 treatment was also observed 
to cause a 12% increase in cell death (PI binding). However, Annexin V binding 
decreased 8% upon ryanodine (20 µM) treatment, recapitulating the results previously 
reported by culturing hippocampal neurons (Korkotian et al., 1999). Treatment with 
ryanodine and MG-132 caused Annexin V binding to decrease to 37%, and cell death to 
decrease to 9.3% (Table 4.1), suggesting that ryanodine alleviates MG-132 induced 
toxicity, and in agreement with the hypothesis that RyRs inhibition recreates a “wild 
type-like” ER folding environment in L444P GC fibroblasts.  
 
Table 4.1. Cell toxicity assay (ryanodine treatment) (p<0.01) 
Cell 
type 
Cell treatment 
Annexin V PI 
Population
1 
Binding
2 
Population
1 
Binding
2 
L444P 
GD 
Thapsigargin 1.1±0.1 18±0.6 5.0±0.3 10±0.1 
Tunicamycin -0.1±0.1 19±0.2 7.5±0.1 8.2±0.1 
MG-132 -3.4±0.1 43±0.3 12±0.4 7.0±0.1 
Ryanodine -0.3±0.1 -7.9±0.7 4.7±0.6 -1.6±0.2 
MG-132+ryanodine -2.2±0.1 37±0.5 9.3±0.5 1.8±0.1 
WT 
Thapsigargin -9.1±0.1 14±0.2 5.7±1.6 21±0.4 
Tunicamycin -11±0.1 13±0.4 7.1±0.7 41±0.2 
MG-132 -3.9±0.1 28±0.7 2.9±0.3 23±0.1 
Ryanodine 1.9±0.2 -12±1.5 0.9±0.6 -13±0.7 
MG-132+ryanodine -3.2±0.1 15±1.8 1.7±0.1 43±0.7 
1
 Change (%) in number of cells bound to Annexin V/PI compared to untreated cells. 
2
 Change (%) in Annexin V/PI binding affinity compared to untreated cells. 
 
Because one of the key mechanisms of MG-132-mediated rescue of mutated GC 
folding is UPR induction, we asked whether cell treatment with thapsigargin and 
tunicamycin could rescue L444P GC folding. GD cells treated with low concentrations  
of thapsigargin and tunicamycin (0.01-1 nM) for up to 48 hrs gave rise to a 4- and 2-fold 
increase in L444P GC activity, an effect that is quickly lost at higher concentrations and 
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longer incubation times (Figure 4.1.11), confirming that mild UPR activation promotes 
mutated GC folding as observed using MG-132. 
 
 
Figure 4.1.11. L444P GC activity of patient-derived fibroblasts treated with 
thapsigargin and tunicamycin. Relative L444P GC activities of cells treated with A) 
thapsigargin (p<0.01), and B) tunicamycin (p<0.01, 48 hrs; p<0.001, 96 hrs). GC 
activities were obtained as described in Figure 4.1.1 and reported as mean ± SD. 
 
4.1.3. Discussion 
We demonstrated that inhibiting glucosylceramide-induced [Ca
2+
]ER depletion via 
RyRs enhances MG-132 ability to restore L444P GC proteostasis. Simply preventing 
[Ca
2+
]ER efflux through inhibition of RyRs or inhibition of glucosylceramide synthesis 
only modestly increased L444P GC activity. In agreement with this finding, 
overexpression of L444P GC in wild-type fibroblasts does not to result in L444P GC 
native folding (Ron and Horowitz, 2005), suggesting that the innate (wild type) folding 
capacity cannot cope with the destabilizing effect of the L444P substitution. However, 
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creating a more “wild-type like” folding environment in the ER of GD cells harboring 
L444P GC via RyRs or glucosylceramide synthesis inhibition enhances MG-132-
mediated L444P GC proteostasis. 
Ong et al. recently reported a study showing rescue of mutated GC folding by 
[Ca
2+
]ER modulation (Ong et al., 2010). siRNA knockdown of RyRs and treatment of GD 
fibroblasts with RyRs inhibitors was reported to modestly increase the pool of L444P GC 
that escapes ERAD and restore L444P GC activity. The enzyme activity in this study was 
measured with a lysed cell GC activity assay. Dantrolene at 25 µM was particularly 
effective (1.3-fold increase in L444P GC activity), in agreement with what is reported 
here using dantrolene and ryanodine (Figure 4.1.1). However, dantrolene (10 µM) 
treatment was reported to lower L444P GC activity, despite increasing the pool of 
EndoH-resistant glycosylated L444P GC that trafficks to the lysosome, implying that in 
cells treated with dantrolene L444P GC is natively folded, but is not enzymatically 
active. This result was attributed to L444P GC hypersensitivity inhibition (Ong et al., 
2010), supported by i) the lowered L444P GC activity rescue observed in cells treated 
with MG-132 (0.25 µM) and dantrolene (10 µM) compared to increase in activity 
observed in cells treated with MG-132 alone, and by ii) dantrolene's (10-300 µM) 
inhibitory effect on wild type GC in vitro. We hypothesize that the lowered L444P GC 
activity observed in cells treated with MG-132 and dantrolene is due to the high 
dantrolene concentration and long incubation times used, which in our hands were 
observed to give rise to cell toxicity. Furthermore, we suggest that chemical chaperones 
can have an inhibitory effect on the folding of L444P GC due to their mechanism of 
action based on binding to the enzyme active site and stabilization of the native enzyme 
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structure (Pelled et al., 2005). This inhibitory effect is likely due to the fact that the 
L444P substitution is located in an independently folding domain (distinct from the 
active-site domain, (Brumshtein et al., 2007)) that is not stabilized by the interaction of 
chemical chaperones with the L444P GC active site. However, this inhibitory effect 
(Sawkar et al., 2002) is not likely to apply to proteostasis regulators, including MG-132, 
or small molecules, such as RyRs inhibitors, that do not directly bind to GC 
intermediates. 
We demonstrated that BiP is upregulated in cells treated with MG-132, and, 
particularly, in cells treated with MG-132 and ryanodine (Figure 4.1.4A), and that BiP 
plasmid and chromosomal overexpression enhances MG-132-mediated L444P GC 
activity increase (Figure 4.1.8 and 4.1.10). BiP upregulation was previously reported to 
delay conformational maturation and ER export of misfolded substrates through 
enhanced formation of complexes with substrate intermediates (Gorbatyuk et al., 2010; 
Muresan and Arvan, 1998; Xu and Robinson, 2009). The concentration-dependence of 
BiP-mediated increase in ER retention was repeatedly observed only for BiP bona fide 
substrates (Dorner and Kaufman, 1994; Dorner et al., 1992). These studies support the 
notion that increasing BiP expression enhances BiP binding to L444P GC that, in turn, 
promotes folding and enhances residence time in the ER. The fact that BiP 
overexpression does not accelerate substrate folding and ER export is also in agreement 
with our finding that BiP overexpression or ryanodine treatment alone does not 
considerably enhance L444P GC activity (Figure 4.1.8A and 4.1.1A).  
BiP is an ER lumenal protein whose specific function as promoter of ER folding 
or ERAD critically depends on a number of interaction partners (Vembar et al., 2010). 
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The question of how BiP plasticity can be channeled for the enhancement of L444P GC 
folding still remains open. However, based on the notions that i) enhanced BiP binding 
retards substrate conformational maturation, but does not promote substrate ERAD and 
ii) this effect is only observed for BiP physiologic substrates, and thus would not 
compromise the folding of other proteins, we speculate that BiP function as an ER 
folding-inducing chaperone rather than ERAD-inducing chaperone. This feature can be 
exploited to effectively rescue the folding of L444P GC. BiP also plays a fundamental 
role in activating the UPR. Accumulation of misfolded proteins results in BiP release and 
activation of the three UPR transducers, IRE1, PERK, and ATF6 (Ron and Walter, 2007). 
We suggest that BiP upregulation mediated by RyRs inhibitors, as well as plasmid or 
chromosome induced BiP overexpression, results in increased ER capacity to cope with 
the accumulation of misfolded proteins without activation of the UPR. This notion is 
supported by evidence that ryanodine treatment does not induce UPR, as shown by global 
gene expression analysis (Figure 4.1.6 and Appendix B), and that it ameliorates the 
cytotoxic effect of MG-132, as shown above (Table 4.1).   
Constitutive overexpression of CNX, among ER chaperones, was previously 
reported to modestly enhance L444P GC proteostasis by increasing the formation of 
complexes between L444P GC and CNX (Ong et al., 2010). Increased binding of CNX to 
endogenous or overexpressed GC mutants, was also previously demonstrated (Ron and 
Horowitz, 2005), and the instability of different GC variants, their ER retention, and 
CNX binding were correlated to their ERAD targeting. As shown herein, L444P GC 
activity increase correlates strongly with the chaperone expression levels, which were 
modulated uniquely through the use of a tetracycline-inducible plasmid. The study 
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reported herein reveals that CNX mRNA levels were upregulated by small molecule 
treatment to a lower extent than what was observed for BiP mRNA (Figure 4.1.4), and 
overexpression of CNX did not significantly increase L444P GC activity (Figure 4.1.8B). 
Our findings, together with previously reported evidence (Ron and Horowitz, 2005), 
suggest that CNX does not play a key role in the rescue of L444P GC folding. 
Cellular [Ca
2+
] measurements reported recently (Ong et al., 2010) revealed an 
increase in [Ca
2+
]ER
 
and decrease in cytoplasmic [Ca
2+
] in cells treated with RyRs 
inhibitors. This data supports our conclusion that RyRs blockers restore a more “wild-
type like” ER environment in L444P GC cells through modulation of Ca2+ homeostasis. 
However, we suggest that careful consideration of small molecule concentrations be used 
in these studies to avoid misinterpreting the effect of cell treatment with [Ca
2+
] 
modulators on the folding of L444P GC activity. For instance, contrary to what has been 
previously reported (Mu et al., 2008a; Ong et al., 2010), we show that thapsigargin 
greatly enhances the folding of L444P GC if used at concentrations (0.01-1 nM) that 
moderately induce UPR, but are too low to have a significant effect on [Ca
2+
]ER depletion 
(100 nM, (Yoshida et al., 2006)) (Figure 4.1.11). Cell treatment with considerably higher 
thapsigargin concentrations (>100 nM) causes [Ca
2+
]ER depletion, sustained UPR 
activation, and induction of apoptosis (Futami et al., 2005; Jin, 2006), and is not 
compatible with L444P GC folding rescue as previously reported (Mu et al., 2008a; Ong 
et al., 2010). 
In summary, results from this study suggest that modulation of Ca
2+
 homeostasis, 
and, particularly, inhibition of excessive [Ca
2+
]ER, synergize with proteostasis regulation 
to rescue the folding and trafficking of L444P GC in fibroblasts derived form GD 
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patients. Partial restoration of L444P GC folding is attributed to the function of the main 
ER chaperone, BiP, and modest upregulation of the UPR. BiP mRNA and protein levels 
were found to be increased (6- and 2-fold, respectively) in cells treated with a RyRs 
blocker (ryanodine) and a proteostasis regulator (MG-132). BiP overexpression and 
chromosomal induction were shown to enhance MG-132 mediated L444P GC activity. 
Global gene expression analysis revealed that UPR genes were upregulated by MG-132 
treatment, as expected (Mu et al., 2008b). However, UPR inhibition genes, normally 
activated as protein homeostasis is restored, were also found to be induced (Figure 4.1.6). 
MG-132 seems to partially restore L444P GC folding by inducing short pulses of UPR, 
or possibly moderate UPR activation, which is likely to promote folding of this 
destabilized GC variant without disruptive effects on native protein homeostasis. Gene 
expression analysis also revealed that ryanodine mediated RyRs inhibition does not 
directly induce heat-shock stress and UPR, but slightly enhances or attenuates MG-132-
induced modulation of key genes of the proteostasis network, thereby boosting the 
folding-promoting activity of MG-132 (Figure 4.1.6). In addition, RyRs inhibition 
partially rescues GD cells from MG-132-induced cytotoxicity and apoptosis induction 
(Table 4.1). These results i) strengthen our hypothesis that RyRs inhibition counteracts 
the deleterious effect of substrate accumulation on Ca
2+
 homeostasis and promotes a 
more “wild-type like” folding environment in L444P GC fibroblasts, and ii) underscore 
the value of RyRs blockers as research tools to investigate proteostasis modulation in GD 
cells.  
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4.2. Lacidipine remodels protein folding and Ca2+ homeostasis 
in Gaucher’s disease fibroblasts: A mechanism to rescue 
mutant glucocerebrosidase activity 
4.2.1. Introduction 
Ca
2+
 homeostasis influences the biogenesis of secretory proteins and the activity 
of a number of ER chaperones (Michalak et al., 2002). The data reported in the previous 
chapter suggested that restoring Ca
2+
 homeostasis in GD fibroblasts enhances the ER 
folding capacity and facilitates native folding of highly unstable, degradation-prone 
L444P GC folding (Wang et al., 2011a). Treatment with ryanodine receptor (RyRs) 
blockers was shown to counteract the effect of glucosylceramide accumulation on 
[Ca
2+
]ER efflux, re-establish Ca
2+
 homeostasis, and create an environment more 
conducive to native folding of L444P GC. However, it resulted in only limited rescue of 
L444P GC folding (Chapter 4.1).  
L-Type Ca
2+
 channel (LTCC, Figure 4.2.1) blockers bind to high-voltage 
activated channels on the plasma membrane and lower cytosolic free [Ca
2+
] (Hockerman 
et al., 1997; Triggle, 2006). Phenylalkylamines, benzothiazepines, and 1,4-
dihydropyridines are the three main classes of LTCC blockers and include molecules that 
bind to three distinct LTCC receptor sites (Hockerman et al., 1997). Verapamil and 
diltiazem, prototypes of phenylalkylamines and benzothiazepines, respectively, are FDA-
approved drugs for the treatment of hypertension and cardiac arrhythmias (Hockerman et 
al., 1997). They were previously reported to partially rescue the folding of GC variants, 
but their mechanism remains elusive (Mu et al., 2008a; Sun et al., 2009). We asked 
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whether this reported rescue of mutated GC folding is a general property of LTCC 
blockers and whether their ability to modulate intracellular [Ca
2+
] correlates with the 
resulting increase in mutated GC activity. We investigated LTCC blockers with 1,4-
dihydropyridine structure including the prototype nifedipine and a series of second and 
third generation derivatives (Epstein, 1999; Pepine, 1989). We found that cell treatment 
with lacidipine, a third generation 1,4-dihydropyridine that antagonizes Ca
2+
 mobilization 
through LTCC and RyRs (Gunther et al., 2008; Wishart et al., 2008) results in enhanced 
folding, trafficking and activity of mutated GC variants. Particularly, we show here that 
lacidipine functions as a proteostasis regulator in patient-derived GD fibroblasts and 
rescues L444P GC folding with considerably higher efficiency than any other Ca
2+
 
channel blocker reported in this study or previously (Mu et al., 2008a; Ong et al., 2010; 
Wang et al., 2011a). By investigating lacidipine-induced modulation of intracellular 
[Ca
2+
] and of cellular folding pathways, we demonstrated that lacidipine functions by 
lowering cytoplasmic [Ca
2+
], by remodeling the expression of ER chaperones and the 
unfolded protein response (UPR), and by reducing cellular toxicity and apoptosis 
induction. Thus, lacidipine activates mechanistically different cellular events that have 
been previously reported in association with distinct small molecule proteostasis 
regulators (Wang et al., 2011a). 
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Figure 4.2.1. Lacidipine modulates intracellular Ca
2+
 homeostasis. [Ca
2+
]ER is 
regulated by ryanodine receptors (RyRs), IP3 receptors, and SERCA pumps. L-type 
voltage-gated Ca
2+
 channels (LTCC) mediate Ca
2+
 flow through the plasma membrane. 
Lacidipine inhibits extracellular Ca
2+
 influx through LTCC and ER Ca
2+
 efflux through 
RyRs.  
 
4.2.2. Results  
Treatment with small molecule LTCC and RyRs blockers enhances folding, 
trafficking and activity of mutated GC in fibroblasts derived from patients with 
Gaucher’s disease  
We investigated a series of LTCC blockers with a 1,4-dihydropyridine structure, 
particularly lacidipine, lercanidipine, nicardipine, nifedipine, and nitrendipine (Appendix 
A; Triggle, 2003). Patient-derived fibroblasts harboring L444P GC were treated with a 
range of Ca
2+
 blocker concentrations for 5 days, and GC activities were evaluated every 
24 hours with the intact cell GC enzymatic activity assay (Mu et al., 2008b). Verapamil 
and Diltiazem, prototypes of the other two classes of LTCC blocker (phenylalkylamines 
and benzothiazepines, respectively; Appendix A) were included for comparison in these 
experiments as they were previously reported to partially rescue mutated GC folding (Mu 
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et al., 2008a). Culturing conditions resulting in maximal rescue of L444P GC activity are 
reported in Figure 4.2.2. L444P GC activity was observed to increase up to 2.0-fold in 
cells treated with lacidipine (20 μM, final medium concentration, p<0.001) for 72 hrs 
compared to untreated cells, which corresponds to about 25% of the WT cellular activity, 
and is expected to ameliorate GD symptoms (Schueler et al., 2004). A milder increase in 
L444P GC activity (1.2-fold, p<0.01) was detected in the same cells treated with 
lercanidipine and nicardipine (20 μM) for 72 hrs, compared to untreated cells (Figure 
4.2.2). Nifedipine and nitrendipine treatment failed to rescue the activity of L444P GC 
(data not shown). Lacidipine was observed to enhance the activity of L444P GC to a 
considerably higher degree than diltiazem and verapamil tested under the same 
conditions. Maximal L444P GC activity increase was observed upon treatment with 
diltiazem (10 μM, 1.4-fold) and verapamil (5 μM, 1.1-fold) for 120 hrs (Figure 4.2.2).  
Similar to diltiazem and verapamil, lacidipine blocks LTCC on the plasma 
membrane as well and RyRs on the ER membrane (Gunther et al., 2008). Nicardipine and 
lercanipine are known to block LTCC and were reported to interfere with the release of 
Ca
2+
 from the ER (Wishart et al., 2008), while nifedipine and nitrendipine are thought to 
only interact with LTCC (Gunther et al., 2008). These reported binding interactions, 
together with results from the GC activity assays described above (Figure 4.2.2), suggest 
a correlation between the mechanism of Ca
2+
 mobilization and the extent of L444P GC 
folding rescue. Specifically, treatment with Ca
2+
 blockers that antagonize both LTCC and 
RyRs result in a higher increase in L444P GC activity.  
 
  
64 
 
 
Figure 4.2.2. Treatment of GD patient-derived fibroblasts with LTCC blockers 
enhances L444P GC activity. Relative L444P GC activities in cells treated with 
lacidipine (20 μM), lercanidipine (20 μM) and nicardipine (20 μM) for 72 hrs, and 
diltiazem (10 μM) and verapamil (5 μM) for 120 hrs. Relative GC activities were 
evaluated by normalizing GC activities measured in treated cells to the activity of 
untreated cells (left y axis), (p<0.01 if not specified; *p<0.001). The corresponding 
fraction of WT GC activity is reported (right y axis). Experiments were repeated three 
times and data points are reported as mean ± SD.  
 
We asked whether treatment with proteostasis regulators, such as MG-132 and 
celastrol, applied in combination with LTCC blockers enhance the rescue of L444P GC 
folding, as previously demonstrated for RyRs blockers (Chapter 4.1). Proteostasis 
regulation was achieved via cell treatment with either MG-132 (0.6 µM) or celastrol (0.6 
µM), which are known to rescue L444P GC folding through a mechanism distinct from 
Ca
2+
 homeostasis modulation (Mu et al., 2008b). Patient-derived fibroblasts were 
cultured in medium supplemented with an LTCC blocker and a proteostasis regulator for 
up to 5 days, and GC activity was measured every 24 hours (Figure 4.2.3A-E). Co-
administration of lacidipine (20 µM) and MG-132 for 72 hrs resulted in a dramatic 
increase in L444P GC activity compared to untreated cells (5.1-fold, p<0.001; Figure 
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4.2.3A), which corresponds to 64% of wild type GC activity and is significantly higher 
than what was observed treating the cells only with lacidipine (2.0-fold, Figure 4.2.2) or 
MG-132 (2.7-fold, Figure 4.2.3A). Addition of lacidipine was observed to also enhance 
celastrol mediated increase in L444P GC activity (2.6-fold, Figure 4.2.3A). Interestingly, 
lercanidipine (20 µM) and nicardipine (5 µM) enhanced MG-132 mediated L444P GC 
activity rescue (4.3-fold and 3.2-fold, respectively; p<0.001), but failed to improve 
celastrol activity (Figure 4.2.3B-C). Diltiazem and verapamil were observed to synergize 
with proteostasis regulators with lower efficiency than 1,4-dihydropyridines. Particularly, 
treatment with diltiazem (10 µM) and verapamil (5 µM) moderately enhanced celastrol 
mediated L444P GC folding rescue (2.1- and 1.9-fold, respectively), and failed to alter 
MG-132 mediated rescue (Figure 4.2.3D-F).  
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Figure 4.2.3. LTCC blockers synergize with proteostasis regulators to enhance 
L444P GC activity patient-derived fibroblasts. Relative L444P GC activities in 
L444P GC cells treated with a proteostasis regulator (MG-132, 0.6 μM; celastrol, 0.6 
μM) and an LTCC blocker: A) lacidipine, B) lercanidipine, and C) nicardipine for 72 
hrs, D) diltiazem, and E) verapamil for 120 hrs. GC activities were obtained as 
described in 4.2.2 and are reported as mean ± SD.  
 
N370S GC is the most prevalent GC variant among patients with GD (Meivar-
Levy et al., 1994). Cellular folding rescue and enhancement of N370S GC activity was 
previously reported (Mu et al., 2008a; Mu et al., 2008b; Offman et al., 2010; Sawkar et 
al., 2002; Wang et al., 2011a; Yu et al., 2007). As opposed to L444P GC, N370S GC 
folding was previously shown to be amenable to rescue with GC specific chemical 
chaperones, suggesting that the location and nature of these two mutations have different 
destabilizing effects on the enzyme’s native folding and cellular trafficking (Sawkar et 
al., 2005; Sawkar et al., 2002). In addition, GD patients carrying the N370S GC variant 
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never present the neuronopathic GD symptoms typically associated with L444P GC 
(Michelakakis et al., 1995). To verify whether lacidipine mediated rescue of mutated GC 
folding is restricted to the L444P GC variant, GD patient-derived fibroblasts carrying 
N370S GC were cultured in the presence of lacidipine and proteostasis regulators, and 
GC activities were measured. Diltiazem was used for comparison, as it was previously 
shown to elicit an increase in N370S GC folding (Mu et al., 2008a). Similar to what was 
reported above for L444P GC fibroblasts, lacidipine (20 µM) treatment for 72 hrs 
resulted in an increase in N370S GC activity (1.8-fold, p<0.001; Figure 4.2.4A), which 
was enhanced by the addition of MG-132 and celastrol (3.4- and 2.0-fold, respectively, 
Figure 4.2.4B). Diltiazem (10 µM, 1.4-fold; Figure 4.2.4A) mediated increase in N370S 
GC activity was enhanced by the addition of MG-132 and celastrol (3.1- and 1.7-fold, 
respectively, Figure 4.2.4C). These results suggest that lacidipine rescues the folding and 
activity of different mutated GC variants and thus functions as a proteostasis regulator in 
fibroblasts derived from patients with GD.  
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Figure 4.2.4. The activity of N370S GC is enhanced in cells treated with LTCC 
blockers. A) Relative N370S GC activities in cells treated with lacidipine (20 μM) and 
diltiazem (10 μM) for 72 hrs. Relative N370S GC activities in cells treated a proteostasis 
regulator (MG-132, 0.6 μM; celastrol, 0.6 μM) and an LTCC blocker: B) lacidipine, and C) 
diltiazem. Relative GC activities were obtained as described in Figure 4.2.2 and are 
reported as mean ± SD.  
 
In order to confirm that the increase in activity detected in cells treated with 
lacidipine results from rescue of mutated GC folding and trafficking to the lysosome, we 
tested the glycosylation state and cellular localization of L444P GC.  
GC glycosylation state was investigated by endoglycosidase H (EndoH) treatment 
(Maley et al., 1989), which, as describe in Chapter 4.1, allows distinguishing between 
partially glycosylated GC retained in the ER (low molecular weight) and fully 
glycosylated, lysosomal GC (high molecular weight) in Western blot analyses. The total 
protein content of cells cultured in media supplemented with lacidipine (20 µM), MG-
132 (0.6 µM), celastrol (0.6 µM), or a combination thereof for 48 hrs was subjected to 
EndoH treatment, and GC was detected by western blot. A representative western blot is 
shown in Figure 4.2.5A, and quantification of EndoH-resistant and EndoH-sensitive GC 
bands is shown in Figure 4.2.5B. In untreated cells, nearly all L444P GC was detected as 
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EndoH-sensitive, as expected (Mu et al., 2008b). However, a band corresponding to 
EndoH-resistant L444P GC was detected in cells treated with lacidipine and its intensity 
was comparable to that detected in cells cultured with MG-132 or celastrol (the results 
obtained from the experiments conducted with MG-132 and celastrol have been 
published previously (Mu et al., 2008b), and are reported here for comparison). 
Interestingly, lacidipine treatment resulted in an about 1.5-fold increase of total L444P 
GC, and a decrease of the EndoH-sensitive fraction to 80% of total GC. Co-treatment 
with lacidipine and MG-132 was observed to cause a 2.5- and 1.7-fold increase in the 
EndoH-resistant pool of L444P GC, compared to cells treated only with lacidipine and 
MG-132, respectively (Figure 4.2.5A-B). This increase in mature, fully glycosylated GC 
correlates with results obtained from GC enzymatic assays.   
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Figure 4.2.5. Treatment of GD patient-derived fibroblasts with lacidipine promotes 
L444P GC glycosylation. A) Western blot analyses of EndoH treated and untreated total 
protein content of L444P GC fibroblasts cultured with lacidipine (20 µM), MG-132 (0.6 
µM), and celastrol (0.6 µM) for 48 hrs and detected using GC-specific antibody. The solid 
and dashed arrows indicate, respectively, EndoH resistant and EndoH sensitive bands. PR, 
proteostasis regulator. Lac, lacidipine; Dil, diltiazem; MG, MG-132; Cel, celastrol. B) 
Quantification of GC bands detected by western blot. Lower MW, EndoH-sensitive bands 
corresponding to GC retained in the ER were quantified and are reported in the white 
portion of the bars, and quantification of higher MW, EndoH-resistant bands 
corresponding to lysosomal GC are reported in the black top portions. Band analyses and 
quantifications were conducted using NIH Java Image analysis software.  
 
L444P GC cellular localization was evaluated using immunofluorescence 
microscopy of fibroblasts derived from patients with GD carrying the L444P GC variant 
treated with lacidipine (20 µM) and/or MG-132 (0.6 µM) for 48 hrs and using antibodies 
specific for GC, for an ER marker (Calnexin, CNX), and for a lysosomal marker (LAMP-
1). Co-localization of GC and CNX (Figure 4.2.6A) and GC and LAMP-1 (Figure 
4.2.6B) is reported in green. L444P GC was barely detectable in untreated cells, 
presumably due to extensive ERAD (Figure 4.2.6A-B), as previously reported 
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(Michelakakis et al., 1995). Analysis of merged images revealed the presence of a large 
pool of enzyme in the ER (Figure 4.2.6A) and in the lysosome (Figure 4.2.6B) in 
lacidipine-treated cells, suggesting that lacidipine treatment increases the pool of folded 
L444P GC that escapes ERAD and trafficks to the lysosomes. Moreover, co-treatment 
with lacidipine and MG-132 further increased the pool of ER and lysosomal GC (Figure 
4.2.6A-B), demonstrating that these two molecules synergize to rescue L444P GC folding 
and trafficking, and confirming the results obtained from enzymatic assays (Figure 
4.2.3A). 
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Figure 4.2.6. Cellular localization of L444P GC in patient-derived fibroblasts treated 
with lacidipine. Immunofluorescence microscopy of (A) GC and CNX (an ER marker), 
and (B) GC and LAMP1 (a lysosomal marker) in L444P GC fibroblasts. Cells were 
treated with lacidipine (20 µM) and MG-132 (0.6 µM) for 48 hrs. Colocalization of CNX 
(red, column 1) and GC (grey, column 2) is shown in green (column 3). Colocalization of 
LAMP1 (red, column 1) and GC (blue, column 2) is also shown in green (column 3). 
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We previously showed that RyRs inhibition creates an ER environment more 
amenable to L444P GC proteostasis in patient-derived fibroblasts (Chapter 4.1). The 
results reported here suggest that combining inhibition of RyRs and LTCC enables direct 
rescue of L444P GC proteostasis. Lacidipine treatment, however, seems to rescue L444P 
GC folding and activity more efficiently than the other LTCC blockers tested. This result 
suggests that lacidipine is a more potent modulator of intracellular [Ca
2+
] than other Ca
2+
 
blockers used here and previously (Mu et al., 2008a; Ong et al., 2010; Wang et al., 
2011a) or that cell treatment with lacidipine rescues mutant GC folding by activating 
other cellular mechanisms that influence the mutated GC folding free energy diagram. 
The following studies were conducted to investigate these possibilities. Diltiazem was 
used as comparison in these studies because, although it also inhibits LTCC and RyRs 
and was reported to enhance the folding of mutated GC variants (Mu et al., 2008a), it is 
shown here to rescue L444P GC folding to a significantly lower extent than lacidipine. In 
addition, the mechanism involved in rescue of folding for GC variants by diltiazem 
treatment still remains elusive. 
 
Lacidipine depletes cytosolic free [Ca
2+
] in fibroblasts derived from patients 
with Gaucher’s disease 
Glucosylceramide buildup causes [Ca
2+
]ER efflux and elevation of cytosolic [Ca
2+
] 
in GD cells (Korkotian et al., 1999). Lacidipine and diltiazem, by binding to LTCC and 
RyRs, are expected to lower cytosolic [Ca
2+
] and increase [Ca
2+
]ER, respectively. We 
asked whether the larger increase in GC activity observed upon cell treatment with 
lacidipine compared to diltiazem correlates with their different effects on intracellular 
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Ca
2+
 mobilization. Cytosolic free [Ca
2+
] was evaluated by monitoring changes in Fura-2 
fluorescence (Ong et al., 2010) in fibroblasts carrying L444P GC, N370S GC, or wild 
type GC treated with lacidipine or diltiazem (Figure 4.2.7). Lacidipine treatment was 
observed to deplete cytosolic [Ca
2+
] with higher efficiency than diltiazem treatment in all 
cell types. In addition, depletion of cytosolic [Ca
2+
] is markedly more enhanced in L444P 
GC than in N370S GC cells, suggesting a correlation between LTCC blocker mediated 
Ca
2+
 homeostasis modulation and rescue of mutated GC variants’ folding. 
 
 
 
Figure 4.2.7. LTCC blockers reduce cytosolic [Ca
2+
] levels in patient-derived 
fibroblasts.  A) L444P GD, B) N370S GD, and C) WT fibroblasts were cultured with 
lacidipine (20 μM) and diltiazem (20 μM) for 5, 10, 20, 40 and 60 min respectively. 
Cytosolic [Ca
2+
] was evaluated by measuring excitation 340/380 ratio of fura-2 
acetoxymethyl ester and normalized to that at time zero. The data is reported as mean ± 
SD. 
 
Lacidipine treatment upregulates BiP expression in fibroblasts derived from 
patients with Gaucher’s disease carrying the L444P GC variant 
We previously reported that the ER luminal chaperone BiP plays a key role in 
L444P GC folding. Upregulation of BiP expression, in combination with moderate UPR 
induction through MG-132 treatment, was shown to dramatically enhance the folding of 
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L444P GC (Chapter 4.1). We asked whether cell treatment with lacidipine influences the 
expression of ER chaperones and conducted quantitative RT-PCR analyses to measure 
the expression of the representative chaperones BiP, Calnexin (CNX), and Calreticulin 
(CRT) in L444P GC fibroblasts treated with lacidipine (20 µM), diltiazem (10 µM), MG-
132 (0.6 µM), celastrol (0.6 µM), or a combination thereof (Figure 4.2.8A-C). BiP 
expression (Figure 4.2.8A) was upregulated by lacidipine treatment (5.6-fold, p<0.01) 
and by lacidipine and MG-132 co-treatment (13.1-fold, p<0.01). Diltiazem treatment 
resulted in a milder increase in BiP expression (1.8-fold), even when used in combination 
with MG-132 (3.1-fold). Even though celastrol treatment was observed to cause a modest 
increase in BiP expression (1.9-fold), supplementing celastrol-containing medium with a 
LTCC blocker did not influence BiP transcription.  
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Figure 4.2.8. Upregulation of BiP transcription in patient-derived fibroblasts treated 
with lacidipine. Relative mRNA expression levels of A) BiP (p<0.01), B) CNX 
(p<0.05), and C) CRT in L444P GC fibroblasts treated with lacidipine (20 μM), diltiazem 
(10 μM), MG-132 (0.6 μM), and celastrol (0.6 μM) for 24 hrs were obtained by 
quantitative RT-PCR, corrected by the expression of the housekeeping gene GAPDH, 
and normalized to those of untreated cells. The data is reported as mean ± SD (p<0.05).  
 
ER chaperone expression in cells treated with lacidipine (20 µM), diltiazem (10 
µM), and MG-132 (0.6 µM) was confirmed by Western blot using chaperone specific 
antibodies (Figure 4.2.9). BiP protein accumulation was enhanced by treatment with 
lacidipine alone or in combination with MG-132 compared to untreated cells, but only 
slightly enhanced by diltiazem and MG-132 treatment. CNX and CRT protein levels did 
not seem to be drastically altered. These results are consistent with RT-PCR analyses, 
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and confirm the key role of BiP expression in promoting native folding of L444P GC 
(Wang et al., 2011a).  
 
 
Figure 4.2.9. Protein accumulation levels of ER chaperones in cells treated with 
lacidipine. Western blot analyses of BiP, CNX, CRT, and GAPDH (used as loading 
control) accumulation in cells treated with lacidipine (20 μM) and MG-132 (0.6 μM) for 
48 hrs. Lac, lacidipine; Dil, diltiazem. 
 
As opposed to what was previously observed in investigating RyRs blockers, 
which despite dramatically enhancing MG-132 mediated L444P GC folding rescue do 
not directly modulate the expression of ER chaperones (Chapter 4.1), this data indicates 
that lacidipine’s mechanism of action is based on extensive remodeling of ER chaperone 
pathways. However, we found that although cell treatment with lacidipine significantly 
enhances BiP expression, it does not alter its cellular localization. Particularly, 
immunofluorescence studies conducted to test BiP localization in the ER and in the Golgi 
revealed that BiP is still primarily localized in the ER (Figure 4.2.10). 
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Figure 4.2.10. BiP cellular localization upon lacidipine treatment. 
Immunofluorescence microscopy of A) CNX (an ER marker) and BiP, and B) GM130 
(a Golgi marker) and BiP in L444P GC fibroblasts. Cells were treated with lacidipine 
(20 M) for 48 hrs. Colocalization of CNX (blue, column 1) and BiP (red, column 2) is 
shown in green (column 3). Colocalization of GM130 (blue, column 1) and BiP (red, 
column 2) is also shown in green (column 3). 
 
Lacidipine treatment causes modest activation of all three arms of the UPR, 
but does not induce cytotoxicity in fibroblasts derived from patients with Gaucher’s 
disease carrying the L444P GC variant 
We next investigated the activation of the unfolded protein response (UPR), 
which, as described previously (Chapter 4.1) plays a significant role in the native folding 
of severely destabilized GC variants and is often induced by cell tratement with 
proteostasis regulators (Wang et al., 2011a). As described above, the UPR is a tripartite 
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signal transduction cascade activated in response to the accumulation of misfolded 
proteins in the ER. Briefly, UPR induction is mediated by the activation of three integral 
ER membrane proteins, namely inositol requiring kinase 1 (IRE1), activating 
transcription factor 6 (ATF6), and double-stranded RNA-activated ER kinase (PERK) 
(Schroder and Kaufman, 2005), which lead to the upregulation of UPR related genes, 
including chaperones and ERAD proteins. The expression of ATF6, PERK, and IRE1 
was investigated in this study to evaluate UPR induction in fibroblasts derived from GD 
patients treated with lacidipine and diltiazem. Lacidipine was found to activate two of the 
three arms of the UPR, and with higher efficiency than diltiazem. The increase in 
expression of genes of the UPR pathway in cells treated with lacidipine was considerably 
enhanced by the addition of MG-132. These results correlate with measurements of 
L444P GC activity reported above, in which maximal increase was obtained upon co-
treatment with lacidipine and MG-132 (Figure 4.2.3A).  
Activation of IRE1 causes X-box binding protein-1 (Xbp-1) mRNA cleavage 
(Ron and Walter, 2007). The product of Xbp-1 spliced mRNA acts as an activator of 
UPR target genes, whereas the product of the unspliced Xbp-1 precursor acts as a 
repressor (Ron and Walter, 2007). RT-PCR experiments followed by gel electrophoresis 
were conducted to evaluate the accumulation of the spliced and unspliced forms of Xbp-1 
in L444P GC fibroblasts treated with LTCC blockers (lacidipine (20 µM) or diltiazem 
(10 µM)) and a proteostasis regulator (MG-132 (0.6 µM) or celastrol (0.6 µM)) for 24 hrs 
(Figure 4.2.11A). Treatment with MG-132 enhanced Xbp-1 splicing in L444P GC 
fibroblasts, as previously reported (Mu et al., 2008b). Spliced Xbp-1 was barely 
detectable in cells treated with lacidipine. However, a 4.8-fold increase in spliced Xbp-1 
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accumulation was observed upon co-treatment with lacidipine and MG-132 compared to 
treatment with MG-132 only (Figure 4.2.11A-B), recapitulating the synergistic effect of 
lacidipine and MG-132 observed in enzymatic assays (Figure 4.2.3A). A 4.3-fold 
increase in spliced Xbp-1 was detected in L444P GC fibroblasts treated with diltiazem 
and MG-132 compared to that measured in fibroblasts treated with MG-132 only. Even 
though cell treatment with celastrol causes increase in Xbp-1 splicing and in L444P GC 
folding rescue (Mu et al., 2008b), addition of celastrol to the media of lacidipine- or 
diltiazam-treated cells did not increase Xbp-1 splicing. Taken together, these results 
suggest a synergistic effect of LTCC blockers lacidipine and diltiazem and the 
proteostasis regulator MG-132 on the activation of the IRE1 arm of the UPR in L444P 
GC patient-derived fibroblasts. Among the culturing conditions investigated, the highest 
degree of Xbp-1 splicing was observed in cells displaying the maximum increase of 
L444P GC activity (lacidipine and MG-132 treatment, Figure 4.2.1), suggesting a key 
role of IRE1 activation in rescuing L444P GC folding. 
The second arm of the UPR is mediated by ATF6 activation (Ron and Walter, 
2007). Quantitative RT-PCR was used to evaluate ATF6 expression in cells treated as 
described above. Lacidipine treatment resulted in ATF6 upregulation (2.1-fold), which 
was further enhanced by the addition of MG-132 (3.5-fold), suggesting that the ATF6 
arm of the UPR is also activated by treatment with lacidipine, particularly when used in 
combination with MG-132 (Figure 4.2.11C). Diltiazem treatment barely affected ATF6 
expression, and the addition of neither MG-132 nor celastrol to diltiazem-supplemented 
media caused significant changes.  
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The third branch of the UPR is induced by PERK oligomerization and 
phosphorylation of the eukaryotic translation initiation factor-2 (eIF2α). eIF2α induces 
the expression of the transcription factor ATF4 and a subset of ATF4 target genes, 
including CHOP (Ron and Walter, 2007). Lacidipine treatment caused CHOP 
upregulation (3.7-fold), which was considerably enhanced by the addition of MG-132 
(5.0-fold), indicating that the PERK arm of the UPR is activated in response to lacidipine 
treatment (Figure 4.2.11D). Treatment with diltiazam alone or in combination with a 
proteostasis regulator did not cause significant changes in CHOP expression (Figure 
4.2.11D). 
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Figure 4.2.11. Upregulation of UPR genes in patient-derived fibroblasts treated with 
lacidipine. Cells were treated with lacidipine (20 μM), diltiazem (10 μM), MG-132 (0.6 
μM), and celastrol (0.6 μM) for 24 hrs. A) Xbp-1 expression and splicing was determined 
by RT-PCR and separation on agarose gel and quantification of spliced Xbp-1 band 
intensities B) conducted using the NIH Java Image analysis software. PR, proteostasis 
regulator; Lac, lacidipine; Dil, diltiazem; MG, MG-132; Cel, celastrol. Relative mRNA 
expression levels of C) ATF6 and D) CHOP were obtained by quantitative RT-PCR and 
calculated as described in Figure 4.2.8. The data is reported as mean ± SD (p<0.01). 
 
Prolonged induction of the UPR and inability of the ER folding capacity to cope 
with the load of misfolded proteins leads to apoptosis. A number of genes are involved in 
the regulation of apoptosis induction, including the pro-apoptotic genes encoding for Bcl-
2 homologous antagonist (BAK) and Bcl-2-associated X protein (BAX) (Scorrano et al., 
2003), and the anti-apoptotic gene encoding the apoptosis regulator Bcl-2 (Rodriguez et 
al., 2010). The expression of BAK, BAX, and Bcl-2 was investigated in cells treated with 
LTCC blockers and proteostasis regulators as described before. MG-132 and celastrol 
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treatments caused upregulaton of the pro-apoptotic proteins BAK and BAX. Specifically, 
MG-132 induced upregulation of BAK (2.1-fold, Figure 4.2.12A) and celastrol induced 
upregulation of BAX (3.1-fold, Figure 4.2.12B). Lacidipine did not significantly alter 
either BAX or BAK expression, while diltiazem caused upregulation of both BAK (1.9-
fold) and BAX (2.1-fold). Co- treatment with lacidipine and MG-132 was compared to 
treatment with MG-132. When cells were co-treated with lacidipine and MG-132, BAK 
expression was barely altered, but BAX expression was observed to decrease, compared 
to cells treated with MG-132 only. This result is interesting because lacidipine and MG-
132 were shown to have a synergistic effect on the rescue of L444P GC activity (Figure 
4.2.1C) and on UPR activation (Figure 4.2.11A-D). Since enhanced UPR activation 
typically leads to enhanced apoptosis induction, both BAX and BAK expression would 
be expected to increase in cells treated under these conditions. Particularly, BAX 
expression was lowered 2.9-fold in cells treated with lacidipine and MG-132, suggesting 
that the mechanism of lacidipine-mediated L444P GC folding rescue involves inhibition 
of apoptosis via BAX downregulation. Interestingly, when diltiazem was used in 
combination with a proteostasis regulator, MG-132 mediated BAK upregulation was 
enhanced (2.9-fold), but celastrol-mediated BAX upregulation was lowered, which may 
explain why treatment with celastrol, but not with MG-132, results in enhancement of 
L444P GC activity increase mediated by diltiazem.  
The expression of the anti-apoptotic Bcl-2 encoding gene was also evaluated 
(Figure 4.2.12C). Bcl-2 contributes to maintaining ER Ca
2+
 homeostasis by reducing 
[Ca
2+
]ER efflux (Eckenrode et al., 2010; Rong et al., 2009), and was found to be 
upregulated in L444P GC fibroblasts cultured with either lacidipine or diltiazem (1.9-
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fold), underscoring the therapeutic potential of Ca
2+
 homeostasis modulation in L444P 
GC fibroblasts. MG-132 treatment lowered Bcl-2 expression (0.8-fold), whereas celastrol 
treatment did not seem to affect it. The addition of a proteostasis regulator to lacidipine-
treated cells resulted in lowered Bcl-2 expression, returning it to the level detected in 
untreated cells, whereas the addition of a proteostasis regulator to diltiazem-treated cells 
resulted in substantial downregulation of Bcl-2 (MG-132 and diltiazem: 2.3-fold; 
celastrol and diltiazem: 2.0-fold). Similar to what was reported above regarding the 
expression of pro-apoptotic genes, modulation of Bcl-2 expression correlates with the 
ability of LTCC blockers to rescue L444P GC folding when used alone or in combination 
with an UPR-inducing proteostasis modulator.  
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Figure 4.2.12. Upregulation of the anti-apoptotic gene Bcl-2 in patient-derived 
fibroblasts treated with lacidipine. Cells were treated with lacidipine (20 μM), 
diltiazem (10 μM), MG-132 (0.6 μM), and celastrol (0.6 μM) for 24 hrs. Relative mRNA 
expression levels of A) BAK, B) BAX, and C) Bcl-2 were obtained by quantitative RT-
PCR and calculated as described in Figure 4.2.8. The data is reported as mean ± SD 
(p<0.01). 
 
We next tested whether lacidipine-mediated changes in the expression of pro- and 
anti-apoptotic genes translate into differences in cytotoxicity and cell death, a common 
marker of cells treated for L444P GC folding rescue through UPR activators, such as 
MG-132, tunicamycin, and thapsigargin (Chapter 4.1). L444P GC patient-derived 
fibroblasts treated with Ca
2+
 blockers and proteostasis regulators as described above were 
tested using the CytoGLO
TM
 Annexin V-FITC Apoptosis Detection Kit to monitor 
membrane rearrangement (Annexin V binding) and fragmentation (propidium iodide (PI) 
binding), which occur during early and late apoptosis, respectively (Table 4.2). Treatment 
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of L444P GC fibroblasts with lacidipine (20 µM) did not cause cytotoxicity, and the 
apoptosis induction was not significantly altered compared to untreated cells. MG-132 
(0.6 µM) and celastrol (0.6 µM) resulted in 47% and 10% increase in Annexin V binding, 
and 7.4% and 4.7% increase in dead cell population, respectively. The addition of 
lacidipine to MG-132 or celastrol treated cells led to a decrease in Annexin V binding to 
41% and 8.3% and to a decrease in dead cell population to 4.5% and 4.1%, respectively. 
These results indicate that lacidipine treatment under conditions observed to rescue 
mutated GC folding and induce UPR not only does not cause cytotoxicity, but also 
partially counteracts the cytotoxic effect of UPR inducing proteostasis regulators.  
Interestingly, lacidipine mechanism of L444P GC folding rescue differs 
significantly from that of RyRs blockers shown in Chapter 4.1. While cell treatment with 
RyRs blockers does not activate the UPR but rescues GD fibroblasts from UPR-induced 
toxicity, lacidipine treatment concurrently activates the UPR and ameliorates UPR-
induced toxicity in GD fibroblasts.  
 
Table 4.2. Cell toxicity assay (lacidipine treatment) (p<0.01) 
Cell treatment 
Annexin V PI 
Population
1
 Binding
2
 Population
1
 Binding
2
 
Lacidipine 1.8±0.4 -2.9±1.8 -3.3±0.9 2.5±1.3 
MG-132 7.2±0.1 47±1.0 7.4±0.4 28±0.9 
Lacidipine+MG-132 3.6±0.2 41±1.1 4.5±0.3 15±1.8 
Celastrol 1.8±0.9 10±0.3 4.7±0.2 19±1.2 
Lacidipine+Celastrol 1.0±0.5 8.3±1.2 4.1±1.0 13±0.2 
1
 Change (%) in number of cells bound to Annexin V/PI compared to untreated cells. 
2
 Change (%) in Annexin V/PI binding affinity compared to untreated cells. 
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Lacidipine treatment upregulates GC chromosomal expression in fibroblasts 
derived from patients with Gaucher’s disease carrying the L444P GC variant 
As indicated previously (Figure 4.2.5A-B), the total amount of L444P GC seems 
to be enhanced by lacidipine treatment. Upregulation of the gene encoding GC (GBA) as 
well as of other genes encoding for lysosomal enzymes involved in lipid metabolism was 
previously reported in cells treated for the rescue of L444P GC folding through UPR 
induction (Chapter 4.1). Particularly, we found that a number of genes associated with the 
development of lysosomal storage disorders, such as Niemann-Pick, Tay-Sachs, and 
Fabry diseases, were upregulated upon MG-132-induced UPR (see chapter 4.1). This 
finding resonates with the general increase in lipid metabolism that normally occurs 
during UPR (Schroder and Kaufman, 2005) and was suggested as a potentially 
therapeutic “side-effect” of mutated GC proteostasis regulation via UPR activation 
(Chapter 4.1).   
Quantitative RT-PCR and western blot analyses were conducted to understand 
whether the increase in cellular concentration of L444P GC observed in cells treated with 
lacidipine is due to upregulation of GC expression in addition to enhanced folding of 
L444P GC and lowered ERAD. L444P GC fibroblasts were treated with lacidipine (20 
µM), diltiazem (20 µM), MG-132 (0.6 µM), celastrol (0.6 µM), or a combination thereof 
(Figure 4.2.13A). Lacidipine treatment was observed to enhance GC mRNA expression 
(3.1-fold) to an extent similar to MG-132 (3.1-fold) or celastrol (3.4-fold). Treatment 
with diltiazem resulted in a lower increase in GC expression (2.5-fold), most likely 
reflecting diltiazem’s milder effect on UPR induction. Interestingly, addition of MG-132 
resulted in an increase in both lacidipine- and diltiazem-mediated GC upregulation (4.5- 
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and 4.6-fold, respectively), whereas celastrol slightly lowered this expression (2.9- and 
2.2-fold, respectively). These transcriptional changes were confirmed at the translational 
level by western blot analyses (Figure 4.2.13B). L444P GC fibroblasts were cultured with 
lacidipine (20 µM), MG-132 (0.6 µM), and celastrol (0.6 µM) for 48 hrs, and bands 
detected with a GC-specific antibody were quantified using NIH Java Image analysis 
software (Figure 4.2.13C). The L444P GC content of lacidipine-treated cells increased 
about 50% compared to that of untreated cells, similarly to what was observed in MG-
132-treated cells. In addition, the combination of lacidipine and MG-132 caused a 2.3-
fold increase in total L444P GC, which is higher than what was observed in cells treated 
with either one of these molecules, and is in agreement with the results obtained from 
quantitative RT-PCR. Celastrol treatment did not significantly affect GC protein 
accumulation. In summary, this data indicates that GC chromosomal expression is 
enhanced upon treatment with lacidipine and suggests that GC upregulation contributes 
to L444P GC folding rescue mediated by UPR induction.  
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Figure 4.2.13. Upregulation of L444P GC expression in fibroblasts treated with 
lacidipine and diltiazem. A) Relative GC mRNA expression level was evaluated by 
quantitative RT-PCR in L444P GC fibroblasts treated with lacidipine (20 μM), diltiazem 
(10 μM), MG-132 (0.6 μM), and celastrol (0.6 μM) for 24 hrs (p<0.01). mRNA 
expression levels were calculated as described in Figure 4. The data is reported as mean ± 
SD. B) Representative Western blot analysis of cells treated with lacidipine (20 μM), 
MG-132 (0.6 μM), and celastrol (0.6 μM) for 48 hrs using GC specific antibody. C) 
Western blots band quantification. GC bands were quantified by NIH Java Image 
analysis software. GAPDH expression was used as a loading control. PR, proteostasis 
regulator; MG, MG-132; Cel, celastrol. 
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4.2.3. Discussion 
Ubiquitously expressed voltage-gated LTCCs support inward current of Ca
2+
 ions. 
The function of Ca
2+
 ions as an intracellular second messenger has been reported in many 
cellular processes, ranging from gene expression to cardiac and smooth muscle 
contraction. Because Ca
2+
 mediates both physiological and pathological events, 
considerable effort has been devoted to the study of Ca
2+
 channel antagonists, a 
chemically and pharmacologically heterogeneous group of drugs widely used as 
therapeutic agents as well as research tools. The prototypical LTCC antagonists are 
diltiazem (a benzothiazepine), verapamil (a phelylalkylamine) and nifedipine (an 1,4-
dihydropyridine) (Triggle, 2006). Diltiazem and verapamil are FDA-approved drugs for 
the treatment of hypertension and cardiac arrhythmias (Hockerman et al., 1997). They 
were reported to rescue folding, trafficking and activity of GC variants in fibroblasts 
derived from patients with GD (Mu et al., 2008a), but failed to rescue mutated GC 
activity in mice (Sun et al., 2009). In an effort to discover small molecules that efficiently 
rescue the folding of mutated GC variants by enhancing the cellular folding capacity but 
without inducing cytotoxicity, we tested a series of 1,4-dihydropyridines, a class of 
LTCC antagonists known to lower intracellular [Ca
2+
] with higher selectivity than 
benzothiazepines and phelylalkylamine (Triggle, 2003).  
Lacidipine was found to rescue the activity of GC variants carrying the two most 
common mutations, L444P and N370S, in fibroblasts derived from patients with GD. In 
particular, lacidipine mediates a substantially higher increase in L444P GC activity than 
what was observed using any other LTCC and RyRs blockers to date (Mu et al., 2008a; 
Ong et al., 2010; Wang et al., 2011a), and this increase is markedly enhanced by co-
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treatment with proteostasis modulators MG-132 and celastrol. The nature of the chemical 
structure of LTCC blockers – with lacidipine highly hydrophobic, diltiazem and 
verapamil charged at physiologic pH (Triggle, 2003) – is likely to influence their cell 
permeability and explain why treatment of GD fibroblasts with lacidipine resulted in 
higher depletion of cytosolic [Ca
2+
] and more effective remodeling of L444P GC 
proteostasis compared to diltiazem and verapamil. 
L444P GC fibroblasts treated with lacidipine (and diltiazem for comparison) were 
used to conduct mechanistic studies and gain a better understanding of the molecular 
mechanisms involved in L444P GC proteostasis. We demonstrated that lacidipine 
induced rescue of mutated GC folding (Figures 4.2.1-4.2.6) and that this behavior 
correlates with its ability to i) lower cytoplasmic [Ca
2+
], thereby counteracting the effect 
of GC substrate accumulation (Figure 4.2.7), ii) enhance the ER’s folding capacity via 
substantial upregulation of BiP expression (Figures 4.2.8 and 4.2.9), confirming that BiP 
plays a key role in the folding of L444P GC, iii) induce the UPR (Figure 4.2.11) and 
upregulate GC expression (Figure 4.2.13), and iv) lower cytoxicity and limit UPR 
mediated apoptosis induction (Figure 4.2.12 and Table 4.2). An analogous mode of action 
was previously reported to explain the synergistic effect of two distinct small molecules, 
a proteostasis regulator (MG-132) and a RyRs blocker (ryanodine), on L444P GC folding 
rescue. Particularly, MG-132 was reported to induce BiP upregulation and UPR induction 
and ryanodine to lower intracellular [Ca
2+
] and counteract UPR induced cytotoxicity 
(Chapter 4.1), suggesting that combining these different mechanisms of proteostasis 
regulation is an effective strategy to rescue mutated GC folding. In summary, this study 
sheds light on the cellular pathways involved in mutated GC folding and introduces a 
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novel strategy to rescue mutant GC folding via small molecule treatment that combines 
remodeling of two general cellular pathways involved in protein homeostasis: protein 
folding and Ca
2+
 homeostasis.  
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4.3. Inhibition of ER-associated degradation rescues native 
folding in frobroblasts derived from patients with lysosomal 
storage diseases 
4.3.1. Introduction 
In the previous chapters, we demonstrated that reporgramming the proteostasis 
network via modulation of intracellular Ca
2+
 homeostasis enables rescue of mutated, 
degradation-prone GC vairants (see Chapters 4.1 and 4.2; or papers Wang et al., 2011a 
and Wang et al., 2011b). Mechanistic studies conducted to investigate changes induced 
by Ca
2+
 blockers on the proteostasis network that directly influence rescue of mutated GC 
variants led to the observation that enhancing the pool of mutated GC folding 
intermediate in the ER amenable to folding rescue is critical to increase foding and 
trafficking of native GC. Specifically, increase in mutated GC activity correlates with i) 
upregulation of the main ER chaperone BiP, which is known to enhance ER retention and 
prevent ERAD of misfolding intermediates (Muresan and Arvan, 1998), and ii) 
upregulation of GBA transcription (Chapters 4.1 and 4.2). Both strategies, BiP and GC 
upregulation, increase the pool of GC folding intermediates that escapes ERAD and is 
amenable to folding rescue. 
We hypothesized that native folding of mutated enzyme variants is limited by the 
rapid disposal of unstable folding intermediates via ERAD. Hence, we sought to 
investigate ERAD inhibition in LSD patient-derived cells and establish the role of this 
pathway in the development of loss-of-function phenotypes. We identified two small 
molecules ERAD inhibitors: Kifunensine (Kif), which inhibits ER mannosidase I 
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(Avezov et al., 2008; Fagioli and Sitia, 2001) and thus interferes with early substrate 
recognition, and Eeryastatin I (EerI), which inhibits p97 ATPase activity (Fiebiger et al., 
2004; Wang et al., 2010), thereby limiting retrotranslocation of misfolded substrates 
(Appendix A; Figure 4.3.1). Treatment with ERAD inhibitors partially restores folding 
and activity of mutated GC variants in fibroblasts derived from GD patients. Rescue of 
mutated HexA was also observed in Tay-Sachs disease fibroblasts upon treatment with 
EerI, demonstrating the generality of this approach. Furthermore, we investigated the 
transcriptional changes that occur in GD fibroblasts in response to these two different 
mechanisms of ERAD inhibition, with particular attention to the expression of ER 
chaperones, the gene encoding GC, and UPR activation. Results from this study show 
that ERAD regulates the processing of unstable secretory proteins and that ERAD 
inhibition is a viable strategy to rescue native folding and activity of mutated lysosomal 
enzymes associated with the development of LSDs. EerI mediated inhibition of substrate 
retrotranslocation, although possibly more efficient in rescuing mutated GC folding, was 
observed to cause UPR induction and cytotoxicity. Kif-mediated inhibition of early 
substrate recognition, however, which is likely to prolong ER retention and substrate 
folding without causing accumulation of irremediably misfolded proteins, caused 
minimal activation of the UPR and did not result in induction of apoptosis. 
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Figure 4.3.1. ERAD pathways and mechanisms of ERAD inhibition. As newly 
synthesized polypeptides are translocated into the ER, they are immediately recognized 
by BiP, which promotes substrate folding and solubility. They are then marked with an 
oligosaccharide precursor (GlcNAc2-Man9-Glc3), which is sequentially trimmed to 
allow substrate interaction with the lectin chaperones calnexin (CNX) and calreticulin 
(CRT). Specifically, interaction with the lectin chaperones occurs upon cleavage of the 
two terminal glucoses by glucosidase I and II and is terminated by removal of the last 
outermost glucose residue (GlcNAc2-Man9) by glucosidase II. At this point, natively 
folded proteins exit the ER while partially folded intermediates are reglucosylated by 
UDP-glucose:glycoprotein glucosyltransferase (UGGT) and re-enter the lectin folding 
cycle. In order to prevent excessive accumulation of folding intermediates, unstable 
misfolding-prone substrates are processed by ER mannosidase I, which cleaves three to 
four mannose residues from the oligosaccharidic group and promotes substrate binding 
with the ER degradation-enhancing α-mannosidase-like lectins (EDEM). ERAD 
substrates are then retrotranslocated to the cytoplasm via the Sec61 retrotranslocon, and 
polyubiquitinated. Substrate retrotranslocation is mediated by the p97 complex, which 
includes ubiquitin fusion degradation 1 (Ufd1) and nuclear protein localization 4 (Npl4). 
p97 ATPase provides the driving force for substrate extraction and shuffling to the 
proteasome. As shown in the schematic, Kifunensine and Eeyarestatin I, small molecules 
that function as ERAD inhibitors, block different steps of the ERAD pathway. 
Kifunensine inhibits ER mannosidase I and Eeyarestatin I inhibits p97 ATPase activity. 
(GlcNAc, N-acetylglucosamine; Man, mannose; Glc, glucose) 
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4.3.2. Results 
ERAD inhibition enhances native folding, trafficking and activity of mutated 
GC in fibroblasts derived from patients with GD  
In order to investigate the role of the ERAD pathway in the folding of mutated 
GC variants, L444P GC fibroblasts were cultured in the presence of ERAD inhibitors 
(Eeyarestatin I (EerI) and Kifunensin (Kif)) for 5 days, and GC activities were evaluated 
every 24 hours with the intact cell GC activity assay (Mu et al., 2008b). Culturing 
conditions resulting in maximal rescue of L444P GC activity are reported in Figure 4.3.2 
(blue lines). L444P GC activity was observed to increase up to 2.0-fold in cells treated 
with EerI (8 μM final medium concentration, p<0.001) for 48 hrs compared to untreated 
cells, which corresponds to about 25% of the WT cellular activity (Figure 4.3.2A) and 
would be expected to ameliorate GD symptoms (Schueler et al., 2004).  
We hypothesized that EerI-mediated ERAD inhibition prolongs ER retention of 
mutated GC, thereby enhancing the pool of GC folding intermediates amenable to folding 
rescue. Hence, we asked whether combining ERAD inhibition with enhancement of the 
cellular folding capacity could further increase the pool of natively folded GC that 
trafficks to the lysosomes. To investigate this question, EerI treated cells were cultured in 
the presence of MG-132 and celastrol, small molecules shown to function as proteostasis 
regulators and rescue GC folding through a mechanism distinct from ERAD modulation 
(Chapters 4.1 and 4.2). Experiments were designed to explore the addition of a constant 
concentration of proteostasis regulator (0.4, 0.6, or 0.8 μM) to a range of EerI 
concentrations. Co-administration of EerI (2 µM) and MG-132 (0.6 µM) for 48 hrs 
resulted in a dramatic 4.2-fold increase in L444P GC activity (p<0.001; Figure 4.3.2A) 
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compared to untreated cells, which corresponds to 52.5% of WT GC activity and is 
significantly higher than the activity of cells treated only with EerI (2.0-fold) or MG-132 
(2.4-fold) under the same conditions. Co-treatment with EerI and celastrol was also 
observed to enhance L444P GC activity rescue (Figure 4.3.2B). Specifically, GD cells 
treated with EerI (5 µM) and celastrol (0.4 µM) for 48 hrs displayed a 3.1-fold increase in 
L444P GC activity (p<0.001), which is higher than what was observed in cells treated 
only with EerI (1.3-fold) or celastrol (1.4-fold) under the same conditions.  
A similar set of experiments was conducted using Kif, the other ERAD inhibitor 
selected. Cell treatment with Kif (100 nM) modestly increased L444P GC activity (1.2-
fold, 15% of WT activity; p<0.01), whereas co-administration of Kif (50 nM) and MG-
132 (0.4 µM) led to a dramatic 3.8-fold increase in L444P GC activity (47.5% of WT 
activity; p<0.01) after 120 hours (Figure 4.3.2C). Co-treatment with Kif and celastrol was 
also explored (Figure 4.3.2D). Optimal culturing conditions (Kif 100 nM and celastrol 
0.8 µM) resulted in 2.3-fold increase in L444P GC activity (28.8% of WT activity, 
p<0.01), again higher than what was found upon treatment with either molecule alone. 
Taken together, these results suggest that ERAD limits the folding and trafficking of 
L444P GC and that ERAD inhibition is a viable strategy to promote native folding and 
trafficking of this mutated, degradation-prone enzyme variant.  
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Figure 4.3.2. Cell treatment with ERAD inhibitors enhances L444P GC activity in 
GD patient-derived fibroblasts. Relative L444P GC activities were evaluated in cells 
treated with a range of concentrations of ERAD inhibitors (EerI or Kif) and constant 
doses of proteostasis regulators (MG-132 or celastrol: 0.4, 0.6, or 0.8 μM). Relative GC 
activities of L444P cells treated with A) EerI and MG-132 for 48 hrs, B) EerI and 
celastrol for 48 hrs, C) Kif and MG-132 for 120 hrs, and D) Kif and celastrol for 120 hrs. 
Relative GC activities were evaluated by normalizing GC activities measured in treated 
cells to the activity of untreated cells (left y axis), (p<0.01 if not specified; *p<0.001). 
The corresponding fraction of WT GC activity is also reported (right y axis). Experiments 
were repeated three times and data points are reported as mean ± SD. MG, MG-132; Cel, 
celastrol. 
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In order to confirm that the increase in GC activity measured in cells treated with 
EerI and Kif is caused by partial restoration of L444P GC folding and lysosomal 
trafficking, we investigated L444P GC glycosylation state, and its intracellular 
localization and trafficking. 
L444P GC glycosylation state was investigated by endoglycosidase H (EndoH) 
treatment (see chapter 4.2; Wang et al. 2011b), using culture conditions that resulted in 
maximal GC activity rescue (EerI 6 µM, Kif 50 nM, MG-132 0.6 µM for 48 hrs). The 
total protein content was subjected to EndoH treatment. As described before (Chapter 
4.2), GC detection by Western blot reveals a low MW band corresponding to partially 
glycosylated, ER-retained GC (EndoH-sensitive) and a high MW band corresponding to 
fully glycosylated, lysosomal GC (EndoH-resistant) (Maley et al., 1989). A 
representative Western blot (Figure 4.3.3A) and quantification of EndoH-resistant and 
EndoH-sensitive GC bands (Figure 4.3.3B) are reported. In untreated cells, nearly all 
L444P GC was detected as EndoH-sensitive, as expected (Chapter 4.2). A band 
corresponding to EndoH-resistant L444P GC was detected in cells treated with EerI, and 
its intensity was 1.6-fold higher than that detected in cells treated with MG-132 (results 
obtained using MG-132 were reported previously (Mu et al., 2008b) and are included 
here for comparison). Kif treatment caused a mild increase in GC EndoH-resistant pool, 
corresponding to about 13% of that of MG-132-treated cells. Co-treatment with MG-132 
and EerI (2 µM) or Kif resulted in 2.6- and 1.4-fold increase, respectively, in the EndoH-
resistant L444P GC, compared to treatment with MG-132 only, which is in agreement 
with results obtained from enzymatic assays (Figure 4.3.2A and 4.3.2C). 
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Figure 4.3.3. ERAD inhibitors promote L444P GC glycosylation in GD patient-
derived fibroblasts. A) Western blot analyses of EndoH treated and untreated total 
protein content from L444P GC fibroblasts cultured with EerI (6 μM), Kif (50 nM), and 
MG-132 (0.6 μM) for 48 hrs and detected using GC-specific antibody. The solid and 
dashed arrows indicate EndoH resistant and EndoH sensitive bands respectively. B) 
Quantification of GC bands detected by western blot in EndoH treated samples. 
Quantification of lower MW, EndoH-sensitive bands corresponding to ER retained GC 
are reported in the white portion of the bars, and quantification of higher MW, EndoH-
resistant bands corresponding to lysosomal GC are reported in the black top portions. 
Band analyses and quantifications were conducted using NIH ImageJ analysis software. 
Experiments were repeated three times and data points are reported as mean ± SD. MG, 
MG-132; Cel, celastrol. 
 
L444P GC intracellular localization was evaluated using immunofluorescence 
microscopy and subcellular fractionation of L444P GC patient-derived fibroblasts treated 
with small molecules at concentrations corresponding to maximum activity rescue (EerI 6 
µM, Kif 50 nM, and MG-132 0.6 µM) for 48 hrs. Immunofluorescence microscopy was 
conducted using antibodies specific for GC, for an ER marker (CNX), and for a 
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lysosomal marker (LAMP-1) to evaluate GC localization in the ER and in the lysosome, 
respectively. Co-localizations of GC and CNX (Figure 4.3.4A) and of GC and LAMP-1 
(Figure 4.3.4B) are reported, respectively, in pink and purple (merged colors) and 
analyzed with ImageJ software to provide a co-localization heatmap. L444P GC was 
barely detectable in untreated cells due to extensive ERAD, as previously reported 
(Michelakakis et al., 1995). In agreement with the results obtained from GC enzymatic 
assays (Figure 4.3.2A), a significantly larger pool of GC was detected in the ER and in 
the lysosome upon EerI treatment. Furthermore, GC accumulation was observed to 
increase with increasing concentration of EerI, and to be further enhanced by co-
treatment with EerI and MG-132 (Figure 4.3.4A-B). Kif treatment also enhanced GC 
localization in the ER and in the lysosomes compared to untreated cells, albeit to a lower 
extent than EerI treatment (Figure 4.3.4A-B). Co-treatment with Kif and MG-132 
increased GC accumulation in the ER and in the lysosomes, again supporting the results 
obtained from GC enzymatic assays (Figure 4.3.2C). 
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Figure 4.3.4. ERAD inhibitors promote L444P GC folding and lysosomal trafficking 
in GD patient-derived fibroblasts. Immunofluorescence microscopy of A) GC and 
CNX (an ER marker), and B) GC and LAMP-1 (a lysosomal marker) in L444P GC 
fibroblasts. Cells were treated with EerI (2 and 6 µM), Kif (50 nM) and MG-132 (0.6 
µM) for 48 hrs. Colocalization of CNX (grey, column 1) and GC (red, column 2) is 
shown in pink (column 3). Colocalization of LAMP-1 (blue, column 1) and GC (red, 
column 2) is shown in purple (column 3). Heatmaps of co-localization images were 
obtained with NIH ImageJ analysis software (column 4). Hot colors represent positive 
correlation (co-localization), whereas cold colors represent negative correlation 
(exclusion). 
 
Subcellular fractions of cell homogenates were collected upon Percoll density 
gradient centrifugation, and GC enzyme activity assay for each fraction was performed to 
evaluate L444P GC intracellular localization. Since hexosaminidase A (HexA) trafficking 
and activity are not altered in GD fibroblasts compared to WT fibroblasts, HexA activity 
was first evaluated in each fraction to distinguish fractions containing ER and lysosomes. 
HexA activity was detected in both low-density (#1-2) and high-density (#7-8) fractions 
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in untreated L444P GC cells (Figure 4.3.5, dashed line, right y-axis), which comprise the 
ER and the lysosomes, respectively, as previously reported (Ishii et al., 2007). In 
untreated cells, L444P GC activity (Figure 4.3.5, left y-axis) was barely detectable in 
low-density fractions (ER) and undetectable in high-density fractions (lysosomes). 
Treatment with MG-132 resulted in significant increase in L444P GC activity in both 
low- and high-density fractions, confirming that MG-132 promotes rescue of mutant GC 
folding and trafficking (Figure 4.3.5). A significant increase in GC activity was also 
detected in EerI treated cells, particularly in low-density ER fractions, confirming that 
EerI functions by inhibiting ERAD and prolonging ER retention. Kif treatment also 
enhanced GC activity both in the low- and high-density fractions compared to untreated 
cells, although to a lower extent than EerI treatment, in agreement with the results 
obtained from GC enzymatic assays (Figure 4.3.2A and 4.3.2C).   
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Figure 4.3.5. ERAD inhibitors enhance the activity of L444P GC in subcellular 
homogenate fractions in patient-derived fibroblasts. Relative GC activities of 
subcellular homogenate fractions were measured in untreated cells and cells cultured with 
EerI (6 µM), Kif (50 nM) and MG-132 (0.6 µM) for 48 hrs. Subcellular fractions were 
collected, numbered from low- to high-density (from 1 to 8) and subjected to GC activity 
assays. HexA activity was also measured in each fraction obtained from untreated cells to 
identify fraction containing the ER (#1-2) and lysosomes (#7-8). The total protein 
concentration of each fraction was determined by Nanodrop. GC enzyme activity (left y-
axis) and HexA enzyme activity (right y-axis) of each fraction were normalized to the 
corresponding protein concentrations. Experiments were repeated three times and data 
points are reported as mean ± SD. MG, MG-132. 
     
In order to investigate whether ERAD inhibition is a mutation-dependent strategy 
for the rescue of unstable GC variants, N370S GC fibroblasts were cultured in the 
presence of EerI and a proteostasis regulator, and GC activities were evaluated every 24 
hrs for up to 3 days (Figure 4.3.6). EerI treatment (4 µM) for 72 hrs resulted in a 1.25-
fold increase in GC activity (16% WT activity; p<0.01). Similar to what described for 
L444P GC cells, a lower concentration of EerI (2 µM) combined with MG-132 (0.2 µM) 
further enhanced N370S GC rescue, resulting in a 2.1-fold increase in activity compared 
to untreated cells (26% of WT activity, p<0.001), which is higher than what observed in 
the presence of either molecule alone (EerI 1.2-fold; MG-132 1.5-fold). When the same 
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experiment was conducted using celastrol as a proteostasis modulator, co-treatment with 
EerI (2 µM) and celastrol (0.2 µM) resulted in 1.4-fold increase in activity (18% of WT 
activity, p<0.01), which again is significantly higher than what observed using either 
molecule alone (EerI 1.2-fold; celastrol 1.2-fold).  
 
 
Figure 4.3.6. EerI enhances N370S GC activity in GD patient-derived fibroblasts. 
Relative N370S GC activities were measured in cells treated with proteostasis regulators 
(MG-132 0.2 μM; celastrol 0.2 μM) and a range of EerI concentrations for 72 hrs. 
Relative GC activities were evaluated as described in Figure 4.3.2 (p<0.01 if not 
specified; *p<0.001). Experiments were repeated three times and data points are reported 
as mean ± SD. MG, MG-132; Cel, celastrol.  
 
To confirm that the observed increase in GC activity is due to rescue of the 
enzyme folding and trafficking, N370S GC cellular localization was evaluated by 
immunofluorescence microscopy in cells treated with EerI (2 µM), and MG-132 (0.2 
µM). EerI treatment resulted in an increase in N370S GC accumulation in the ER and in 
the lysosomes compared to untreated cells. Co-administration of EerI and MG-132 
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further enhanced N370S GC concentration both in the ER and in the lysosomes (Figure 
4.3.7A-B), confirming the results obtained from enzymatic assays. 
 
 
Figure 4.3.7. EerI facilitates N370S GC folding and lysosomal trafficking in GD 
patient-derived fibroblasts. Immunofluorescence microscopy images of A) GC and 
CNX (an ER marker), and B) GC and LAMP-1 (a lysosomal marker) in cells treated 
with EerI (2 µM) and MG-132 (0.2 µM) for 48 hrs. Colocalization images were 
analyzed as described in Figure 4.3.4. 
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In summary, these results demonstrate that ERAD prevents native folding of 
mutated, unstable GC and provide compelling evidence that ERAD inhibition is a viable 
strategy to rescue lysosomal activity of degradation-prone GC variants containing 
destabilizing, non-inactivating mutations. Interestingly, the activity rescue measured in 
N370S GC fibroblasts was consistently less pronounced than that observed in L444P GC 
fibroblasts. We suggest that this difference is due to the different destabilizing effects of 
the N370S and L444P substitutions. L444P GC is normally completely targeted to 
ERAD, whereas the N370S GC variant partially escapes degradation and can be detected 
throughout the secretory pathway (Sawkar et al., 2006b). Hence, ERAD is likely to have 
a more direct and rate-limiting role in L444P GC processing, and, not surprisingly, 
ERAD inhibition results in more efficient rescue of L444P GC than N370S GC folding.   
 
ERAD inhibition enhances HexA activity in fibroblasts derived from patients 
with Tay-Sachs disease 
A number of loss-of-function LSDs are caused by destabilizing mutations and 
degradation of secretory proteins. The demonstration that ERAD inhibition enhances 
folding of mutated GC variants motivated asking whether ERAD inhibition is a general 
strategy to rescue activity of mutated proteins containing misfolding, non-inactivating 
mutations associated with the development of LSDs. Thus, we investigated the folding of 
HexA, the protein activity deficient in Tay-Sachs disease. Specifically, we focused on 
one of the most prevalent mutations, the G269S substitution in the HexA α subunit, 
which destabilizes the protein native structure resulting in activity ~10% of WT (Tropak 
et al., 2004). Patient-derived fibroblasts harboring G269S HexA were cultured in the 
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presence of an ERAD inhibitor and a proteostasis modulator and HexA activity was 
measured as previously described (Mu et al., 2008b). Administration of EerI (6 µM) for 
96 hrs led to 1.4-fold increase in G269S HexA α activity (14% of WT activity HexA 
activity; p<0.01. Figure 4.3.8). Addition of MG-132 (0.2 µM) to cells treated with EerI (2 
µM) for 96 hrs caused a further increase in HexA activity (1.7-fold, ~17% of WT; 
p<0.01. Figure 4.3.8).  
 
 
Figure 4.3.8. EerI enhances G269S HexA activities in Tay-Sachs patient-derived 
fibroblasts. Cells were cultured with proteostasis regulators (MG-132 0.2 μM; celastrol 
0.2 μM) and a range of EerI concentrations for 96 hrs. Relative αG269S/1278insTATC 
HexA activities (p<0.01) were evaluated by normalizing HexA activity of treated cells to 
that of untreated cells (left y axis). The corresponding fraction of WT HexA activity is 
also reported (right y axis). Experiments were repeated three times and data points are 
reported as mean ± SD. MG, MG-132; Cel, celastrol. 
 
These findings suggest that ERAD inhibition facilitates folding of destabilized 
enzyme variants prone to degradation. In summary, results from studies in Gaucher’s and 
Tay-Sachs disease patient-derived cells indicate that the activity rescue observed upon 
treatment with ERAD inhibitors is inversely proportional to the loss of lysosomal activity 
normally associated with each enzyme variant.  
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ERAD inhibition via EerI treatment causes upregulation of BiP expression in 
fibroblasts derived from patients with Gaucher’s disease carrying the L444P GC 
variant 
We speculated that small molecule-mediated ERAD inhibition, by inducing 
accumulation of misfolded proteins in the ER, could lead to upregulation of ER 
chaperones. We previously reported that the ER luminal chaperone BiP plays a critical 
role in the rescue of L444P GC folding (Chapters 4.1 and 4.2). We asked whether the 
increase in mutant GC activity observed upon ERAD inhibition could be attributed to 
upregulation of BiP or other ER chaperones induced in response to the sudden load of 
misfolded proteins in the ER. Quantitative RT-PCR experiments were conducted to 
evaluate the expression levels of representative ER chaperones (BiP, CNX and CRT) in 
L444P GC fibroblasts treated with EerI (2 and 6 µM), Kif (50 nM), MG-132 (0.6 µM), or 
a combination thereof (Figure 4.3.9A-C).  
BiP expression (Figure 4.3.9A) was mildly upregulated by EerI treatment at 2 µM 
(1.6-fold, p<0.01) but highly upregulated at 6 µM (9.2-fold) and upon co-treatment with 
EerI (2 µM) and MG-132 (15.7-fold). Hence, the highest upregulation of BiP expression 
was observed at conditions causing maximal rescue of GC activity, namely upon cell 
treatment with high concentration of EerI (6 µM) or co-treatment with MG-132 and low 
concentration of EerI (2 µM). These data demonstrate a correlation between BiP 
transcriptional regulation and GC activity rescue. The dramatic increase in BiP 
expression observed could be part of UPR induction, which was previously shown to 
facilitate GC folding rescue (See chapters 4.1 and 4.2; or papers Wang et al., 2011a and 
Wang et al., 2011b) and is analyzed below in more detail.  
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Interestingly, cell treatment with Kif under conditions observed to maximize 
L444P GC activity rescue only resulted in a moderate increase of BiP expression (2.0-
fold, p<0.01), even when used in combination with MG-132 (2.2-fold, p<0.01). Hence, 
under the conditions tested, Kif-mediated ERAD inhibition does not lead to ER stress or 
chaperone upregulation. We suggest that the lower increase in BiP expression observed 
upon treatment with Kif compared to EerI is not an indication of the lower rescue of 
L444P GC activity, but rather of the two molecules’ different mechanisms of action. In 
support of this hypothesis is evidence that even the addition of MG-132, which 
dramatically increases Kif mediated L444P GC rescue (Figure 4.3.9C), does not cause 
upregulation of BiP expression.  
CNX was mildly upregulated by treatment with EerI or Kif, alone or in 
combination with MG-132 (Figure 4.3.9B). CRT expression was not substantially altered 
by EerI treatment, although it was upregulated (3.5-fold) by co-treatment with MG-132 
and EerI (Figure 4.3.9C). 
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Figure 4.3.9. Upregulation of BiP transcriptional expression in L444P GC 
fibroblasts treated with ERAD inhibitors. Relative mRNA expression levels of A) BiP 
(p<0.01), B) CNX (p<0.05), and C) CRT (p<0.05) in L444P GC fibroblasts treated with 
EerI (2 and 6 µM), Kif (50 nM), and MG-132 (0.6 µM) for 24 hrs were obtained by 
quantitative RT-PCR, corrected by the expression of the housekeeping gene GAPDH, 
and normalized to those of untreated cells. The data is reported as mean ± SD.  
 
Western blot analyses (Figure 4.3.10A) were conducted to confirm ER chaperone 
expression and bands were quantified with ImageJ software (Figure 4.3.10B). BiP protein 
accumulation was enhanced by treatment with EerI in a concentration-dependent fashion 
(EerI 2 µM caused 1.5-fold increase and EerI 6 µM resulted in 2.5-fold increase). Co-
treatment with EerI and MG-132 further enhanced BiP accumulation (2.7-fold) compared 
to untreated cells. Kif treatment, however, caused very modest increase in BiP 
accumulation when used alone (1.2-fold) or in combination with MG-132 (1.6-fold). 
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CNX and CRT protein levels were minimally altered upon small molecule treatment. 
Overall, results from Western blot analyses are consistent with RT-PCR experiments, 
with the exception of CRT expression, for which transcriptional changes are not reflected 
at the translational level, suggesting that CRT upregulation by cell treatment with MG-
132 and EerI does not translate into enhanced accumulation of CRT protein.  
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Figure 4.3.10. BiP protein accumulation in L444P GC fibroblasts treated with 
ERAD inhibitors. A) Western blot analyses of BiP, CNX, CRT, and GAPDH (used as 
loading control) in cells treated with EerI (2 and 6 µM), Kif (50 nM), and MG-132 (0.6 
µM) for 48 hrs. B) Quantification of Western blot bands. ER chaperone band intensities 
were quantified with NIH ImageJ analysis software, corrected by GAPDH band 
intensities, and divided by the values obtained in untreated samples. 
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Induction of UPR depends on the mechanism of ERAD inhibition 
Accumulation of misfolded proteins triggers ER stress, which in turn leads to 
UPR induction. In order to evaluate UPR induction in cells treated with ERAD inhibitors, 
we measured the expression of three representative proteins that are typically upregulated 
as part of the UPR: X-box binding protein-1 (Xbp-1), activating transcription factor 4 
(ATF4), and C/EBP homologous protein (CHOP) (see Chapter 4.2 for a more detailed 
description of the UPR pathway; and Schroder and Kaufman, 2005). Quantitative RT-
PCR was conducted to evaluate the expression of Xbp-1, ATF4, and CHOP in cells 
treated with EerI (2 and 6 µM), Kif (50 nM), MG-132 (0.6 µM), or a combination 
thereof.  
Activation of the IRE1 signaling cascade involves splicing of Xbp-1 mRNA. 
Spliced Xbp-1 mediates induction of UPR genes, whereas the unspliced Xbp-1 precursor 
functions as a repressor (Ron and Walter, 2007). To evaluate activation of the IRE1 arm 
of the UPR, spliced and unspliced Xbp-1 mRNA were quantified by RT-PCR followed 
by gel electrophoresis (Figure 4.3.11A-B). MG-132 was previously shown to enhance 
Xbp-1 splicing (Mu et al., 2008b) and is reported here for comparison. Treatment with 
EerI resulted in Xbp-1 splicing in a concentration dependent fashion (EerI 2 µM, 1.3-fold 
increase in splicing; EerI 6 µM, 2.1-fold increase). Co-administration of EerI (2 µM) and 
MG-132 further increased Xbp-1 splicing (3.6-fold compared to MG-132 treatment). Kif 
treatment did not induce splicing of Xbp-1, and co-treatment with Kif and MG-132 
resulted in increase in spliced Xbp-1 similar to that induced by treatment only with MG-
132. In summary, Xbp-1 splicing was induced upon EerI but not by Kif treatment, 
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suggesting that activation of the IRE1 pathway depends on the specific mechanism of 
ERAD inhibition.  
ATF4 expression was upregulated 4.4-fold by treatment with EerI and 6.0-fold by 
co-treatment with EerI and MG-132 (p<0.05), a clear indication of the PERK arm’s 
activation in cells treated with EerI (Figure 4.3.11D). A considerably lower increase in 
ATF4 expression was observed in cells treated with Kif (2.5-fold, p<0.01). Moreover, co-
treatment with Kif and MG-132 did not result in significant upregulation of ATF4 
expression compared to treatment only with MG-132, again suggesting that UPR 
activation depends on the mechanism of ERAD inhibition. 
CHOP was found to be highly upregulated upon EerI treatment (Figure 4.3.11C). 
Specifically, EerI 2 µM resulted in 4.2-fold increase in CHOP expression, EerI 6 µM in 
19-fold increase, and co-administration of EerI (2 µM) and MG-132 in 24-fold increase 
(p<0.01), indicating that EerI mediated ERAD inhibition causes activation of the ATF6 
pathway. Because CHOP plays a role in the induction of apoptotic pathways (Oyadomari 
and Mori, 2004), these results also suggest that EerI treatment might activate UPR-
induced apoptosis, which is analyzed below. Treatment with Kif alone or in combination 
with MG-132 led to 2.2-fold and 6.5-fold CHOP upregulation, respectively, which are 
significantly lower than the values observed upon EerI treatment and do not exceed those 
observed upon treatment with MG-132 (Figure 4.3.11C).  
In summary, we demonstrated that EerI, but not Kif, when used under conditions 
that promote rescue of L444P GC activity, is associated with dramatic activation of the 
UPR.  
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Figure 4.3.11. UPR activation in L444P GC fibroblasts treated with ERAD inhibitors. 
Cells were treated with EerI (2 and 6 µM), Kif (50 nM), and MG-132 (0.6 µM) for 24 hrs. 
A) Xbp-1 mRNA splicing was determined by RT-PCR followed by gel electrophoresis. B) 
Spliced Xbp-1 band intensities were quantified with the NIH ImageJ analysis software. 
Relative mRNA expression levels of C) CHOP (p<0.01), and D) ATF4 (p<0.05) were 
obtained by quantitative RT-PCR and calculated as described in Figure 4.3.9. The data is 
reported as mean ± SD.  
 
Upregulation of the gene encoding GC (GBA) as well as of other genes encoding 
for lysosomal proteins associated with the development of LSDs was previously reported 
in cells treated with UPR inducing proteostasis regulators (Chapter 4.1). We asked 
whether ERAD inhibition, in addition to preventing GC degradation, it also increases GC 
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accumulation in the ER by upregulating its transcription. Quantitative RT-PCR was 
conducted to measure GC expression in L444P GC fibroblasts treated with EerI (2 and 6 
µM), Kif (50 nM), and MG-132 (0.6 µM) (Figure 4.3.12A-C). EerI treatment was 
observed to enhance GC expression in a concentration-dependent fashion (EerI 2 µM, 
2.3-fold; EerI 6 µM, 3.3-fold; p<0.01). Co-treatment with EerI (2 µM) and MG-132 (0.6 
µM) resulted in 4.4-fold increase in GC expression (p<0.05), which is higher than what 
observed using EerI alone (2.3-fold), but comparable to treatment with MG-132 only 
(4.0-fold). A lower increase in GC expression was measured in cells treated with Kif 
(1.9-fold), as expected, considering the modest UPR induction caused by Kif treatment. 
Similar to what was observed for EerI, the increase in GC expression observed upon co-
treatment with MG-132 (2.8-fold) was lower than that detected in cells treated only with 
MG-132 (4.0-fold).  
GC expression was also investigated by Western blot analyses (Figure 4.3.12B-
C). It is important to notice that changes in protein accumulation detected by Western 
blot are to be attributed to both GC transcriptional modulation caused by ERAD 
inhibition-induced UPR and GC post-translational processing caused by ERAD inhibition 
mediated protein rescue. L444P GC content was barely detectable in untreated cells, as 
expected, due to extensive ERAD (Sawkar et al., 2006b), whereas treatment with either 
ERAD inhibitor enhanced GC accumulation level. GC accumulation increased in EerI 
treated cells in a concentration-dependent fashion (cf. bands corresponding to EerI 2 µM 
and EerI 6 µM treatments). The addition of MG-132 further enhanced GC accumulation 
observed in EerI and Kif treated cells.  
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Figure 4.3.12. Upregulation of GC expression in L444P GC fibroblasts treated with 
ERAD inhibitors. Cells were treated with EerI (2 and 6 µM), Kif (50 nM), and MG-132 
(0.6 µM). A) Relative mRNA expression levels of GC (p<0.05) were obtained by 
quantitative RT-PCR in cells treated with small molecules for 24 hrs and calculated as 
described in Figure 4.3.9. The data is reported as mean ± SD. B) Western blot analysis of 
cells treated with small molecules for 48 hrs using GC specific antibody. GAPDH 
expression was used as a loading control. C) Western blot band quantification. GC bands 
were quantified by NIH ImageJ analysis software and corrected by GAPDH band 
intensities. 
 
In summary, ERAD inhibition resulted in both increase in GC transcription and 
cellular accumulation. GC upregulation was found to be proportional to the extent of 
UPR induction measured upon treatment with each specific ERAD inhibitor. However, 
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co-treatment with an ERAD inhibitor and a proteostasis modulator, MG-132, which was 
demonstrated to have a synergistic effect on the rescue of mutated GC activity (Figure 
4.3.2A and 4.3.2C), did not cause a corresponding synergistic increase in GC 
transcription, suggesting that rescue of mutated GC cannot be solely attributed to the 
effect of ERAD inhibitors on GC expression. 
If ER stress persists, prolonged UPR activation typically leads to induction of 
apoptosis (Schroder and Kaufman, 2005). We asked whether cell treatment with Eer and 
Kif influenced UPR-induced apoptosis. The CytoGLO
TM
 Annexin V-FITC Apoptosis 
Detection Kit was used to detect membrane rearrangement (Annexin V binding, a 
measurement of early apoptosis) and fragmentation (propidium iodide (PI) binding, a 
measurement of late apoptosis) in L444P GC fibroblasts treated with EerI (2 µM), Kif 
(50 nM), and MG-132 (0.6 µM) (Figure 4.3.13A-C). High Annexin V binding and 
consequently dramatic increase in cell fluorescence was observed upon cell treatment 
with EerI compared to untreated cells (Figure 4.3.13A). Addition of MG-132 to EerI 
treated cells resulted in even higher increase in Annexin V binding.  However, we did not 
detect any increase in Annexin V binding in cells treated with Kif compared to untreated 
cells. Moreover, addition of Kif and MG-132 resulted in Annexin V binding 
indistinguishable from that observed in cells treated only with MG-132 (Figure 4.3.13B). 
Measurements of PI binding, which is taken as an estimate of the dead cell population, 
showed similar results. A 4.1% increase in dead cells was observed upon EerI treatment 
compared to untreated cells, whereas a negligible increase (0.4%) was observed upon Kif 
treatment (Figure 4.3.13C). These results demonstrate that while EerI treatment causes 
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dramatic increase in mutated GC activity at the cost of significant cell toxicity and 
apoptosis induction, treatment with Kif facilitates folding without induction of apoptosis.  
 
Figure 4.3.13. Apoptosis induction in L444P GC patient-derived fibroblasts treated 
with ERAD inhibitors. Flow cytometry histograms of Annexin V-FITC fluorescence 
intensities (x-axis, log scale) plotted against cell counts (y-axis, linear scale) obtained 
from the analysis of A) untreated cells and cells treated with MG-132 (0.6 µM), EerI (2 
µM), and EerI (2 µM) and MG-132 (0.6 µM); B) untreated cells and cells treated with 
MG-132 (0.6 µM), Kif (50 nM), and Kif (50 nM) and MG-132 (0.6 µM) for 16 hrs. 
Three independent experiments were conducted and results of one representative 
experiment are reported. C) PI binding population change (%) of cells treated with EerI 
(2 and 6 µM), Kif (50 nM), and MG-132 (0.6 µM) for 16 hrs compared to untreated cells 
(p<0.01). Number of total counted cells: 10,000. The data is reported as mean ± SD.  
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4.3.3. Discussion 
We demonstrated that inhibition of ERAD enhances folding, trafficking and 
lysosomal activity of mutated enzyme variants that cause two clinically distinct LSDs, 
Gaucher’s and Tay-Sachs disease. Results from this work suggest that ERAD limits the 
folding of secretory proteins containing misfolding, destabilizing mutations and provide 
proof-of-principle of ERAD inhibition as a viable strategy to rescue loss-of-function 
phenotypes in fibroblasts derived from patients with LSDs.  
ERAD inhibition was shown to promote folding of the two most common GC 
variants: L444P GC (Figures 4.3.2-4.3.5), which is typically completely targeted to 
ERAD (Grabowski, 1997), and N370S GC (Figures 4.3.6 and 4.3.7), a presumably less 
destabilized variant that is moderately resistant to ERAD and retains partial residual 
activity (Grace et al., 1994). ERAD inhibition was also observed to rescue folding of 
Tay-Sachs disease G269S HexA (Figure 4.3.8), which, similar to N370S GC, retains 
partial activity (Tropak et al., 2004). Interestingly, we consistently observed higher 
activity rescue in L444P GC cells, which normally display complete loss of activity, 
compared to N370S GC and G269S HexA cells. This observation suggests that the rescue 
in protein folding caused by treatment with ERAD inhibitors inversely correlates with the 
stability and residual activity of the mutated substrate. 
Experimental evidence reported previously (Ron and Horowitz, 2005) and in this 
thesis suggests that the single-site mutations considered in this study cause destabilization 
of the protein native, lowest free energy conformation (Chapter 4.2). In order to quantify 
the stability of mutated variants, we conducted in silico analysis of folding free energy 
changes (∆∆G) between WT and mutant proteins using PoPMuSiC software (Gilis and 
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Rooman, 2000; Kwasigroch et al., 2002). ∆∆G values of 0.92 and 4.2 kcal/mol were 
obtained for N370S and L444P GC, respectively, indicating that both mutations have a 
destabilizing effect on native folding with the L444P substitution causing significantly 
higher loss of stability. A similar analysis conducted for the HexA protein revealed the 
∆∆G caused by the G269S substitution to be 0.49 kcal/mol, which is comparable to the 
∆∆G of N370S GC and considerably lower than that of L444P GC. These values 
correlate with the experimental results that indicate a relationship between protein 
stability and degradation.  
ERAD inhibition and proteostasis modulation resulted in synergistic rescue of 
lysosomal activity in patient-derived cells (Figures 4.3.2, 4.3.6, and 4.3.8), indicating that 
a larger pool of unstable proteins that escapes ERAD and can engage the ER folding 
pathway is rescued by combining ERAD inhibition with upregulation of the cellular 
folding capacity. Interestingly, the activity window for EerI alone was consistently 
shifted toward lower concentrations when EerI was combined with a proteostasis 
regulator, implying that ER retention needs to be carefully modulated to meet the 
capacity of the cellular folding machinery. It remains to be determined whether EerI 
treatment results in higher activity rescue than Kif treatment due to higher efficiency of 
the molecular mechanism involved (p97 vs ER mannosidase inhibition).  
Detailed investigations of the molecular mechanism of ERAD inhibition and 
consequent changes in the cellular folding capacity were conducted in L444P GC 
fibroblasts treated to block two different steps of the ERAD pathway and prevent early 
recognition of misfolding intermediates (Kif) or retrotranslocation of irremediably 
misfolded substrates (EerI) (Figure 4.3.1). ER stress and UPR normally observed upon 
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accumulation of misfolded proteins were investigated (Figures 4.3.9-4.3.12) and seemed 
to be highly dependent on the specific mechanism of ERAD inhibition. We speculate that 
by inhibiting retrotranslocation of irremediably misfolded proteins, EerI inevitably leads 
to significant accumulation of misfolded proteins and consequent induction of UPR and 
apoptosis. Kif, however, by preventing targeting of folding intermediates to the ERAD 
pathway, is expected to enhance retention of substrates that can still be assisted by ER 
chaperone pathway and reach native folding. As a result, Kif-mediated ERAD inhibition, 
despite promoting significant ER retention and folding of mutated GC, particularly when 
used in combination with a proteostasis modulator (Figures 4.3.2-4.3.5), does not cause 
ER stress, as demonstrated by investigating changes in ER chaperone expression (Figures 
4.3.9-4.3.10), nor does it cause activation of UPR (Figure 4.3.11) or apoptosis (Figure 
4.3.13). 
Upregulation of the GC encoding gene, which was previously suggested to 
contribute to the rescue of GC activity mediated by UPR inducing proteostasis regulators 
(Chapters 4.1 and 4.2), was also observed in this study in association with UPR activation 
(Figure 4.3.12). Kif treatment, for instance, which did not cause significant UPR, was not 
associated with considerable increase in GC expression. Interestingly, co-treatment with 
Kif and MG-132, despite causing a dramatic increase in GC activity, did not result in 
UPR induction and GC upregulation. These results, taken together, suggest that the 
rescue of GC folding observed in cells treated with ERAD inhibitors, alone or in 
combination with proteostasis regulators, cannot be solely attributed to UPR activation. 
Finally, ERAD inhibitors led to dramatically different levels of apoptosis 
induction (Figure 4.3.13). Specifically, Kif treatment did not cause cytotoxicity and did 
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not increase MG-132 associated induction of apoptosis. A next step would be detailed 
investigation to identify the steps of the ERAD pathway that can be modulated for the 
rescue of degradation-prone substrates without dramatically compromising protein 
homeostasis and disrupting the functioning of the folding quality control system. 
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4.4. Remodeling the proteostasis network to rescue native 
folding of glucocerebrosidase variants by inhibiting ER-
associated degradation and enhancing ER folding 
4.4.1. Introduction 
In the previous chapters, we demonstrated that modulation of Ca
2+
 homeostasis in 
GD fibroblasts creates a folding environment more amenable to rescue of mutated GC 
folding (chapters 4.1 and 4.2) and that inhibiton of ERAD, by increasing ER retention of 
GC intermediates, results in increase in native folding and activity of mutated GC 
variants. Based these results, we speculated that restoring Ca
2+
 homeostasis in GD cells 
would create a folding environment particularly amenable to rescue of mutated GC 
folding via ERAD inhibition. Therefore, we attempted remodeling the proteostasis 
network to increase ER retention of unstable GC variants by inhibiting retrotranslocation 
and ERAD degradation and to enhance chaperone-mediated folding by restoring Ca
2+
 
homeostasis (Figure 4.4.1). We report evidence suggesting that simultaneously inhibiting 
ERAD and enhancing the ER folding capacity by co-administering lacidipine and EerI to 
fibroblasts derived from patients with GD results in synergistic rescue of the folding and 
activity of the severely destabilized L444P GC variant. Moreover, we demonstrated that 
lacidipine treatment lowers EerI-mediated UPR induction and apoptosis. Upregulation of 
the anti-apoptotic gene Bcl-2 associated with lacidipine treatment was found to play a 
key role in preventing the induction of apoptosis in EerI-treated cells.  Results from this 
work provide novel insights for the development of effective therapeutic strategies for the 
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treatment of GD based on remodeling the proteostasis network to rescue folding of 
unstable, degradation-prone GC variants. 
 
 
 
Figure 4.4.1. Inhibition of ERAD and modulation of Ca
2+
 homeostasis synergize to 
enhance the ER folding capacity in cells derived from patients with GD. Lacidipine 
enhances ER folding by restoring Ca
2+
 homeostasis in GD cells. Specifically, lacidipine 
inhibits extracellular Ca
2+
 influx through L-type voltage-gated Ca
2+
 channels (LTCC) on 
the plasma membrane and blocks ER Ca
2+
 efflux through ryanodine receptors (RyRs) on 
the ER membrane, thus restoring the intracellular gradient of [Ca
2+
]. EerI treatment 
enhances retention of unstable proteins in the ER. Specifically, EerI inhibits p97 ATPase 
activity, which promotes retro-translocation of misfolded substrates from the ER to the 
cytoplasm for ER-associated degradation (ERAD). Lacidipine and EerI modulate distinct 
pathways of the proteostasis network involved in promoting native folding of GC. 
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4.4.2. Results 
Inhibition of ERAD and modulation of Ca
2+
 homeostasis synergize to rescue 
L444P GC folding, trafficking and activity in fibroblasts derived from patients with 
Gaucher’s disease 
Experiments were conducted to simultaneously modulate Ca
2+
 homeostasis and 
ERAD inhibition in GD fibroblasts. Specifically, we used the LTCC blocker lacidipine, 
which restores Ca
2+
 homeostasis by inhibiting LTCC on the cell membrane and RyRs on 
the ER membrane (Chapters 4.1 and 4.2), and Eeyarestatin I (EerI), which blocks the 
ERAD pathway by inhibiting the p97 ATPase (Fiebiger et al., 2004; Wang et al., 2010), 
and investigated the activity and intracellular trafficking of mutated GC. Experiments 
were performed by administering a constant concentration of lacidipine (5, 10, or 20 μM) 
to fibroblasts derived from GD patients homozygous for the L444P GC allele that were 
cultured in medium supplemented with a range of EerI concentrations. GC enzymatic 
activity was evaluated every 24 hr for up to 72 hrs with the intact cell GC activity assay 
(Figure 4.4.2). Culturing conditions resulting in maximal rescue of L444P GC activity are 
reported in Figure 4.4.2. Co-treatment with EerI (6 μM) and lacidipine (20 μM) for 48 hr 
resulted in a 2.9-fold increase in L444P GC activity compared to untreated cells 
(p<0.001; Figure 4.4.2), which corresponds to 36% of WT activity and is compatible with 
effective treatment (Schueler et al., 2004). This increase in GC activity is significantly 
higher than that measured in cells treated only with EerI (1.6-fold) or lacidipine (1.8-fold) 
under the same conditions and was still observed after 72 hrs of incubation (EerI 6 μM 
and lacidipine 20 μM, 2.6-fold increase in GC activity, p<0.01). 
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Figure 4.4.2. Co-treatment of GD patient-derived fibroblasts with EerI and 
lacidipine enhances the activity of L444P GC. L444P GC activities were evaluated in 
cells treated with a range of concentrations of EerI and constant doses of lacidipine (5, 
10, or 20 μM) for 72 hrs. Relative GC activities were calculated by normalizing GC 
activities measured in treated cells to the activity in untreated cells (left y axis), (p<0.01 if 
not specified; *p<0.001). The corresponding fraction of WT GC activity is also reported 
(right y axis). Experiments were repeated three times and data points are reported as 
mean ± SD. Lac, lacidipine.  
 
In order to verify that the increase in GC activity observed in cells treated with 
EerI and lacidipine is due to rescue of L444P GC folding and lysosomal trafficking, we 
investigated L444P GC intracellular localization. Cells were treated under culturing 
conditions that gave rise to maximal GC activity increase and analyzed by 
immunofluorescence microscopy. Specifically, L444P GC patient-derived fibroblasts 
were cultured with EerI (6 μM), lacidipine (10 μM) and a combination thereof for 48 hrs. 
GC localizations in the ER and in the lysosomes were detected with antibodies specific 
for GC, for an ER marker (CNX), and for a lysosomal marker (LAMP-1). Co-localization 
of GC and CNX (Figure 4.4.3A) and of GC and LAMP-1 (Figure 4.4.3B) is shown in 
pink and purple, respectively, in merged images. Heatmaps of co-localization images 
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were obtained with NIH ImageJ software. L444P GC was barely detectable in untreated 
cells due to extensive ERAD, as expected (Mu et al., 2008b). Treatment with lacidipine 
or EerI enhanced the pool of GC that accumulates both in the ER and in the lysosomes, as 
shown in Chapters 4.2 and 4.3. The addition of lacidipine to EerI treatment did not 
significantly increase GC accumulation in the ER compared to cells treated only with 
EerI, but resulted in a significantly larger pool of GC in the lysosomes compared to cells 
treated with either EerI or lacidipine. These results demonstrate that combining 
modulation of Ca
2+
 homeostasis and ERAD enhances rescue of GC folding intermediates 
that escape ERAD and promotes their trafficking through the secretory pathway, thereby 
leading to the increase in lysosomal GC activity observed with enzymatic assays (Figure 
4.4.2). 
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Figure 4.4.3. Co-treatment with EerI and lacidipine enhances the folding and 
lysosomal trafficking of L444P GC in patient-derived fibroblasts. 
Immunofluorescence microscopy of A) GC and CNX (an ER marker), and B) GC and 
LAMP-1 (a lysosomal marker) in L444P GC fibroblasts. Cells were treated with EerI (6 
µM), and lacidipine (10 µM) for 48 hrs. Colocalization of CNX (grey, column 1) and GC 
(red, column 2) is shown in pink (column 3). Colocalization of LAMP-1 (blue, column 1) 
and GC (red, column 2) is shown in purple (column 3). Heatmaps of co-localization 
images were obtained with NIH ImageJ analysis software (column 4). Hot colors 
represent positive correlation (co-localization), whereas cold colors represent negative 
correlation (exclusion). Lac, lacidipine. 
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Lacidipine treatment attenuates the cytotoxic effect of EerI-mediated ERAD 
inhibition in fibroblasts derived from patients with Gaucher’s disease 
By inhibiting retrotranslocation of misfolded proteins, EerI treatment causes 
accumulation of misfolded intermediates in the ER and, consequently, ER stress and 
induction of the UPR (Chapter 4.3 or Wang et al., 2011c). UPR is activated to cope with 
the aberrant accumulation of misfolded proteins (Ron and Walter, 2007). Not 
surprisingly, moderate UPR induction was repeatedly reported to promote rescue of 
misfolding-prone GC variants (Mu et al., 2008b and Chapters 4.1-4.3). However, 
prolonged UPR induction observed upon sustained treatment with EerI was also observed 
to cause activation of apoptosis (Chapters 4.2 and 4.3). Cell treatment with lacidipine, on 
the other hand, was shown not to cause cytotoxicity under conditions observed to rescue 
folding of mutated GC variants (Chapters 4.2 and 4.3). Because lacidipine treatment also 
causes moderate UPR induction (Chapter 4.2), we hypothesized an anti-apoptotic effect 
associated with lacidipine treatment that protects cells from UPR-induced apoptosis 
(Rodriguez et al., 2010; Wang et al., 2011b). Therefore, we asked whether lacidipine 
treatment could counteract the cytotoxic effect of EerI and evaluated apoptosis in cells 
co-treated with lacidipine and EerI. 
CytoGLO
TM
 Annexin V-FITC Apoptosis Detection Kit was used to monitor 
membrane rearrangement (Annexin V binding) and fragmentation (propidium iodide (PI) 
binding) that occur during early and late apoptosis, respectively. L444P GC fibroblasts 
were cultured with lacidipine (10 μM) and EerI (6 μM) for 16 hrs (Figure 4.4.4A-B). 
Similar to observations reported in chapters 4.1 and 4.2 (Wang et al., 2011b; Wang et al., 
2011c), Annexin V binding affinity in cells treated with lacidipine was comparable to that 
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measured in untreated cells, whereas a dramatic increase in Annexin V binding was 
observed in cells treated with EerI, reflecting the onset of apoptosis. The addition of 
lacidipine to EerI-treated cells resulted in significant decrease in Annexin V binding 
compared to cells treated only with EerI, suggesting that lacidipine treatment partially 
alleviates EerI cytotoxic effect (Figure 4.4.4A). The dead cell population was evaluated 
by measuring PI binding affinity. A negligible increase (0.3%) in PI binding was 
observed upon lacidipine treatment, whereas EerI treatment caused a 10% increase 
(p<0.01; Figure 4.4.4B). The addition of lacidipine to EerI-treated cells reduced the PI 
binding population to 6.7% (p<0.01), confirming that lacidipine has an anti-apoptotic 
effect.  
These results, taken together, prove that lacidipine treatment enhances EerI-
mediated rescue of mutated GC native folding and activity but that it also counteracts its 
cytotoxic effect, therefore protecting the cells from UPR induced apoptosis, a particularly 
appealing property for development of therapeutic solutions based on the modulation of 
the proteostasis network.  
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Figure 4.4.4. Lacidipine treatment attenuates EerI-mediated apoptosis induction in 
L444P GC patient-derived fibroblasts. A) Flow cytometry histograms of Annexin V-
FITC fluorescence intensities (x-axis, log scale) plotted against cell counts (y-axis, linear 
scale) obtained from the analysis of untreated cells and cells treated with EerI (6 µM) and 
lacidipine (10 µM). Three independent experiments were conducted and results of one 
representative experiment are reported. B) PI binding population change (%) of cells 
treated with EerI (6 µM) for 16 hrs compared to untreated cells (p<0.01). Number of total 
cells counted: 10,000. The data is reported as mean ± SD. 
 
Lacidipine treatment remodels EerI-mediated activation of the UPR pathway 
Previous studies showed that EerI, when administered under conditions that result 
in maximal increase in L444P GC activity, is associated with significant UPR induction 
and cell apoptosis, whereas lacidipine treatment induces UPR but does not cause 
apoptosis (Chapter 4.2; Wang et al., 2011b). We reported above that lacidipine prevents 
apoptosis in cells treated with EerI (Figure 4.4.4). Therefore, we asked whether lacidipine 
affects UPR induction in EerI-treated cells. We measured the expression of three 
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representative UPR target proteins: X-box binding protein-1 (Xbp-1), activating 
transcription factor 4 (ATF4), and C/EBP homologous protein (CHOP) (Schroder and 
Kaufman, 2005). Quantitative RT-PCR was conducted to evaluate the expression levels 
of Xbp-1, ATF4, and CHOP in cells treated with lacidipine (10 µM) and EerI (6 µM).  
The precursor mRNA of Xbp-1 is spliced upon activation of the IRE1 signaling 
cascade. Spliced Xbp-1 mRNA functions as an activator of the IRE1 branch of the UPR, 
while the unspliced precursor acts as a repressor (Ron and Walter, 2007). Spliced and 
unspliced forms of Xbp-1 mRNA were analyzed by RT-PCR followed by gel 
electrophoresis. Bands corresponding to spliced Xbp-1 mRNA were quantified with NIH 
ImageJ software to evaluate the activation level of the IRE1 arm of the UPR (Figure 
4.4.5A-B). In agreement with results reported in Chapter 4.2, the amount of spliced Xbp-
1 in lacidipine treated cells was similar to that of untreated cells (Wang et al., 2011b), 
whereas a considerable amount of spliced Xbp-1 was observed in cells treated with EerI 
(Wang et al., 2011c). In cells treated with both lacidipine and EerI, the amount of spliced 
Xbp-1 was found to further increase 1.7-fold compared to cells treated only with EerI, 
suggesting a synergistic effect of lacidipine and EerI on the induction of the IRE1 arm. 
Xbp-1 is an essential pro-survival UPR component and its activation is associated with 
attenuated apoptosis under ER stress conditions (Gupta et al., 2010). Hence, enhanced 
splicing of Xbp-1 in cells treated with lacidipine and EerI correlates with the decrease in 
apoptosis induction observed under same conditions.  
The expression level of ATF4 was evaluated in order to monitor the activation of 
the PERK branch. ATF4 transcriptional expression was upregulated 1.8- and 4.4-fold in 
cells treated with lacidipine and EerI, respectively, compared to untreated cells, 
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indicating that these two proteostasis modulators have different effects on the induction 
of this arm of the UPR. Interestingly, the addition of lacidipine to EerI-treated cells was 
observed to reduce ATF4 expression to only 2.1-fold increase (p<0.05) compared to 
untreated cells, indicating that lacidipine suppresses EerI-mediated activation of the 
PERK arm (Figure 4.4.5C).  
CHOP, a downstream effector of the ATF6 branch, was found to be highly 
upregulated by both lacidipine and EerI treatment (6.1- and 19-fold, respectively; Figure 
4.4.5D). The addition of lacidipine to EerI-treated cells lowered CHOP upregulation to 
15-fold (p<0.05). CHOP mediates UPR induced apoptosis activation (Oyadomari and 
Mori, 2004). These results confirm that lacidipine treatment suppresses UPR-induced 
apoptosis caused by EerI treatment as reported in Figure 4.4.4.  
In summary, treatment with lacidipine was found to remodel the UPR pathway 
and lower UPR-induced apoptosis caused by treatment with EerI. Particularly, lacidipine 
inhibits the activation of PERK and ATF6 arms, which mediate induction of apoptosis, 
and enhances the activation of the pro-survival IRE1/Xbp-1 arm, thus counteracting the 
progression of the apoptotic cascade.  
In Chapter 4.2, lacidipine treatment was shown to alter the expression of genes 
involved in the regulation of UPR-induced apoptosis, and, particularly, that it causes 
upregulation of the anti-apoptotic gene Bcl-2 (Wang et al., 2011b). We therefore asked 
whether the protective effect of lacidipine treatment observed in Eer-treated cells could 
be attributed to the upregulation of Bcl-2. The expression level of Bcl-2 was evaluated by 
performing quantitative RT-PCR in cells cultured with lacidipine (10 µM) and EerI (6 
µM). Lacidipine treatment resulted in 3.0-fold increase in Bcl-2 expression compared to 
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untreated cells, whereas EerI treatment caused a 2.0-fold decrease. Co-treatment with 
lacidipine and EerI resulted in considerable upregulation of Bcl-2 expression (4.2-fold; 
p<0.05; Figure 4.4.5E). Interestingly, Bcl-2 was shown to prevent apoptosis induction 
mediated by CHOP (Szegezdi et al., 2006), for which expression is lowered in 
association with the upregulation of Bcl-2 in cells co-treated with lacidipine and EerI, 
again supporting the notion that lacidipine treatment lowers UPR-induced apoptosis.  
Upregulation of the gene encoding GC (GBA) in cells treated with proteostasis 
modualtors was previously reported (Wang et al., 2011b; Wang et al., 2011c). We asked 
whether the synergistic effect of Ca
2+ 
homeostasis modulation and ERAD inhibition 
could be attributed to GC transcriptional upregulation in addition to inhibition of GC 
degradation. Quantitative RT-PCR was conducted to measure the expression of GC in 
GD patient-derived fibroblasts treated with lacidipine (10 µM) and EerI (6 µM). Co-
administration of lacidipine and EerI resulted in 5.2-fold upregulation of GC expression 
(p<0.05) compared to untreated cells, which is higher than what observed in cells treated 
only with lacidipine (2.5-fold) or EerI (3.3-fold) (Figure 4.4.5F).  
  
137 
 
 
 
Figure 4.4.5. Lacidipine treatment remodels the UPR pathway in EerI-treated 
fibroblasts derived from GD patients. Cells were treated with EerI (6 µM) and lacidipine 
(10 µM) for 24 hrs. A) Xbp-1 mRNA splicing was determined by RT-PCR followed by gel 
electrophoresis. B) Spliced Xbp-1 band intensities were quantified with the NIH ImageJ 
analysis software. Relative mRNA expression levels of C) ATF4, D) CHOP, E) Bcl-2, and 
F) GC were obtained by quantitative RT-PCR, corrected by the expression of the 
housekeeping gene GAPDH, and normalized by that of untreated cells (p<0.05). The data 
is reported as mean ± SD. G) Western blot analysis of cells treated with EerI (6 µM) and 
lacidipine (10 µM) for 48 hrs using GC specific antibody. GAPDH expression was used as 
a loading control. H) Western blot band quantification. GC bands were quantified by NIH 
ImageJ analysis software and corrected by GAPDH band intensities. 
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GC expression was also evaluated by Western blot (Figure 4.4.5G-H). As shown 
in Figure 4H, L444P GC content was barely detectable in untreated cells, as expected, 
due to extensive ERAD (Sawkar et al., 2006b), whereas treatment with either lacidipine 
or EerI significantly enhanced GC protein accumulation. Co-treatment with lacidipine 
and EerI further enhanced GC accumulation (1.4-fold increase compared to EerI 
treatment alone) in agreement with the results obtained from quantitative RT-PCR.  
In Chapters 4.1-4.3, we demonstrated that the increase in lysosomal GC activity 
observed upon chemically induced inhibition of ERAD or modulation of Ca
2+
 
homeostasis in cells derived from patients with GD is partially due to the upregulation of 
BiP expression associated with UPR induction. Therefore, we analyzed BiP expression in 
fibroblasts derived from GD patients co-treated with lacidipine and EerI. BiP protein 
accumulation was evaluated by Western blot using a BiP-specific antibody (Figure 
4.4.6A), and bands were quantified with NIH ImageJ software (Figure 4.4.6B). Co-
administration of lacidipine and EerI resulted in 3.5-fold increase in BiP cellular 
accumulation, which is lower than that observed in cells treated only with EerI (4.4-fold). 
Similar to results reported in Chapters 4.2 and 4.3 describing cell treatment with 
lacidipine and EerI (Wang et al., 2011b; Wang et al., 2011c), CNX and CRT protein 
levels were not altered by lacidipine and EerI treatment. BiP is normally upregulated 
upon activation of the UPR (Schroder and Kaufman, 2005). Thus, the decrease in BiP 
expression observed in cells treated with EerI and lacidipine reflects lacidipine-mediated 
attenuation of UPR induction.  
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Figure 4.4.6. Lacidipine treatment attenuates BiP upregulation caused by EerI-
mediated UPR activation. A) Western blot analyses of BiP, CNX, CRT, and GAPDH 
(used as loading control) in cells treated with EerI (6 µM) and lacidipine (10 µM) for 48 
hrs. B) Quantification of Western blot bands. ER chaperone band intensities were 
quantified with NIH ImageJ analysis software, corrected by GAPDH band intensities, 
and divided by the values obtained in untreated samples. 
 
Chemically induced upregulation of Bcl-2 enhances mutated GC activity 
rescue and cell viability 
Bcl-2 is the prototype of an expanding family of proteins that regulate cell 
survival and apoptosis in multiple cell types (Chipuk et al., 2010). As discussed above, 
treatment with lacidipine prevents UPR induced apoptosis and cell death caused by EerI 
treatment. The addition of lacidipine to EerI treated cells results in upregulation of Bcl-2 
expression to a considerably higher level than EerI treatment alone (Figure 4.4.5E). In 
order to investigate the role of Bcl-2 in cells treated for the rescue of mutated GC folding 
via UPR induction, we attempted to chemically induce Bcl-2 upregulation in cells 
derived from patients with GD. Fluvastatin was previously reported to prevent H2O2-
induced apoptosis by upregulating Bcl-2 expression (Xu et al., 2008). We asked whether 
fluvastatin could counteract the apoptotic effect of prolonged UPR induction. Fluvastatin 
was administered to cells treated with UPR inducing proteostasis modulators known to 
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rescue native folding of mutated GC. MG-132 inhibits proteasomal degradation, which, 
in turn, causes induction of UPR and upregulation of chaperones in GD cells (Mu et al., 
2008b). Co-treatment with EerI and MG-132 was found to dramatically enhance the 
activity of L444P GC (to 52% of WT activity), but at the cost of even higher induction of 
apoptosis (Chapter 4.3). We administered fluvastatin (100 nM) to cells treated with EerI 
(2 and 6 µM) and MG-132 (0.6 µM) and tested Bcl-2 expression, apoptosis and GC 
activity rescue. Fluvastatin treatment caused dramatic upregulation of Bcl-2 in GD cells 
(18.4-fold compared to untreated cells; p<0.05) and did not cause any cytotoxicity 
(Figure 4.4.7A-B). Upregulation of Bcl-2 and lowered apoptosis induction were also 
observed upon addition of fluvastatin in EerI-treated cells. Specifically, fluvastatin 
treatment caused a 4.6-fold increase in Bcl-2 expression in cells treated with EerI 2 µM 
and 5.2-fold in cells treated with EerI 6 µM compared to cells treated only with EerI 
(p<0.05; Figure 4.4.7A). Fluvastatin treatment also reduced apoptosis by 0.9% in cells 
treated with EerI 2 µM and by 3.7% in cells treated with EerI 6 µM (p<0.01; Figure 
4.4.7B). Similar results were obtained upon addition of MG-132. Bcl-2 expression in 
cells treated with both EerI and MG-132 was downregulated (0.83-fold) compared to 
untreated cells. However, the addition of fluvastatin caused upregulation of Bcl-2 
expression (2.8-fold; p<0.05) and decrease in dead cell population (4.0%; p<0.01). These 
results demonstrate that the upregulation of Bcl-2 expression enhances cellular tolerance 
to UPR-induced stress and cell survival, therefore preventing apoptosis in cells treated for 
the rescue of mutated GC folding.  
To investigate whether chemically induced upregulation of Bcl-2 expression 
affects mutated GC activity rescue, patient-derived fibroblasts harboring L444P GC were 
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cultured with EerI (2 and 6 µM), MG-132 (0.6 µM), and fluvastatin (100 nM) for up to 
72 hrs and GC activity was measured every 24 hrs (Figure 4.4.7C). Interestingly, 
chemically induced upregulation of Bcl-2 expression did not reduce the increase in 
L444P GC activity mediated by UPR induction. Compared to treatment with EerI (2 or 6 
µM) alone, co-treatment with fluvastatin and EerI for 48 hrs did not affect L444P GC 
activity at low EerI concentration, but resulted in a modest increase at high EerI 
concentration (to 2.0-fold; p<0.01). Co-administration of EerI and MG-132 resulted in a 
3.0-fold increase (p<0.01) in L444P GC activity as expected, which was further enhanced 
to 3.3-fold upon the administration of fluvastatin, indicating that upregulating Bcl-2 
expression to maintain cell viability enhances EerI and MG-132 mediated L444P GC 
activity rescue. 
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Figure 4.4.7. Upregulation of Bcl-2 protects GD cells from apoptosis caused by 
chemical modulation of the proteostasis network. A) Relative mRNA expression 
levels of Bcl-2 in cells treated with EerI (2 and 6 µM), MG-132 (0.6 µM), and fluvastatin 
(100 nM) for 24 hrs were obtained by quantitative RT-PCR and calculated as described in 
Figure 4.4.5 (p<0.05). B) PI binding population change (%) of cells treated with EerI (2 
and 6 µM), MG-132 (0.6 µM), and fluvastatin (100 nM) for 16 hrs compared to untreated 
cells (p<0.01). The data is reported as mean ± SD. Number of total counted cells: 10,000. 
C) Relative L444P GC activities of GD fibroblasts treated with EerI (2 and 6 µM), MG-
132 (0.6 µM), and fluvastatin (100 nM) for 48 hrs. Relative GC activities were evaluated 
as described in Figure 4.4.2 (p<0.01). Experiments were repeated three times and data 
points are reported as mean ± SD. MG, MG-132; Flu, fluvastatin. 
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4.4.3. Discussion 
Inhibition of specific steps of the ERAD pathway results in rescue of L444P GC, 
a severely destabilized mutant commonly associated with neuronopathic GD. ERAD 
inhibition, however, while enhancing retention of unstable GC in the ER and ultimately 
resulting in increased lysosomal trafficking and activity, also leads to significant UPR 
induction and apoptosis (Chapter 4.3). In this study, we attempted to combine ERAD 
inhibition with modulation of Ca
2+
 homeostasis. Restoring Ca
2+
 homeostasis via 
lacidipine treatment proved to be an effective strategy to rescue L444P GC folding and 
activity by modulating the cell folding capacity, without, however, inducing apoptosis 
(Chapter 4.2). We found that restoring Ca
2+
 homeostasis in GD cells results in a folding 
environment more amenable to rescue native folding of mutated GC via ERAD 
inhibition. Combining these two distinct mechanisms of action (Figure 4.4.1) causes 
synergistic increase of lysosomal trafficking and activity of mutated GC (Figures 4.4.2 
and 4.4.3). We found that cell treatment with lacidipine not only enhanced EerI-mediated 
rescue of mutated GC folding but also protected GD cells from UPR-induced apoptosis 
caused by ERAD inhibition (Figure 4.4.4).  
Mechanistic studies revealed that lacidipine remodels the induction of UPR 
caused by ERAD inhibition. Signal transducers of the UPR can activate either 
cytoprotective or proapoptotic pathways (Lin et al., 2009). A pro-survival response is 
first initiated to reduce the load of misfolded proteins by boosting the ERAD pathway 
(Termine et al., 2009). This response is mediated by the induction of the IRE1 signaling 
cascade (Lin et al., 2007) via Xbp-1 splicing and activation (Gupta et al., 2010). If the 
proteotoxic stress persists,  pro-apoptotic signals are elicited through the activation of 
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PERK and ATF6 signaling cascades via expression of ATF4 and its transcriptional target 
CHOP, which are upregulated simultaneously to attenuate IRE1 signaling (Kitamura, 
2008; Lin et al., 2009). Analysis of the UPR in GD cells co-treated with EerI and 
lacidipine revealed that this combination enhances Xbp-1 splicing while lowering the 
activation of ATF4 and CHOP. These results imply that lacidipine remodels EerI-
mediated UPR induction by enhancing the expression of the anti-apoptotic IRE1 arm and 
inhibiting the activations of the pro-apoptotic PERK and ATF6 arms (Figure 4.4.5). 
The Bcl-2 protein family plays a key role in the activation of UPR-induced 
apoptosis (Youle and Strasser, 2008). It consists of anti-apoptotic proteins including Bcl-
2, and pro-apoptotic proteins such as BAX and BAK (Youle and Strasser, 2008). 
Oligomerization and activation of BAX and BAK mediate induction of apoptosis (Youle 
and Strasser, 2008). CHOP upregulation causes downregulation of the anti-apoptotic Bcl-
2 gene (McCullough et al., 2001; Zong et al., 2003), which, in turn, enables the activation 
of pro-apoptotic proteins (Szegezdi et al., 2006). Bcl-2 upregulation, on the other hand, 
blocks CHOP-induced apoptosis (McCullough et al., 2001). Moreover, Bcl-2 contributes 
to maintaining Ca
2+
 homeostasis by reducing [Ca
2+
]ER efflux (Eckenrode et al., 2010; 
Rong et al., 2009). Bcl-2 was upregulated in L444P GC fibroblasts cultured with 
lacidipine (Wang et al., 2011b). Our results showed that lacidipine treatment enhances 
the expression of Bcl-2 in EerI-treated cells and protects cells from EerI-mediated 
apoptosis (Figure 4.4.4 and 4.4.5E). In addition, chemical induction of Bcl-2 expression 
enhances cell viability in GD cells treated with proteostasis modulators that induce the 
UPR (Figure 4.4.7). 
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In summary, this work demonstrates that combining modulation of Ca
2+
 
homeostasis and ERAD inhibition synergistically enhances the ER folding capacity 
leading to dramatic increase in L444P GC folding, lysosomal trafficking and activity. The 
results reported herein provide insights for the development of strategies to modulate the 
proteostasis network without triggering activation of apoptosis. 
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Chapter 5 
Materials and methods 
5.1. Cell lines and cell culture 
Patient-derived fibroblasts were obtained from Coriell Cell Repositories (Table 
5.1). 
Fibroblasts were grown in minimal essential medium with Earle’s salts 
supplemented with 10% heat-inactivated fetal bovine serum and 1% glutamine Pen-Strep 
at 37°C in 5% CO2. Cell medium was replaced every 3 or 4 days. Monolayers were 
passaged upon reaching confluency. 
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Table 5.1. Cell lines 
Cell line Disease Diagnosed Genotype Protein Mutation 
GM10915 Gaucher disease, type I 1448T>C L444P homozygous 
GM00852 Gaucher disease, type I 1226A>G N370S, 84GG 
GM13204 Tay-Sachs disease 
805G>A, 
1278insTATC 
G269S, 
1278insTATC 
GM00498 Wild-type - - 
 
5.2. Plasmids and primers 
The human cDNA clones of BiP, Calnexin, Calreticulin, and GRP94 were 
obtained from Origene., The Tetracycline-Regulated Expression System (T-REx™) was 
from Invitrogen and is composed of the two plasmids pcDNA™4/TO and 
pcDNA™6/TR.  
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Table 5.2. Plasmids 
Plasmid Phenotype Source 
BiP P11021; Human cDNA clone Origene (SC108086) 
Calnexin (CNX) P27824; Human cDNA clone Origene (SC108288) 
Calreticulin (CRT) P15253; Human cDNA clone Origene (SC320287) 
GRP94 P14625; Human cDNA clone Origene (SC108810) 
pcDNA™4/TO T-REx™; Inducible vector Invitrogen (V102020) 
pcDNA™6/TR T-REx™; Regulatory vector Invitrogen (V102520) 
 
 
Tables 5.3 and 5.4 include primers used in this study to construct plasmids and to 
perform quantitative RT-PCR, as described below. 
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Table 5.3. Cloning Primers 
Gene Primer Sequence 
BiP  
(HindIII/BamHI) 
BiP.f 5'-GCGCGCGGTACCATGAAGCTCTCCCTGGTG-3' 
BiP1.r 
5'-GATGAGTTTTTGTTCGGCGCCGG 
CCAACTCATCTTTTTCTGCTGTATCCTC -3' 
BiP2.r 
5'-GCGCGCGTATTGGGATCCTCACAG 
ATCCTCTTCTGAGATGAGTTTTTGTTC-3' 
CNX  
(KpnI/EcoRI) 
Cnx.f 5'-GCGCGCGGTACCATGGAAGGGAAGTGG-3' 
Cnx1.r 
5'-GAGTTTTTGTTCGGCGCCGGCCT 
CTCTTCGTGGCTTTCTGTTTCTTG -3' 
Cnx2.r 
5'-GCGCGCGTATTGGAATTCTCACA 
GATCCTCTTCTGAGATGAGTTTTTGTTC-3' 
CRT 
(HindIII/EcoRI) 
Crt.f 
5'-ATGCTACGAAAGCTTATGCTGCTA 
TCCGTGCCGCTGC -3' 
Crt1.r 
5'-TAATCAGTTTCTGTTCACCACCACC 
CAGCTCGTCCTTGGC-3' 
Crt2.r 
5'-GCGCCGCCCGAATTCTTACAGATCT 
TCTTCGCTAATCAGTTTCTGTTCAC-3' 
GRP94  
(EcoRI/XbaI) 
Grp94.f 
5'-TAGATACATGAATTCATGAGGGCCC 
TGTGGGTGCTGGG-3' 
Grp941.r 
5'-CGCTAATCAGTTTCTGTTCACCACC 
ACCCAATTCATCTTTTTCAGCTGT-3' 
Grp942.r 
5'-GCGCCGCCCTCTAGATTACAGATCT 
TCTTCGCTAATCAGTTTCTGTTCAC-3' 
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Table 5.4. RT-PCR Primers 
Gene 
GenBank 
Accession 
Code 
Primer Sequence 
BiP NM_005347 
BiP.f 5'-GCC TGT ATT TCT AGA CCT GCC-3' 
BiP.r 5'-TTC ATC TTG CCA GCC AGT TG-3' 
CNX NM_001746 
Cnx.f 5'-GCG TTG TGG GGC AGA TGA T-3' 
Cnx.r 5'-CCG GTT GAG GTG CAT CAG T-3' 
CRT NM_004343 
Crt.f 5'-AAG TTC TAC GGT GAC GAG GAG-3' 
Crt.r 5'-GTC GAT GTT CTG CTC ATG TTT C-3' 
Xbp-1 NM_005080 
Xbp1.f 5'-TTA CGA GAG AAA ACT CAT GGC-3' 
Xbp1.r 5'-GGG TCC AAG TTG TCC AGA ATG C-3' 
ATF4 NM_182810 
ATF4.f 5’- GAC CAC GTT GGA TGA CAC TTG -3’ 
ATF4.r 5’- GGG AAG AGG TTG TAA GAA GGT G-3’ 
ATF6 NM_007348 
ATF6.f 5’-TGC TTC CAG CAG CAC CCA AGACT-3’ 
ATF6.r 5’-CCC AGC AAC AGC AAG GAC TGG C-3’ 
CHOP NM_004083 
CHOP.f 5'-ACC AAG GGA GAA CCA GGA AAC G-3' 
CHOP.r 5'-TCA CCA TTC GGT CAA TCA GAG C-3' 
BAK NM_001188 
BAK.f 5'-GTT TTC CGC AGC TAC GTT TTT-3' 
BAK.r 5'-GCA GAG GTA AGG TGA CCA TCT C-3' 
BAX NM_004324 
BAX.f 5'-GGG TGG TTG GGT GAG ACT C-3' 
BAX.r 5'-AGA CAC GTA AGG AAA ACG CAT TA-3' 
Bcl-2 NM_000633 
Bcl-2.f 5'-GGG GAG GAT TGT GGC CTT C-3' 
Bcl-2.r 5'-CAG GGC GAT GTT GTC CAC C-3' 
GC NM_000157 
GC.f 5'-CCA AGC CTT TGA GTA GGG TAA G-3' 
GC.r 5'-CCC GTG TGA TTA GCC TGG AT-3' 
HEXA NM_000520.2 
HEXA.f 5'-CAA CCA ACA CAT TCT TCT CCA-3' 
HEXA.r 5'-CGC TAT CGT GAC CTG CTT TT-3' 
TPP1 NM_000391.2 
TPP1.f 5'-GAT CCC AGC TCT CCT CAA TAC G-3' 
TPP1.r 5'-GCC ATT TTT GCA CCG TGT G-3' 
LAMP1 NM_005561.2 LAMP1.f 5'-ACG TTA CAG CGT CCA GCT CAT-3' 
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LAMP1.r 5'-TCT TTG GAG CTC GCA TTG G-3' 
ATP6V1H NM_213619.1 
ATP6V1H.f 5'-GGA AGT GTC AGA TGA TCC CCA-3' 
ATP6V1H.r 5'-CCG TTT GCC TCG TGG ATA AT-3' 
PSAP NM_002778.1 
PSAP.f 5'-GCC AAC AGT GAA ATC CCT TCC-3' 
PSAP.r 5'-TCA GTG GCA TTG TCC TTC AGC-3' 
TFEB NM_007162.2 
TFEB.f 5'-CCA GAA GCG AGA GCT CAC AGA T-3' 
TFEB.r 5'-TGT GAT TGT CTT TCT TCT GCC G-3' 
M6PR NM_002355.2 
M6PR.f 5'-CTG GAG GAC TGG ACT GCT ACT-3' 
M6PR.r 5'-CTC CTA CCA AGT CGC AAG TTT T-3' 
LIMP2 NM_005506.2 
LIMP2.f 5'-GGC CGA TGC TGC TTC TAC A-3' 
LIMP2.r 5'-GGT CTC CCC TCT GAG GAT CTC-3' 
GAPDH NM_002046 
GAPDH.f 5'-GTC GGA GTC AAC GGA TT-3' 
GAPDH.r 5'-AAG CTT CCC GTT CTC AG-3' 
 
5.3. Chemicals and reagents 
Celastrol and thapsigargin were purchased from Calbiochem. MG-132 and 
kifunensine were from Cayman Chemical. N-(n-Nonyl)-deoxynojirimycin (NN-DNJ), 
Conduritol B Epoxide (CBE), lacidipine and 4-Methylumbelliferyl 6-Sulfo-2-acetamido-
2-deoxy-β-D-glucopyranoside (MUGS) were from Toronto Research Chemicals. 
Eeyarestatin I was from ChemBridge. 4-Methylumbelliferyl β-D-glucoside (MUG), 
tunicamycin, nicardipine and lercanidipine were from Sigma-Aldrich. DHBP Dibromide, 
ruthenium red, dantrolene, ryanodine, diltiazem and verapamil were from Tocris 
Bioscience. Fluvastatin was from Enzo Life Sciences. Fura-2, AM was from Anaspec. T-
REx™ complete kit and lipofectamine 2000 were from Invitrogen. Bovine Serum 
Albumin was from Jackson ImmunoResearch Laboratories. TMB reagent, Propidium 
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Iodide solution, FITC Annexin V and its binding buffer were from BioLegend. Cell 
culture media were from Lonza.  
 
5.4.  Enzyme activity assays 
The glucocerebrosidase (GC) activity assay was performed as previously 
described (Mu et al., 2008b). Briefly, 100 μl aliquots of 104 cells were plated in each 
well of a 96-well plate and incubated overnight to allow cell attachment. The medium 
was replaced with fresh medium containing small molecules on the next morning and the 
plates were incubated at 37°C (small molecule concentrations and time of incubation are 
specified in each experiment). The medium was then aspirated and monolayers were 
washed with PBS three times. The assay reaction was started by the addition of 50 μl of 
2.5 mM MUG in 0.2 M acetate buffer (pH 4.0) and stopped by the addition of 150 μl of 
0.2 M glycine buffer (pH 10.8) to each well after 7 hrs of incubation at 37°C. Liberated 
4-methylumbelliferone was measured (excitation 365 nm, emission 445 nm) with a 
SpectraMax Gemini plate reader (Molecular Device). Non-lysosomal GC activity was 
evaluated by measuring GC activities in the presence of Conduritol B Epoxide (CBE) at 1 
mM final concentration. Relative GC activities were calculated by subtracting the 
background of non-lysosomal activity and normalizing the obtained values by the activity 
of untreated cells. 
The hexosaminidase A (HexA) activity assay was performed as previously 
described (Mu et al., 2008b; Tropak et al., 2004). Cells were seeded and cultured as 
described for GC activity assay. HexA assay reaction was started by lysing the cells with 
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60 μl of 10 mM citrate/phosphate buffer (CP buffer, pH 4.2) containing 0.5% human 
serum albumin and 0.5% Triton X-100. The buffer was pipetted up and down three times 
to yield a well mixed cell lysate solution. Aliquots of 30 μl lysates were transferred to a 
new 96-well plate and mixed with 25 μl of 3.2 mM MUGS (dissolved in 10 mM CP 
buffer, pH 4.2) and incubated at 37°C for 1 hr. The reaction was stopped by the addition 
of 200 μl aliquotes of 0.1 M 2-amino-2-methyl-1-propanol (pH 10.5). HexA activity was 
evaluated by measuring the fluorescence intensity of the solution at excitation 365 nm 
and emission 450 nm. Relative HexA activities were calculated by normalizing the 
obtained fluorescence values of treated cells to that of untreated cells. 
 
5.5.  Protein overexpression 
The human cDNA encoding BiP (P11021), Calnexin (P27824), Calreticulin 
(P15253) and GRP94 (P14625) were cloned into pcDNA4/TO (Invitrogen). cDNA 
sequences were amplified by PCR using the primers reported in Table 5.3, adding the 
myc tag (N-EQKLISEEDL-C) at the 3’ end of each sequence. PCR products were 
digested with the appropriate restriction enzymes (Table 5.3), and ligated into the 
inducible expression vector pcDNA4/TO digested likewise. Plasmid sequences were 
confirmed by automated sequencing. 
Transfection procedures were performed as described: 10
4
 cells were plated in 
each well of a 96-well plate and incubated overnight to allow cell attachment. 
Transfection reactions were performed when cells reached 70-80% confluency. The 
medium was replaced with fresh growth medium supplemented with serum but without 
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antibiotics. DNA concentrations of both the inducible pcDNA4/TO (containing genes 
encoding for ER chaperones) and the regulatory pcDNA6/TR plasmid (expressing the 
tetracycline repressor) were measured by Nanodrop 2000 and were diluted in optiMEM 
in 1:6 (w/w) ratio. For each well of a 96-well plate, 12.5 μl aliquots of diluted DNA were 
mixed with the same volume of optiMEM containing Lipofectamine 2000 reagent. After 
incubating the cells for 20 hrs, the transfection solution was replaced with complete 
culture medium to allow cell recovery for 24 hrs. Tetracycline was then added to the 
medium at concentrations ranging from 0 to 1.5 μg/ml every 24 hrs. Lysosomal GC 
activity was measured after 24, 48, and 72 hrs. 
 
5.6.  qRT-PCR and Xbp-1 splicing analysis 
Quantitative RT-PCR was performed as following: 7×10
4
 cells were plated in 
each well of a 24-well plate and incubated overnight before addition of small molecules 
to the culture medium. After 24 hrs of incubation with small molecules, cells were 
washed, collected in PBS and centrifuged at 200 g for 5 min. Following removal of the 
supernatant, cell pellet was resuspended in 5 μl Silver buffer provided in the RNAGEM™ 
reagent kit (ZyGEM). 1 μl of RNAGEM was added to each centrifuge tube and water was 
filled to a final volume of 50 μl. Total mRNA was extracted by incubating samples at 75 
°C for 10 min. cDNA was synthesized by adding 4 μl qScript™ cDNA SuperMix reagent 
(Quanta Biosciences) to 16 μl of total RNA. The resulting solution was incubated first at 
42 °C for 30 min and subsequently at 85 °C for 5 min in a thermal cycler. Total cDNA 
amount was measured by NanoDrop 2000 (Thermo Scientific) and diluted to 200 ng/μl. 
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Each quantitative RT-PCR reaction was prepared with 5 μl of total cDNA, 10 μl of 
PerfeCTa™ SYBR Green FastMix™ (Quanta Biosciences), 2 μl of 10 μM primer 
solution (Table 5.4), and 3 μl of deionized water. qRT-PCR was performed using the 
CFX96™ Real-Time PCR detection system (Bio-Rad). Samples were heated for 2 min at 
95 °C and amplified in 45 cycles of 1 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C. 
Analyses were conducted using CFX manager software (Bio-Rad) and the threshold 
cycle (CT) was extracted from the PCR amplification plot. The ΔCT value was calculated 
to describe the difference between the CT of a target gene and the CT of the housekeeping 
gene, GAPDH: ΔCT = CT (target gene) - CT (GAPDH). The relative mRNA expression 
level of each target gene in treated cells was normalized to that measured in untreated 
cells: relative mRNA expression level = 2 exp [-(ΔCT (treated cells) - ΔCT (untreated 
cells))]. Each data point was evaluated in triplicate and measured three times. 
RT-PCR analysis of Xbp-1 splicing was performed using total cDNA at 200 ng/μl 
concentration. Taq DNA polymerase and the Xbp-1 primers listed in Table 5.4 were used 
for the reverse transcription reactions. PCR products were separated on a 2.5% agarose 
gel. Spliced Xbp-1 bands were quantified using the NIH ImageJ analysis software. 
 
5.7.  Endoglycosidase H treatment 
10
6
 cells were plated in a 10 cm
2
 cell culture dish and incubated overnight at 37 
°C. Following treatment with small molecules for 48 hrs, cells were collected and lysed 
with the complete lysis-M buffer supplemented with the protease inhibitor cocktail 
(Roche). Total protein concentrations were determined by Bradford assay, and each 
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sample was diluted to the same protein concentration. Endoglycosidase H (EndoH) 
treatment was performed by heating 9 μl of total protein content with 1 μl glycoprotein 
denaturing buffer (New England Biolabs) at 95 °C for 10 min, followed by incubation 
with 2 μl EndoH enzyme (New England Biolabs) at 37 °C for 1 hr. Aliquots of cell 
lysates were separated by 10% SDS-PAGE gel, and analyzed by Western blot.  
 
5.8. Western blot analyses 
Western blot analyses were performed using primary antibodies (rabbit anti-BiP, 
and mouse anti-CRT (Stressgen), mouse anti-CNX, and rabbit anti-Glucocerebrosidase 
(Sigma-Aldrich), or rabbit anti-GAPDH (Santa Cruz Biotechnology)) and appropriate 
secondary antibodies (HRP-conjugated goat anti-rabbit (Santa Cruz Biotechnology) or 
goat anti-mouse IgG (Stressgen)). Blots were visualized using SuperSignal West Femto 
Maximum (Pierce) and quantified by NIH ImageJ processing and analysis software.  
 
5.9.  Immunofluorescence microscopy 
Glass coverslips were sterilized in 70% ethanol solution under UV radiation 
overnight. Coverslips were washed with PBS three times and placed in each well of a 6-
well plate. In order to achieve better cell attachment, 500 μl aliquots of 100 μM poly-l-
lysine solution were added on top of each coverslip and coverslips were incubated for 2 
hrs at room temperature. After aspirating the poly-l-lysine solution, 10
5
 cells in 2 ml 
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culture medium were seeded in each well and plates were incubated overnight. Cells were 
cultured in the presence of small molecules for 48 hrs, and fixed with 4% 
paraformaldehyde for 30 min. Following permeabilization with 0.1% Triton-X for 5 min, 
cells were incubated with 8% BSA/PBS for 1 hr. Primary antibodies diluted in 1% 
BSA/PBS were added to the cells and plates were incubated for 1 hr (rabbit anti-
Glucocerebrosidase, and mouse anti-CNX (Sigma-Aldrich), or mouse anti-GM130 (BD 
Biosciences)). Upon washing three times with 0.1% Tween-20/PBS, cells were incubated 
with secondary antibodies for 1 hr (Dylight 488 goat anti-mouse IgG and Dylight 549 
goat anti-rabbit IgG from KPL, and FITC anti-LAMP1 from Biolegend). After washing 
with 0.1% Tween-20/PBS for three times, coverslips were taken out from the plate and 
placed upside down on a new coverglass. Immunofluorescence images were obtained 
using an Olympus IX81 confocal microscope and analyzed using the Fluoview software. 
Co-localization heatmap images were analyzed using NIH ImageJ analysis software.  
 
5.10.  Subcellular fractionation 
Subcellular fractionations were conducted as previously described (Ishii et al., 
2007). Briefly, 10
6
 cells were plated in a 10 cm
2
 culture dish and incubated overnight for 
cell attachment. Cells were incubated with small molecules for 48 hrs, collected and 
centrifuged at 1,000 rpm for 5 min. Cell pellets were resuspended in sucrose buffer (0.25 
M sucrose, 10 mM Hepes, and 1 mM EDTA, pH 7.4) on ice. Cells were homogenized 
with a Potter-Elvehjem Teflon-glass homogenizer and centrifuged at 1,000 g for 5 min. 1 
ml of the supernatant was layered on top of a 40% Percoll solution in sucrose buffer 
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(9ml) and centrifuged at 25,000 g for 1 hr. Cell homogenates were collected into 8 
fractions from the top of the centrifuge tube and used for GC enzymatic assay. 
 
5.11. Immunocytochemistry studies 
2×10
5
 cells were seeded in each well of a 6-well plate and incubated overnight at 
37 °C. Cells were transfected with both the inducible pcDNA4/TO plasmid (containing 
genes encoding ER chaperones) and the regulatory pcDNA6/TR plasmid (constitutively 
expressing the tetracycline repressor) as described in Chapter 5.5. Chaperone expression 
was induced with 0.2 μg/ml tetracycline every 24 hrs for 48 hrs. Cells were collected and 
lysed with the complete lysis-M buffer containing a protease inhibitor cocktail (Roche). 
Total protein concentrations were determined by Bradford assay (Pierce), and each 
sample was diluted to the same protein concentration. Because a Myc tag was fused to 
the C-terminus of BiP, CNX, CRT and GRP94, ELISA experiments were conducted 
using an anti-Myc antibody to capture only recombinantly expressed proteins, and 
chaperone-specific antibodies were used for detection. 96-well ELISA plates were coated 
with 100 µl/well of 1 µg/ml capturing Myc tag antibody (Abcam) in 0.1 M sodium 
bicarbonate. Following overnight incubation at 4 ºC, plates were washed three times with 
0.1% Tween-20/PBS, and incubated overnight with 200 µl/well of blocking buffer 
containing 0.01 g/ml BSA in PBS at 4 ºC. Plates were washed with 0.1% Tween-20/PBS 
again and 100 µl of PBS containing 1 mg/ml BSA was added to each well. 100 µl of 
antigen solution were added to first column of wells in a 96-well plate and serial dilutions 
were obtained by transferring 100 µl across the plate. Negative controls were included 
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and consisted of samples that did not contain antigen solution. Plates were incubated for 
4 hrs at room temperature. Upon washing three times with 0.1% Tween-20/PBS, plates 
were incubated for 2 hours at room temperature with primary antibodies (rabbit anti-BiP, 
rabbit anti-CNX, and mouse anti-CRT (Stressgen), rabbit anti-GRP94 (Santa Cruz 
Biotechnology)), and subsequently with secondary antibodies (HRP conjugated goat anti-
rabbit (Santa Cruz Biotechnology) or goat anti-mouse IgG (Stressgen)) for 1 hour. TMB 
substrate reagent was used to detect antibody binding according to the manufacturer’s 
procedures.  
 
5.12. Cytoplasmic [Ca2+] measurement 
Fura-2, AM was used to measure cytosolic [Ca
2+
] according to the company’s 
instructions (Anaspec). Briefly, 10
4
 cells were plated in each well of a 96-well plate and 
incubated overnight to allow cell attachment. Ca
2+
 blockers were added to the culture 
medium of different samples and incubated for 5, 10, 20, 40 and 60 min respectively. 
Cells were washed twice with PBS and incubated with 30 µl of Ca
2+
 and Mg
2+
-free PBS 
containing 5 µM Fura-2, AM and 0.05% (w/v) Pluronic F-127 (Invitrogen) at 37 ºC for 
30 min. Following additional washing steps, fluorescence was measured using excitation 
at 340 nm and 380 nm and emission at 510 nm with a TECAN Infinite M1000 
fluorescence plate reader. Fluorescence ratio of excitation at 340 and 380 nm reflects 
relative intracellular Ca
2+
 level. Each data point was the average of at least 6 replicates.   
 
  
160 
 
5.13. mRNA chip analysis 
7×10
4
 cells were plated in each well of a 24-well plate and treated with small 
molecules for 24 hrs at 37 ºC before total RNA was extracted. 200 ng of total RNA was 
amplified and purified using Illumina TotalPrep RNA Amplification Kit (Ambion) 
following kit instructions. Briefly, the first strand cDNA was synthesized by incubating 
RNA with T7 oligo (dT) primer and reverse transcriptase mix at 42 ºC for 2 hours. RNase 
H and the DNA polymerase master mix were added into the reaction mix immediately 
following reverse transcription and reactions were incubated for 2 hours at 16 ºC to 
synthesize the second strand of cDNA. RNA, primers, enzymes and salts that would 
inhibit in vitro transcription were removed through cDNA filter cartridges (provided with 
the amplification kit). Following in vitro transcription, biotinylated cRNA was 
synthesized by 14-hour amplification with dNTP mix containing biotin-dUTP and T7 
RNA polymerase. Amplified cRNA was subsequently purified, and concentration was 
measured by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). An 
aliquot of 750 nanograms of amplified products was loaded onto Illumina Sentrix 
Beadchip Array Human-8 arrays, hybridized at 58 ºC in an Illumina Hybridization Oven 
(Illumina) for 17 hours, washed and incubated with streptavidin-Cy3 to detect biotin-
labeled cRNA on the arrays. Arrays were dried and scanned with BeadArray Reader 
(Illumina). The data was analyzed using BeadStudio software (Illumina). Clustering and 
pathway analysis were performed with GenomeStudio and Ingenuity Pathway Analysis 
(Ingenuity Systems, Inc.) software, respectively. 
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5.14. Cell toxicity assay 
2×10
5
 cells were seeded in each well of a 6-well plate and cultured with small 
molecules for 16 hrs at 37 ºC. Cells were collected and centrifuged at 200 g for 5 min. 
Cell pellets were resuspended in 100 µl binding buffer provided with CytoGLO
TM
 
Annexin V-FITC Apoptosis Detection Kit (IMGENEX). 5 µl aliquots of both Annexin 
V-FITC reagent and Propidium Iodide (PI) solution were added to each sample and 
incubated in the dark for 20 min. Cell toxicity were analyzed by flow cytometry 
(FACSCantoTM II, Beckon Dickingson) with a 488-nm Argon laser. Fluorescence 
intensities of both Annexin V-FITC and PI in each sample were evaluated and compared 
to the values obtained from untreated cells. A total number of 10,000 cells were counted, 
and the number of cells that bind to Annexin V-FITC or PI in treated cells was compared 
to that of untreated cells. 
 
5.15. Statistical analysis  
All data is presented as mean ± s.d., and statistical significance was calculated 
using a two-tailed t-test. 
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Chapter 6 
Conclusions 
In this work, we reported a number of cell and protein engineering strategies to 
restore the folding and activity of unstable, degradation-prone lysosomal enzymes 
associated with the development of lysosomal storage disorders (LSDs). The overarching 
goal was to modulate endogenous pathways underlying management of protein folding to 
enhance the innate cellular folding capacity. Specifically, we focused on reprogramming 
the ER folding quality control (QC) system to promote the native folding of mutated 
enzymes processed through the secretory pathway. The outcomes of this study include 
the design of chemical and genetic approaches to rescue the native folding of mutated, 
degradation-prone lysosomal enzymes. In addition, mechanistic studies were conducted 
to identify rate-limiting steps in the processing of these unstable protein variants that 
could be targeted for therapeutic applications.  
Gaucher’s disease (GD), the most common LSD, was used as a model system in 
this work. Currently, enzyme replacement therapy is available for most GD patients, but 
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this method fails to treat several affected areas, particularly the skeleton and the brain 
(Wraith, 2006). Bone marrow transplantation, although rarely performed, can reverse 
non-neurological aspects (Hoogerbrugge et al., 1995), but is not effective for the brain 
damage that occurs in the most severe cases of GD. Small molecule based oral treatments 
present a number of advantages over protein therapy, particularly for conditions requiring 
lifelong care management. Inhibitors of glucosylceramide synthesis are available for the 
treatment of GD patients with moderate clinical manifestations for which enzyme 
replacement therapy is not an option (Ficicioglu, 2008). Chemical chaperones, small 
molecules that rescue native folding of mutated GC enabling lysosomal trafficking and 
activity (Sawkar et al., 2006b), provide a promising alternative, but they are highly 
mutation-specific (Sawkar et al., 2005) and rarely proved effective to rescue 
glucocerebrosidase variants associated with neuronopathic manifestations of the disease 
(Khanna et al., 2010). Thus, therapeutic solutions for neuronopathic GD as well as other 
LSDs are still an urgent medical need. The L444P GC allele is a severely destabilized 
mutant always associated with neuronopathic symptoms in homozygous patients. We 
used fibroblasts derived from patients carrying L444P GC allele to develop strategies to 
restore the folding and activity of mutated GC variant.  
Modulation of proteostasis modulation to enhance the cellular folding capacity 
was previously explored as a strategy to rescue the folding and lysosomal activity of 
destabilized GC variants in cells derived from patients with neuronopathic GD (Mu et al., 
2008b). This strategy is based on the use of small molecules that modulate the 
composition of the proteostasis network and remodel cellular folding pathways. Owing to 
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their non-substrate-specific mechanisms, these regulators were shown to restore the 
activity of different enzymes associated with distinct LSDs (Mu et al., 2008b).  
We first investigated strategies to modulate intracellular Ca
2+
 homeostasis. The 
accumulation of GC substrate glucosylceramide depletes Ca
2+
 storage in the ER through 
ryanodine receptors. Since [Ca
2+
]ER
 
affects ER chaperone expression and activity, we 
hypothesized that the depletion of [Ca
2+
]ER hampers the folding of unstable GC variants. 
Thus, we used RyR blockers to restore Ca
2+
 homeostasis in GD patient-derived 
fibroblasts. We demonstrated that modulation of [Ca
2+
]ER
 
through RyRs inhibition in 
L444P GC fibroblasts re-establishes an ER folding environment more amenable to 
proteostasis regulation. Particularly, we found that the ER luminal chaperone BiP plays 
an important role in promoting the folding of mutated GC variants.  
In order to identify small molecule Ca
2+
 channel blockers that restore intracellular 
Ca
2+
 homeostasis more efficiently than RyR blockers, we investigated cell treatment with 
LTCC blockers and identified their effect on mutated GC folding rescue. We used a 
number of LTCC blockers and found that treatment of fibroblasts derived from GD 
patients with lacidipine, an LTCC blocker that antagonizes Ca
2+
 mobilization through 
LTCC and RyRs (Gunther et al., 2008; Wishart et al., 2008), results in enhanced folding, 
trafficking and activity of mutated GC variants. Particularly, we demonstrated that 
lacidipine functions as a proteostasis regulator in patient-derived GD fibroblasts and 
rescues L444P GC folding with considerably higher efficiency than any other Ca
2+
 
channel blocker reported before (Mu et al., 2008a; Ong et al., 2010; Wang et al., 2011a). 
We showed that lacidipine functions by i) lowering cytoplasmic [Ca
2+
], ii) remodeling 
the expression of ER chaperone and the unfolded protein response (UPR), and iii) 
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reducing cellular toxicity and apoptosis induction. Interestingly, the mechanism of action 
of lacidipine is significantly different from that activated by small molecules previously 
reported to function as proteostasis modulators (Mu et al., 2008b; Wang et al., 2011a).  
Mechanistic studies conducted to investigate changes in the cellular folding 
network induced by treatment with proteostasis modulators also suggested that 
augmenting the pool of mutated GC in the ER via upregulation of the GC encoding gene 
is critical to promote its folding and trafficking (Wang et al., 2011a; Wang et al., 2011b). 
We hypothesized that enhancing ER retention and preventing ERAD of GC misfolding 
intermediates would lead to increasing the pool of GC folding intermediates that is 
amenable to folding rescue. To test this hypothesis, we treated fibroblasts derived from 
GD patients with small molecules that interfere with recognition or retrotranslocation of 
misfolded substrates. The generality of this approach was demonstrated by treating Tay-
Sachs disease cells with an ERAD inhibitor to rescue the folding of mutated HexA. The 
different mechanisms of ERAD inhibition investigated were shown to enhance ER 
retention of mutated proteins, but were associated with dramatically different levels of 
ER stress, unfolded protein response (UPR) activation and UPR-induced apoptosis. 
Therefore, molecular targets of ERAD inhibition need to be carefully selected to prevent 
the disruption of functioning of the folding quality control system. 
Furthermore, we proved that restoring Ca
2+
 homeostasis in GD cells creates a 
folding environment particularly amenable to mutated GC folding rescue via ERAD 
inhibition. Specifically, we remodeled the proteostasis network to simultaneously 
increase ER retention of unstable GC variants by inhibiting retrotranslocation and ERAD 
degradation and to enhance chaperone-mediated folding by restoring Ca
2+
 homeostasis. 
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We showed that this approach results in significantly higher rescue in the folding and 
activity of L444P GC than either approach applied individually. We also demonstrated 
that lacidipine treatment lowers EerI-mediated UPR induction and apoptosis through the 
upregulation of the anti-apoptotic gene Bcl-2, which plays a key role in preventing 
cytotoxicity that may result from modulation of the proteostasis network. 
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Chapter 7 
Recommendations 
for further studies 
In this work, we presented strategies to modulate the proteostasis network in 
fibroblasts derived from patients with LSD and restore the folding of mutated, 
degradation-prone lysoosomal enzyme variants. This study enabled the identification of 
endogenous proteins that influence the folding of unstable lysosomal enzymes and that 
could be targeted for therapeutic intervention in the development of treatments for 
multiple LSDs.  
We identified a number of folding modulators that mediate significant increase in 
GC activity in fibroblasts derived from patients with GD. Some of these small molecules 
restore the folding and activity of GC mutants at the cost of cell apoptosis, whereas others 
enhance GC activity without causing cytotoxicity. Among the non-toxic proteostasis 
modulators, we reported the LTCC blocker lacidipine, which is an FDA approaved drug 
for the treatment of hypertension. Testing the function of lacidipine in mouse models of 
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GD will allow establishing its therapeutic potential and, particularly, its ability to 
ameliorate neuronopathic symptoms. 
We also reported clear evidence that BiP upregulation is critically involved in the 
folding of GC mutants. Since GC folding and lysosomal trafficking is a multi-step 
process and is closely regulated by numerous enzymes of the proteostasis network, we 
expect that other endogenous proteins might affect the folding and activity of GC 
mutants. We recommend conducting a genetic screen for the isolation of genes that 
enhance folding of mutated GC variants. Optimization of the enzymatic assay currently 
available to measure GC activity, which is characterized by a narrow signal window, will 
be necessary to adapt it for high throughput applications.  
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Appendix A 
Small molecules used in this study 
Small 
Molecules 
Chemical Structures Functions 
MG-132 
 
Proteostasis regulator 
(Mu et al., 2008b) 
Celastrol 
 
Proteostasis regulator 
(Mu et al., 2008b) 
Ryanodine 
 
RyR blocker 
(Buck et al., 1992;  
Nagasaki and Fleischer, 1988) 
Dantrolene 
 
RyR blocker 
(Ward et al., 1986) 
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Lacidipine 
 
LTCC blocker;  
also inhibits RyRs 
(Gunther et al., 2008) 
Lercanidipine 
 
LTCC blocker, also prevents Ca
2+
 
efflux from the ER 
(Wishart et al., 2008) 
Nicardipine 
 
LTCC blocker, also prevents Ca
2+
 
efflux from the ER 
(Wishart et al., 2008) 
Nifedipine 
 
LTCC blocker 
(Gunther et al., 2008) 
Nitrendipine 
 
LTCC blocker 
(Gunther et al., 2008) 
Diltiazem 
 
LTCC blocker; 
also inhibits RyRs 
(Gunther et al., 2008) 
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Verapamil 
 
LTCC blocker; 
also inhibits RyRs 
(Gunther et al., 2008) 
Eeyarestatin I 
(EerI) 
 
ERAD inhibitor; 
inhibits p97 ATPase activity 
(Fiebiger et al., 2004;  
Wang et al., 2010) 
Kifunensine 
(Kif) 
 
ERAD inhibitor; 
inhibits the activity of 
ER mannosidase I 
(Avezov et al., 2008;  
Fagioli and Sitia, 2001) 
Thapsigargin 
 
UPR inducer; 
inhibits the activity of  
SERCA pumps 
(Chen et al., 2007)  
Tunicamycin 
 
UPR inducer; 
inhibits protein glycosylation 
(Duksin and Bornstein, 1977)  
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A23187 
 
BiP promoter inducer 
(BiP 670); 
Ca
2+
 ionophore 
(Chao and Lin-Chao, 1992; 
Drummond et al., 1987) 
NB-DNJ 
 
Glucosylceramide synthesis 
inhibitor; 
Glucosyltransferase inhibitor 
(Cox et al., 2000;  
Platt et al., 2001) 
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Appendix B 
Global gene expression profile in fibroblasts derived from patients 
with GD treated with ryanodine and MG-132. 
(M, MG-132; R, ryanodine; MR, MG-132 + Ryanodine) 
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